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1 INTRODUCTION 
1.1 Tetrapyrroles 
1.1.1 Structure and Function of Naturally Occurring Tetrapyrroles 
Tetrapyrroles consist of four pyrrolic rings, in general attached to each other in a cyclic or 
linear form via methine bridges. One exception are the corrinoids which lack one brigde 
carbon. The basic structure of a cyclic tetrapyrrole is the porphyrin macrocycle shown in  
Fig. 1.  
 
Fig. 1: Basic structure of cyclic tetrapyrroles, the porphyrin ring. 
 
Pyrrole rings are denoted A-D, carbon and nitrogen atoms are numbered. 
 
The pyrrole rings of the macrocycle are denoted A – D around the circle in clockwise 
direction. Within the pyrrole ring, carbon atoms adjacent to the nitrogens are named  
α-carbons (e.g. C1). Carbon atoms in distal position to the nitrogens are β-carbons (e.g. C2) 
while the methine bridge carbons are in meso-position. The macrocyclic tetrapyrrole 
contains a system of fully conjugated double bonds, resulting in the red color of human 
blood and the green color of plants. Another important property of porphyrins is their ability 
to chelate diverse divalent metal ions such as Fe2+, Mg2+, Ni2+ or Co2+. In vivo, the cyclic 
tetrapyrroles differ in the oxidation state of their ring systems, the nature of the chelated 
metal ion and the ring substituents (Frankenberg et al., 2003, Jahn et al., 1996). 
Hemes are true porphyrins whereas tetrapyrroles with variations of the basic porphyrin 
structure are known as porphinoids.  Examples include more reduced cyclic tetrapyrroles 
such as chlorophylls (a chlorin), bacteriochlorophylls (chlorins or bacteriochlorins), 
siroheme (an isobacteriochlorin), coenzyme F430 and heme d1 (Raux et al., 2003, Thauer and 
Bonacker, 1994). Finally, tetrapyrroles like vitamin B12 belong to the class of corrinoids 
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characterized by a missing methine bridge in the porphyrin ring (Banerjee and Ragsdale, 
2003). Linear tetrapyrroles like bilins also contain only three bridge carbons and all result 
from the cleavage of previously cyclic tetrapyrroles. The structures of important 
representatives of natural occurring porphyrins, porphinoids and corrinoids are depicted in 
Fig. 2.  
Tetrapyrroles fulfill diverse functions and are essential compounds for almost all living 
organisms. Iron-containing heme as a cofactor of hemoglobin coordinates molecular oxygen 
and carbon dioxide and is responsible for their transport in the cardiovascular system from 
the lungs to the tissues and vice versa. Many enzymes such as peroxidases and catalases 
also rely on heme as prosthetic group. Furthermore, heme plays an important role in 
respiration, since heme-containing cytochromes are part of various electron transfer chains 
(Panek and O'Brian, 2002). Heme proteins can serve as sensors for diatomic gases such as 
O2, CO and NO and for CO2 in signal transduction pathways (Rodgers, 1999). Magnesium-
chelating chlorophylls – the origin of the green color in plants – and bacteriochlorophylls 
are essential to the photosynthetic apparatus of plants and bacteria (Beale, 1999). The 
yellow nickel-containing coenzyme F430 is the cofactor of methylcoenzyme M reductase 
involved in methane formation (Thauer and Bonacker, 1994). 
 
Fig. 2: Structures of important tetrapyrrole representatives. 
 
Depicted are naturally occurring tetrapyrroles and their common precursor molecule uroporphyrinogen III.  
A = acetate side chain; P = propionate side chain; M = methyl group; V = vinyl group. 
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Derivatives of the cobalt-containing vitamin B12 are the cofactors of a number of enzymes 
that catalyze radical-dependent reactions such as methyl transfer reactions or nucleotide 
reduction (Banerjee and Ragsdale, 2003). The iron chelating siroheme is a greenish cofactor 
involved in reactions during assimilatory nitrite or sulfite reduction (Raux et al., 2003). In 
contrast, linear tetrapyrroles do not contain a tightly bound metal. They are employed as 
chromophoric photoreceptors in cyanobacterial and higher-plant light-harvesting systems 
(Frankenberg and Lagarias, 2003). The variety of functions fulfilled by tetrapyrroles 
underscores their importance in nature, and explains the extensive effect of disorders in 
tetrapyrrole anabolism.   
1.1.2   Biosynthesis of Tetrapyrroles 
The shared structural core of tetrapyrroles intuitively implies a related biosynthetic pathway. 
All tetrapyrroles derive from the common precursor molecule 5-aminolevulinic acid (ALA) 
and the initial biosynthetic steps are highly conserved. The major branching point occurs 
after the formation of uroporphyrinogen III, the first cyclic intermediate. It is either 
converted into protoporphyrin IX or precorrin-2. Protoporphyrin IX is utilized to synthesize 
hemes, chlorophylls and bacteriochlorophylls, while precorrin-2 gives rise to siroheme, 
heme d1, coenzyme F430 and corrinoids. An overview of the divergent biochemical pathways 
of tetrapyrroles is given in Fig. 3.  
 
 
Fig. 3: The biosynthesis of tetrapyrroles.  
 
The names of the enzymes and their respective genes (bacterial) are given above the arrows. A = acetate side 
chain; P = propionate side chain; M = methyl group; V = vinyl group. 
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In eukaryotes, tetrapyrrole biosynthesis is limited to the formation of heme, siroheme, 
chlorophyll and bilins. Prokaryotes additionally synthesize complicated tetrapyrroles as 
corrinoids, coenzyme F430 and heme d1 (Jahn et al., 1996). 
 
1.1.3  Heme Biosynthesis 
1.1.3.1 Biosynthesis of 5-Aminolevulinc Acid 
The biosynthesis of all tetrapyrroles (Fig. 3) starts with the formation of ALA. This small 
molecule is the sole source of all carbon and nitrogen atoms required for the formation of 
the tetrapyrrolic macrocycle. There are, however, two alternate routes leading to ALA 
formation. Of these, the “Shemin pathway” was discovered first. It is formed in non 
photosynthetic eukaryotes such as animals and fungi as well as in the α-group of 
proteobacteria (Shemin and Russel, 1953). The pyridoxal-5’-phosphate dependent enzyme 
ALA synthase (ALAS; encoded by hemA; EC 2.3.1.37) synthesizes ALA in a single step 
through condensation of glycine and succinyl-CoA under elimination of carbon dioxide 
(Kikuchi et al., 1958, O´Brian and Thöny-Meyer, 2002). The second route of ALA 
formation is the “C5 - pathway” found in most bacteria, archaea and plants (Beale and 
Castelfranco, 1973). Here, glutamyl-tRNA serves as initial substrate and two enzymatic 
steps are required to form ALA (Jahn et al., 1992). The first enzyme of this path, glutamyl-
tRNA reductase (GluTR; encoded by hemA; EC 6.1.1.17), is NADPH dependent and 
catalyzes the reduction of glutamyl-tRNA to the instable glutamate-1-semialdehyde (GSA) 
(Jahn et al., 1991, Moser et al., 1999). In the following step glutamate-1-semialdehyde-2,1-
aminomutase (GSAM; encoded by hemL; EC 5.4.3.8) converts GSA to ALA in a pyridoxal-
5’-phosphate-dependent transamination reaction (Ilag and Jahn, 1992). Thus, the 5-carbon 
skeleton of glutamate is incorporated into ALA, giving rise to the name “C5 - pathway”. 
Since GSA is a highly reactive aldehyde, a coordinated action of the two enzymes is 
required. This led to the proposal of a GluTR/GSAM complex, which is in line with the 
structural complementarity of the two enzymes (Moser et al., 2001). This complex was 
shown to exist in vivo (Luer et al., 2005) and allows direct channeling of the instable 
intermediate to prevent solvent exposure. The photosynthetic phytoflagellate Euglena 
gracilis is currently the only organism reported to use both the C5 - pathway and ALAS for 
heme biosynthesis. Here, ALA derived by ALAS is incorporated into mitochondrial 
tetrapyrroles, whereas plastidic pigments are made from ALA synthesized by the  
C5 - pathway (Weinstein and Beale, 1983). Both pathways for ALA were also discovered in 
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Streptomyces nodosus subsp. askuaensis. However, the ALA produced via the Shemin way 
is utilized exclusively for the production of the antibiotic asukamycin and is not 
incorporated into heme (Petricek et al., 2006). 
 
1.1.3.2 The Central Pathway from 5-Aminolevulinic Acid to Uropor-
phyrinogen III 
The following three steps in heme biosynthesis are common to the biosynthesis of all 
tetrapyrroles. Two molecules of ALA are asymmetrically condensed to yield the pyrrole 
derivative porphobilinogen. This reaction is catalyzed by porphobilinogen synthase (PBGS; 
encoded by hemB; EC 4.2.1.24). PBGS enzymes from different organisms are all metal-
dependent but variable regarding the nature of the utilized cations. Four molecules of 
porphobilinogen are linked consecutively by porphobilinogen deaminase (PBGD; encoded 
by hemC; EC 4.3.1.8) to produce the linear tetrapyrrole pre-uroporphyrinogen. Interestingly, 
porphobilinogen is both the substrate as well as a component of the cofactor for PBGD. The 
dipyrromethane cofactor is a porphobilinogen dimer covalently attached to the enzyme 
through its free amino group (Jordan and Warren, 1987, Warren and Jordan, 1988). It 
primes the sequential addition and deamination of the tetrapolymerization with a transient 
porphobilinogen hexamer of which pre-uroporphyrinogen is hydrolyzed (McNeill and 
Shoolingin-Jordan, 1998). Pre-uroporphyrinogen is passed directly on to uroporphyrinogen 
III synthase (UROS; encoded by hemD; EC 4.2.1.75), which converts it to 
uroporphyrinogen III, the first cyclic intermediate of the pathway. UROS catalyzes the 
inversion of ring D of pre-uroporphyrinogen via a spiro-mechanism with spiro-pyrrolenine 
as an intermediate creating uroporphyrinogen III (Chadwick, 1994, Shoolingin-Jordan and 
Cheung, 1999). The inversion of ring D at this point causes cyclic tetrapyrroles to be 
asymmetric molecules.  
1.1.3.3 Conversion of Uroporphyrinogen III into Heme 
The conversion of uroporphyrinogen III to heme is outlined in Fig. 3. Uroporphyrinogen III 
decarboxylase (UROD; encoded by hemE; EC 4.1.1.37) catalyzes the sequential 
decarboxylation of the four acetate residues of uroporphyrinogen III to yield the 
corresponding methyl groups of the product coproporphyrinogen III. The decarboxylations 
proceed in an ordered manner beginning with the acetate side chain of ring D, followed by 
A, B and finally C (Akhtar, 1991, Luo and Lim, 1993). Genes encoding UROD have been 
isolated from various sources (Chelstowska et al., 1992, Hansson and Hederstedt, 1992, 
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Kiel et al., 1990, Nishimura et al., 1993, Romana et al., 1987, Romana et al., 1987). So far 
identified proteins have been found to be highly conserved and are likely to function in a 
very similar way. In the next step, coproporphyrinogen III oxidase (CPO; encoded by 
hemF/N; EC 1.3.3.3) catalyzes the transformation of coproporphyrinogen III to 
protoporphyrinogen IX. During this reaction the propionate side chains on rings A and B are 
oxidatively decarboxylated to the corresponding vinyl groups (Dailey, 2002). Eukaryotic 
CPOs are structurally conserved and require oxygen for the oxidative reaction (HemF). 
Most bacteria also contain an oxygen-independent CPO (HemN), which was shown to be a 
“Radical-SAM” enzyme (Layer et al., 2002). Protoporphyrinogen IX oxidase (PPO; 
encoded by hemG/Y; EC 1.3.3.4) converts protoporphyrinogen IX to protoporphyrin IX, 
which requires the elimination of six electrons and results in the formation of a system of 
completely conjugated double bonds. Oxygen-dependent PPO (HemY), found in eukaryotes 
and some bacteria, is a flavin-containing enzyme that employs molecular oxygen as the final 
electron acceptor (Hansson and Hederstedt, 1994, Koch et al., 2004). Oxygen independent 
PPO (HemG) is a rather small protein with a relative molecular mass of 21,000 with flavin 
mononucleotide (FMN) as cofactor, which transfers electrons to fumarate via menaquinone 
(Sasarman et al., 1979, Sasarman et al., 1993, Möbius et al., unpublished data). The last 
step of heme biosynthesis is the insertion of iron into protoporphyrin IX which is catalyzed 
by ferrochelatase (FC; encoded by hemH; EC 4.99.1.1) (Dailey, 2002). Metabolic 
channeling between PPO and FC has only recently been shown to exist in vivo and prevents 
solvent exposure of the photoreactive protoporphyrin IX in Thermosynechococcus elongatus 
(Masoumi et al., unpublished data).  
1.1.4  Conversion of Uroporphyrinogen III into Siroheme 
After formation of uroporphyrinogen III the pathways for vitamin B12, coenzyme F430,  
heme d1 and siroheme formation branch from the pathway leading to heme and chlorophyll 
formation. Siroheme, the prosthetic group of sulphite and nitrite reductases, is synthesized 
from uroporphyrinogen III in three steps as outlined in Fig. 4. Uroporphyrinogen III is 
therefore converted into precorrin-2, a 2,7-dimethyl derivative, via two consecutive 
methylation reactions. These are catalyzed by uroporphyrinogen III methyltransferase  
(EC 2.1.1.107) with S-adenosyl-L-methionine (SAM) as methyl donor under release of  
S-adenosyl-L-homocysteine. The second step resulting in an overall oxidation of the 
macrocycle is catalyzed by precorrin-2 dehydrogenase (EC 1.3.1.76), which requires NAD+ 
as a cofactor. Finally, siroheme is synthesized by insertion of ferrous iron into 
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sirohydrochlorin in a reaction catalyzed by sirohydrochlorin ferrochelatase (EC 4.99.1.4) 
(Raux-Deery et al., 2005, Raux et al., 2003). In some bacteria, these three steps are 
executed by a single multifunctional protein called CysG (Spencer et al., 1993), whereas in 
Bacillus megaterium three separate enzymes are required for each step (Leech et al., 2002). 
 
Fig. 4: The biosynthesis of siroheme from uroporphyrinogen III.  
 
 
Siroheme is formed from uroporphyrinogen III in three steps via the intermediates precorrin-2 and 
sirohydrochlorin. A = acetate side chain; P = propionate side chain; M = methyl group. 
 
1.1.5 Diseases and Growth Defects Caused by Tetrapyrrole Deficiency 
Heme is an essential cofactor for most archaea, bacteria and eukaryotes. Consequently, its 
biosynthesis is an attractive target for antibacterial drug discovery and herbicide treatment 
(Matringe et al., 1989, Padmanaban and Rangarajan, 2000). Perturbation of the tetrapyrrole 
anabolism in plants induces photodynamic cell damage due to accumulation of 
photoreactive chlorophyll intermediates. This can result in a decrease of chlorophyll 
synthesis and thus lowering of the photosynthesis capacity (Lermontova et al., 1997, Mock 
and Grimm, 1997, Mock et al., 1999). PPO for example is the target for diphenylether 
herbicides such as acifluorfen-methyl. The phytotoxicity of these herbicides is based on the 
accumulation of protoporphyrinogen IX, which is transported from the chloroplasts to other 
parts of the cell, where it is non-enzymatically oxidized and generates reactive oxygen 
species, thereby damaging cellular components (Matringe et al., 1989). 
On the other hand a variety of genetic disorders concerning the involved enzymes have 
severe consequences on human health. Mutations in the different human heme biosynthetic 
genes cause disorders commonly known as porphyrias (Sarkany, 1999, von und zu 
Fraunberg et al., 2002). Porphyrias are a group of inherited or acquired disorders of certain 
enzymes in the heme biosynthetic pathway. They are broadly classified as hepatic 
porphyrias or erythropoietic porphyrias, based on the site of the overproduction and 
accumulation of the porphyrins or their chemical precursors. Patients suffer from cutaneous 
photosensitivity and a propensity to develop acute neurovisceral crises (Meissner et al., 
1996, Meissner et al., 1986). 
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1.2  Porphobilinogen Synthase 
PBGS from prokaryotes and eukaryotes share a high degree of sequence similarity with 
each other.  All catalyze the asymmetric condensation of two molecules of ALA to yield the 
first pyrrole porphobilinogen (see Fig. 3) (Frankenberg et al., 2003, Jordan, 1994). PBGS 
from various organisms have been intensively studied over the past years and crystal 
structures of many PBGS enzymes have been published (Breinig et al., 2003, Erskine et al., 
1999, Erskine et al., 1997, Frankenberg et al., 1999). The enzyme catalyzed reaction is 
initiated by the formation of Schiff base bonds between the two ALA substrate molecules 
and two conserved lysine residues in the active site. It involves multiple bond-braking and 
bond-making events (Erskine et al., 1999). The substrate ALA molecule that becomes the 
acetyl-substituted half of porphobilinogen is called A-site ALA. The propionyl-coordinating 
half of porphobilinogen derives from P-site ALA. The corresponding substrate binding sites 
of PBGS consequently are termed the A-site and P-site, respectively. The PBGS reaction 
starts with the binding of P-site ALA with subsequent binding of the second substrate 
molecule to the A-site. A proposed order derived from various crystal structures has 
recently been published and experimentally underlined and is illustrated in Fig. 5 (Frere et 
al., 2006).  
 
Fig. 5: Proposed catalytic mechanism of the porphobilinogen synthase.  
 
The reaction starts with the binding of P-site ALA (I) and subsequent binding of A-site ALA via Schiff base 
(II). The abstraction of a proton from C3 of A-site ALA follows yielding an A-site enamine (III). The next step 
is the aldole addition forming the C-C bond between A-site and P-site ALA (IV), with subsequent Schiff base 
exchange producing a C-N bond between A-site and P-site ALA (V) with following transfer of a proton to 
Lys260 (VI). Finally, the trans elimination of P-site lysine occurs (VII) followed by the abstraction of the pro-
R proton from C5 of P-site ALA (VIII) with subsequent aromatization and release of the product PBG (Frere et 
al., 2006). 
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PBGS are usually enzymes with a relative molecular mass of 280 - 300,000 and are 
composed of eight identical subunits. They carry a high degree of structural conservation 
but a considerable diversity in the use of metal ion cofactors. Zinc and magnesium-
dependent enzymes have been described (Jaffe, 2000), with each PBGS octamer containing 
only four functional actives sites (Cheh and Neilands, 1973, Jaffe et al., 1992, Shemin, 
1976). Pseudomonas aeruginosa PBGS crystallographic data showed an asymmetric dimer 
as the fundamental structural unit (Frankenberg et al., 1999). A flexible loop covers the 
active site in the “closed” conformation and separates it from the surrounding medium. The 
bound Mg2+ ion is separated 14 Å from the Schiff base lysine, which is too far to play a 
direct catalytic role. The “open” conformation of the asymmetric dimer was not shown to 
contain an Mg2+ ion. It was suggested that the open and closed conformation of each 
monomer is governed by Mg2+ binding. The dimer is illustrated in Fig. 6. In the active site 
cavity two lysine residues, i.e. Lys205 and Lys260, are responsible for substrate 
coordination via stable Schiff base formation (Frankenberg et al., 1999). 
 
Fig. 6: Crystal structure of P. aeruginosa porphobilinogen 
synthase. 
 
Each PBGS monomer is a TIM barrel with a long N-terminal arm. In 
monomer A the β-strands are colored in orange, α-helices in blue 
and loops in pink. The lid (shown in green) sits atop the active site 
and isolates the center of the barrel from solvent exposure. The side-
chains of a number of residues in the active site (Asp139 and 
Lys260) and the neighboring Mg2+-binding site (Arg181 and 
Glu245) are also shown. The competitive inhibitor levulinic acid is 
covalently attached via a Schiff base to Lys260. The Mg2+ is shown 
as a sphere colored in magenta. Monomer B is depicted in grey 
(Frankenberg et al., 1999). 
 
 
 
 
 
1.2.1 Alaremycin, an Antibiotic Structurally Related to 5-Aminolevulinic 
Acid 
The lately discovered antibiotic alaremycin (Awa et al., 2005) was isolated from the culture 
broth of the actinomycete strain Streptomyces sp. A012304. Its structure was determined as 
5-acetamido-4-oxo-5-hexenoic acid and is thus structurally related to ALA (Fig. 7) (Awa et 
al., 2005). The biosynthesis pathway has not been solved but attempts in this direction are 
currently being made (Masaaki Wachi, Tokyo Institute of Technology, Japan, personal 
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communication). Alaremycin revealed enhanced antimicrobial activity against Escherichia 
coli in the presence of ALA (Awa et al., 2005), and was proposed to execute its 
antimicrobial activity via the inhibition of tetrapyrrole biosynthesis. Firstly it was proposed 
that alaremycin competes with ALA and inhibits PBGS, which utilizes ALA as substrate. 
However, excessive addition of ALA to the medium did not relieve the lethal effect of 
alaremycin, but in contrast enhanced the antibacterial effect (Awa et al., 2005). Thus, it was 
suggested that alaremycin affects the heme biosynthetic pathway by a mechanism other than 
competitive inhibition of PBGS or that the antibacterial activity is caused by a mechanism 
indifferent to heme biosynthesis. Until now, no further attempts have been made to resolve 
the mode of action. 
 
Fig. 7: Structure of 5-aminolevulinic acid and 
alaremycin.   
The structural core of the novel isolated antibiotic 
alaremycin resembles the structure of 5-aminolevulinic 
acid, the first common precursor of tetrapyrrole 
biosynthesis. Carbon atoms are numbered. 
 
 
 
1.3 Uroporphyrinogen III Synthase 
Another open question in heme biosynthesis regards the identity of the fourth enzyme in 
chlorophyll and heme biosynthesis, UROS, in plants. Although UROS has been cloned from 
many organisms, the level of sequence conservation between them is very low. No gene 
from plants has been assigned to UROS so far and no obviously recognizable homolog has 
been identified from the Arabidopsis thaliana genome.  
UROS catalyzes the cyclization of pre-uroporphyrinogen with a concomitant inversion of 
the fourth ring of the porphyrin macrocycle to give rise to uroporphyrinogen III (Battersby, 
1979). In the absence of UROS, pre-uroporphyrinogen cyclizes non-enzymatically to form 
toxic uroporphyrinogen I without any rearrangement of the fourth pyrrole ring. Since it is 
not a precursor for biologically active tetrapyrroles, uroporphyrinogen I cannot be 
metabolized past the following step in the pathway. Congenital erythropoetic porphyria, a 
human disease caused by UROS deficiency, is characterized by the accumulation of 
uroporphyrin I and coproporphyrin I in the plasma, tissues, and red blood cells. This leads to 
severe photosensitivity with skin fragility, hypertrichosis, and lesions on light-exposed areas 
(Desnick et al., 1998, Kappas, 1995). In bacteria, the genes encoding PBGD (hemC) and 
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UROS (hemD) are usually organized in an operon, leading to a coordinated expression of 
both genes. This might be necessary for a direct substrate transfer of the instable 
intermediate pre-uroporphyrinogen III from PBGD to UROS to prevent solvent exposure 
and spontaneous cyclization to uroporphyrinogen I (Hansson et al., 1991, Mohr et al., 
1994). UROS has been purified from a variety of sources including the bacterium E. coli 
(Alwan et al., 1989), the protozoan Euglena gracilis (Hart and Battersby, 1985), rat liver 
(Kohashi et al., 1984), and human erythrocytes (Tsai et al., 1987). In all cases, the purified 
enzyme was a monomer with a molecular mass of about 30,000 Da. Interestingly, the UROS 
from different sources were all found to be remarkably susceptible to heat denaturation. 
This is in contrast to other enzymes of the biosynthetic pathway, which are rather 
thermostable (Noriega et al., 2002, Sasarman et al., 1987). A comparison between UROS 
sequences showed that there are seven invariant residues and conservative substitutions in 
further 15 positions. The crystal structure of the human enzyme revealed that it consists of 
two α/β domains linked by a β-ladder as depicted in Fig. 8 (Mathews et al., 2001). The 
active site appears to be located between the domains suggesting an enzyme mechanism 
including variations in the relative domain positions.  
Fig. 8: Structure of the human uroporphyrinogen III synthase. 
Human UROS consists of two α/β domains linked by a β-ladder. The 
active site is located between these two domains. The C- and the  
N-terminus are labeled. 
 
 
 
 
 
 
 
 
 
 
However, the overall amino acid sequence similarity between UROSs from different 
organisms is low. For example the Bacillus subtilis and mouse amino acid sequences share 
less than 22 % identity. Furthermore, both show very little homology to E. coli UROS. This 
is in contrast to other tetrapyrrole biosynthesis enzymes, such as PBGD and CPO that are up 
to 55 – 60 % identical between prokaryotes and eukaryotes. Primary amino acid sequence 
conservation is a necessary prerequisite to identify putative orthologues by sequence 
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database miming. The lack of similarities between the various known UROSs reduced the 
possibility to identify a UROS gene from higher plants by simple BLAST searching, even 
after the publication of the complete genome sequence of A. thaliana (The Arabidopsis 
Genome Initiative, 2000, O´Brian and Thöny-Meyer, 2002). However, UROS activity has 
been described for plants and is necessary for chlorophyll biosynthesis (Higuchi and 
Bogorad, 1975).  
 
1.4 Protoporphyrinogen IX Oxidase  
The penultimate step in heme biosynthesis is the oxygen-dependent aromatization of 
protoporphyrinogen IX to protoporphyrin IX (see Fig. 3) catalyzed by PPO (Brenner and 
Bloomer, 1980). It is the last common step of tetrapyrrole biosynthesis for the formation of 
hemes and chlorophylls. Initially, the enzyme was characterized from yeast (Poulson and 
Polglase, 1975) and mammalian liver (Dailey and Karr, 1987, Poulson, 1976). The six-
electron oxidation of protoporphyrinogen IX is catalyzed by PPO using a flavin cofactor and 
molecular oxygen as terminal electron acceptor, resulting in a fully conjugated tetrapyrrole 
macrocycle. PPO belongs to a flavin adenine dinucleotide (FAD) superfamily that also 
includes monoamine oxidase and phytoene desaturase (Dailey and Dailey, 1998). PPO has 
been described as soluble monomer in Bacillus subtilis (Hansson and Hederstedt, 1992), as 
membrane-associated monomer in bovine (Siepker et al., 1987) or as homodimer in 
Myxococcus xanthus and humans (Dailey and Dailey, 1996, Dailey and Dailey, 1996, 
Maneli et al., 2003). In eukaryotes PPO is associated with the outer surface of the inner 
mitochondrial membrane (Deybach et al., 1985), while the plant enzyme is additionally 
located in chloroplasts (Dailey, 2002, Jacobs and Jacobs, 1984). In humans, partial PPO 
deficiency causes a disease known as variegate porphyria (VP, OMINTM accession number 
176200) that is inherited as an autosomal dominant trait displaying incomplete penetrance 
(Mustajoki, 1980). The biochemical abnormalities found in VP patients include 
overproduction and increased excretion of porphyrins and porphyrin precursors. VP 
manifests clinically with photosensitivity and acute attacks, which includes various 
neuropsychiatric symptoms (Dean, 1971). In South Africa VP is common due to a founder 
effect, where mainly one amino acid exchange from Arg59 to tryptophan causes the disease 
(Meissner et al., 1996, Roberts et al., 1998, Warnich et al., 1996). However, there are 
various additional mutations known to cause VP (von und zu Fraunberg et al., 2002).  
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1.4.1 Tobacco Protoporphyrinogen IX Oxidase 
In plants two isoforms of PPO, plastidic PPO (PPO1) and mitochondrial PPO (PPO2) have 
been found (Beale, 1999, Jacobs and Jacobs, 1984, Lermontova et al., 1997). They share an 
amino acid sequence identity of less than 30 %. Both enzymes operate as homodimers and 
use FAD as cofactor. The crystal structure of Nicotiana tabacum mitochondrial PPO 
(NtPPO2) with the bound inhibitor 4-bromo-3-(5’-carboxy-4’-chloro-2’-fluoro-phenyl)-1-
methyl-5-trifluoromethyl-pyrazol and non-covalently bound FAD has been solved recently 
(Fig. 9) (Koch et al., 2004). Furthermore, the M. xanthus structure was published recently 
(Corradi et al., 2006). The structure of NtPPO2 revealed a loosely associated dimer, each 
monomer consisting of a membrane-, a FAD- and a substrate-binding domain, respectively. 
The inhibitor was found to be located in the active site domain and consists of a phenyl- and 
pyrazol-ring system. Even though the FAD is not covalently bound to the enzyme it was 
found in close proximity to the co-crystallized inhibitor in the active site cavity. A potential 
reaction mechanism was proposed based on the fact that the substrate has only limited space 
to rotate in the active site. The six electron oxidation of protoporphyrinogen IX to 
protoporphyrin IX is supposedly catalyzed via three steps. Three times the FAD cofactor is 
reduced by two electrons from the tetrapyrrole ring and re-oxidized by molecular oxygen 
which in turn is reduced to H2O2. The reduction is proposed to start at the C20 atom of the 
tetrapyrrole via enamine-imine-tautomerisation and H-rearrangements (Koch et al., 2004). 
 
 
 
 
Fig. 9: Dimeric structure of mitochondrial tobacco protoporphyrinogen IX oxidase.  
The three-domain monomer consists of a FAD-binding, a substrate-binding and a membrane-binding domain. 
The inhibitor (green) binds into the active site cavity near the cofactor FAD (red–orange). The product channel 
in the membrane-binding domain starts at the bound Triton X-100 detergent molecule (blue). (modified from 
Koch et al., 2004). 
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Very recently PPO has been shown to build a tight complex with FC in vivo (Masoumi et 
al., unpublished data). This complex has been postulated for a long time since the 
intermediate protoporphyrin IX is highly photoreactive and induces cell death when released 
to the cell.  
 
1.5 Heme Biosynthesis in Archaea 
Despite the fact that heme biosynthesis has been investigated for a long time, there are still 
various fundamental questions to be answered. One concerns heme biosynthesis in archaea. 
Archaea have been shown to possess hemes and heme-dependent proteins (Gartner, 1991, 
Lubben and Morand, 1994, Schutz et al., 2000). Furthermore, essential metabolic pathways 
such as methanogenesis in methanogenic archaea are dependent on tetrapyrrole cofactors, 
such as F430 (Thauer and Bonacker, 1994). Nevertheless, the genes necessary for the late 
steps of heme biosynthesis could not be identified (see Tab. 1). 
Tab. 1: Genes for heme biosynthesis in different organisms (modified after Panek and O'Brian, 2002). 
 
The letters B, C, D etc. refer to hemB, hemC, hemD, and so on. Since there are two pathways leading to ALA 
formation, genes for the corresponding enzymes Glu and L for the C5 pathway and A for the Shemin pathway 
are given. 
Organism Genes present [hem] 
   
Eukarya    
Homo sapiens sapiens  A, B, C, D, E, F, Y, H 
     
Bacteria    
Escherichia coli Glu, L, B, C, D, E, F/N, G, H 
Pseudomonas aeruginosa Glu, L, B, C, D, E, F, N, H 
Staphylococcus aureus Glu, L, B, C, D, E, N, Y, H 
Bacillus subtilis Glu, L, B, C, D, E, N, Y, H 
Aquifex aeolicus Glu, L, B, C, D, E, N, Y, H 
Desulfovibrio vulgaris  B, C, D 
     
Archaea    
Sulfolobus solfataricus Glu, L, B, C, D 
Archaeoglobus fulgidus Glu, L, B, C, D 
Methanosarcina barkeri Glu, L, B, C, D 
Halobacterium sp. NRC-1 Glu, L, B, C, D 
Thermoplasma volcanium Glu, L, B, C, D, E, N, H 
 
Biochemical and genomic information indicate that heme biosynthesis starts from ALA 
which is synthesized from glutamate, and proceeds via porphobilinogen, pre-
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uroporphyrinogen and uroporphyrinogen III as intermediates (Diekert et al., 1981, 
Friedmann and Thauer, 1987, Galagan et al., 2002). At this stage the pathway appears to 
deviate from that known to be operative in eukaryotes and most bacteria. In the 
conventional pathway, the four methyl groups of the porphyrin are derived from 
decarboxylation of the acetate groups of uroporphyrinogen III to yield coproporphyrinogen 
III. Thus, all methyl groups and carbons are derived from ALA. Nevertheless, most archaeal 
genomes lack gene homologs of hemE, hemF or N, hemG or Y and hemH encoding the 
enzymes catalyzing the successive conversion of uroporphyrinogen III via 
coproporphyrinogen III, protoporphyrinogen IX and protoporphyrin IX to protoheme  
(Tab. 1) (Panek and O'Brian, 2002). One exception is the genome of Thermoplasma 
volcanium in which gene homologs of hemE, hemN, and hemH are present (Kawashima et 
al., 2000, Panek and O'Brian, 2002).  
1.5.1  A Second Pathway for Heme Biosynthesis in Desulfovibrio vulgaris 
The absence of typical late heme biosynthesis genes in most archaea raises the question for 
an alternate biosynthetic route. For the sulfate-reducing Desulfovibrio vulgaris utilizing 
cytochromes b and c, hemE, hemF or N, hemG or Y and hemH genes have not been 
identified in its known genome sequence (Heidelberg et al., 2004, Matias et al., 2005). The 
synthesis of protoheme in D. vulgaris has been shown to involve precorrin-2 as intermediate 
(Akutsu et al., 1993, Ishida et al., 1998). The formation of precorrin-2, which is a  
2,7-dimethyl derivative of uroporphyrinogen III, is known to proceed in two consecutive 
methylation reactions with SAM as methyl donor (Vevodova et al., 2004). The so far 
observed pathway thus resembles the initial steps of siroheme biosynthesis rather than the 
late steps of heme biosynthesis (see Fig. 10).  
 
 
Fig. 10: Proposed alternate pathway of porphyrin biosynthesis in D. vulgaris. 
 
An alternate pathway for porphyrin biosynthesis from uroporphyrinogen III to coproporphyrinogen III was 
proposed for D. vulgaris (Ishida et al., 1998). A, M, P stand for acetate group, methyl group and propionyl 
group, respectively.  
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The intermediates and proteins involved in precorrin-2 conversion into protoheme in  
D. vulgaris have not yet been identified. In cell extracts of this organism precorrin-2 was 
converted under strictly anaerobic conditions into 12,18-didecarboxyprecorrin-2 indicating 
that the following step is a decarboxylation reaction (Ishida et al., 1998). These are first 
indications for a novel, but most likely ancient pathway, which may apply to archaea as 
well. In Fig. 10 the tetrapyrrole pathway postulated by Ishida and coworkers (Ishida et al., 
1998) for D. vulgaris is depicted. They proposed that porphyrin biosynthesis reenters the 
common pathway at the step of coproporphyrinogen III. 
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1.6 Aim of the Study 
Several open questions related to various steps of heme biosynthesis in bacteria, archaea and 
plants had to be investigated in the cause of this thesis. 
 
1. The target of the inhibitory capacity of the antibiotic alaremycin should be explored 
using inhibition studies with various bacteria and recombinant, purified 
porphobilinogen synthases from various sources. Finally, a crystal structure of 
alaremycin bound to its target enzyme was the ultimate goal.  
 
2. The previously unknown uroporphyrinogen III synthase from plants should be 
functionally identified in close cooperation with the group of Alison Smith at 
Cambridge, UK.  
 
3. The substrate binding of tobacco protoporphyrinogen IX oxidase should be defined 
using site directed mutagenesis and kinetic testing, all based on the known crystal 
structure of the enzyme. 
 
4. Finally, the principal biosynthetic route for the late steps of archaeal heme 
biosynthesis was of interest. 
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2 MATERIALS AND METHODS 
2.1 Instruments and Chemicals 
2.1.1  Instruments 
Agarose gel electrophoresis Agagel Biometra 
Agarose gel documentation GelDoc  Bio-Rad  
Anaerobic chamber Type B Flexible vinyl chamber Coy Laboratories 
Autoclave LVSA 50/70  Zirbus 
Blotting equipment Semidry-Blot Trans-Blot®SD BioRad 
Centrifuges 5415 C  Eppendorf 
 Minispin  Eppendorf 
 RC 5B Plus Sorvall 
 L8-70M ultracentrifuge Beckman 
 Speed Vac SPD 110B  Savant 
DNA sequencing Genetic Analyzer  ABI Prism™ 310  Applied Biosystems  
Electrophoresis power supply  PowerPac 300 BioRad 
Electroporation Gene Pulser II TM BioRad 
Fluorescence spectrometer PA LS50B PerkinElmer 
FPLC  Äkta PurifierTM Amersham Biosciences 
French press French® Pressure Cell Press Amersham Biosciences 
pH-determination pH meter C 6840 B  Schott 
Photometer  Ultrospec 2000 Amersham Bioscience 
Protein concentration cells Amicon 8010 Millipore 
 Amicon 8050 Millipore 
Scales BL 1500 Sartorius 
 BL 61S Sartorius 
 SBA 52 Scaltec 
Scintillation analyzer Tri-Carb 2900 TR Bio-Rad 
SDS-PAGE-system Mini Protean II  Bio-Rad 
Thermocycler Tpersonal Biometra 
 Tgradient Biometra 
Thermomixer  Thermomixer compact  Eppendorf 
Ultrasonic bath  Merck eurolab 
Ultrasound device Sonoplus HD 2070  Bandelin 
UV/visible spectrophotometer Ultrospec 2000 Amersham Biosciences 
 Lambda 2 PerkinElmer 
Vortex Vortex-Genie 2 Scientific Industries 
Water purification Milli-Q System  Millipore 
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2.1.2 Chemicals and Kits 
 
Chemicals and reagents not specifically listed here were purchased from the following 
manufacturers: Amersham Biosciences, Fluka, Gerbu, Merck, Roth, Sigma. 
 
 
5-aminolevulinic acid Sigma 
[14C]-5-aminolevulinic acid PerkinElmer 
BigDye Terminater v1.1 Cycle Sequencing Kit Applied Biosystems 
Coproporphyrin IX Porphyrin Products 
Crystal Screen and Crystal Screen 2  Hampton Research 
CrystalClear strip racks  Douglas Instruments 
Enzymes for molecular biological applications MBI Fermentas, New England Biolabs, Amersham 
Biosciences, Promega, Qiagen 
FAD Sigma 
Fibrous cation exchange resign  Whatman 
Dialysis visking, type 27/32 exclusion 14000 Roth 
Glutathione sepharose XK26 column Amersham Biosciences 
Hemin Fluka 
L-[methyl-14C]methionine Amersham Biosciences 
L-[methyl-D3]methionine Sigma 
Micro BCA Protein Assay Kit Pierce 
Ni-IDA resign Macherey Nagel 
Ni-chelating Sepharose Fast Flow Amersham Biosciences 
Opti-Phase HiSafe2 (scintillation cocktail) PerkinElmer 
Porphobilinogen Porphyrin Products 
Prepacked PD10 columns General Electric Company 
PreScissionTM Protease Amersham Biosciences 
Protoporphyrin IX Porphyrin Products 
QIAquick Gel Extraction Kit Qiagen 
QIAquick PCR Purification Kit Qiagen 
S•Tag Rapid Assay Kit Merck 
S-adenosyl-L-[methyl-14C]methionine Amersham Biosciences 
Size standards for agarose gels  
GeneRulerTM DNA Ladder Mix MBI Fermentas 
MassRulerTM DNA Ladder Mix MBI Fermentas 
Size standards for SDS-PAGE  
Protein Molecular Weight Marker MBI Fermentas 
Superdex 200 HR 10/30 General Electric Company 
Uroporphyrin III Porphyrin Products 
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2.2 Strains and Plasmids 
All strains and plasmids used for this work are listed in Tab. 2 and Tab. 3. 
 
Tab. 2: Employed bacterial and archaeal strains. 
 
 
Strain Description  Reference 
   
Escherichia coli DH10b F- mcrA ∆(mrr-hsdRMS-mcrBC) 
Φ80lacZ∆M15 ∆lacX74 recA1 endA1 
ara∆139 ∆(ara, leu)7697 galU galK λ- rpsL 
(StrR) nupG 
 
Invitrogen 
Escherichia coli 
BL21(DE3)RIL 
F- ompT hsdS(rB- mB-) dcm+ Tetr gal ∆(DE3) 
endA The[argU ileY leuW Camr] 
 
Stratagene 
Escherichia coli EV61  thr-l ara-14 leuB6 A(gpt-proA)62 lacYl tsx-33 
supE44 galK2 Rac- hisG4 rfbDl mgl-51 rpsL31 
kdgK51 xyl-5 mtl-l argE3 thi-J recB21 recC22 
sbcBJ5 sbcC201 λ- ΔhemA::kan, Kanr 
 
Verkamp and Chelm, 
1989 
Escherichia coli CSA Hemepermable variant of E. coli EV61 
designed by chemical mutagenesis ∆hemA, env 
 
Claudia Schulz,  
TU Braunschweig 
Bacillus subtilis JH652 trpC2 pheA1 Bacillus Genetic Stock 
Center 1A96 
 
Bacillus megaterium   
DSM 319 
 
 Hunger and Claus, 1981 
Pseudomonas aeruginosa 
strain PAO1 
 
 Dunn and Holloway, 1971
Staphylococcus aureus 
DSM 20714 
 
 Schleifer and Kocur, 1973
Streptomyces sp. A012304 
 
 Awa et al., 2005 
Streptomyces coelicolor  
DSM 40233 
 
 Berger and Edberg, 1987, 
Skerman et al., 1980 
 
Streptomyces avermitilis 
DSM 46492 
 
 Burg et al., 1979 
 
Methanosarcina barkeri  
strain Fusaro, DSM 804 
 Kandler and Hippe, 1977 
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Tab. 3: Plasmids used in this study. 
 
 
 
 
Plasmid Description  Reference 
   
pET32a Expression vector carrying C-terminal His- 
Tag® and S●tag sequence, T7 promoter, ampr 
 
Novagen 
 
pGEX-6P-1 Expression vector carrying N-terminal sequence for 
GST from Schistosoma japonicum and recognition 
sequence for PreScission™ Protease, lac promoter, ampr 
 
Amersham Biosciences 
pIH45 pET32a derivative encoding PBGS from M. barkeri  
 
this work 
pGEXPahemB pGEX-6P-1 derivative encoding P. aeruginosa PBGS  
 
Frankenberg et al., 1999 
pUROSfull pET28a derivative encoding A.  thaliana UROS 
 
Alison Smith, Cambridge, 
UK 
pUROSmat pET28a derivative encoding A. thaliana UROS missing 
the first 81 amino acids  
 
Alison Smith, Cambridge, 
UK 
pIH41 pETcoco2 derivative enconding M. barkeri cobA, 
Methanothermobacter thermoautotrophicum hemB and 
B. megaterium hemC and hemD 
 
Evelyne Deery, Kent, UK 
pIH1 pET32a derivative encoding mitochondrial PPO from  
N. tabacum; Mutation from lysine 244 to glutamine 
(K224Q). Resulting protein is referred to as wildtype 
protein 
 
Koch et al., 2004 
pIH2 pIH, with exchange of triplet CGC (nucleotides 292-
294) to AAG, protein carries Lys instead of Arg 
 
this work 
pIH3 pIH, with exchange of triplet CGC (nucleotides 292-
294) to GAG, protein carries Glu instead of Arg 
 
this work 
pIH4 pIH, with exchange of triplet CGC (nucleotides 292-
294) to GCC, protein carries Ala instead of Arg 
 
this work 
pIH5 pIH, with exchange of triplet CTT (nucleotides 1066-
1068) to AAT, protein carries Asn instead of Lys 
 
this work 
pIH6 pIH, with exchange of triplet CTT (nucleotides 1066-
1068) to GTT, protein carries Val instead of Lys 
 
this work 
pIH7 pIH, with exchange of triplet CTC (nucleotides 1114-
1116) to AAC, protein carries Asn instead of Lys 
 
this work 
pIH8 pIH, with exchange of triplet CTC (nucleotides 1114-
1116) to GTC, protein carries Val instead of Lys 
 
this work 
pIH9 pIH, with exchange of triplet TTT (nucleotides 1174-
1176) to CAT, protein carries His instead of Phe 
 
this work 
pIH10 pIH, with exchange of triplet TTT (nucleotides 1174-
1176) to GAG, protein carries Glu instead of Phe 
 
this work 
pIH11 pIH, with exchange of triplet TCT (nucleotides 1120-
1122) to GAT, protein carries Asp instead of Ser 
 
this work 
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2.3 Growth Media and Media Additives 
2.3.1 Growth Media 
As a standard medium for growth of all bacterial strains Luria Bertani (LB) medium was 
used (Sambrook, 1989), unless indicated otherwise. For the production of recombinant 
PBGS, UROS and PPO wildtype and mutant proteins, E. coli BL21(DE3)RIL carrying the 
respective plasmids were grown in LB media. Minimal inhibitory concentrations (MIC) for 
alaremycin were determined in complex and defined media. LB-medium was used for most 
strains except for S. avermitilis which was cultured in medium DSM425 and S. coelicolor 
which was grown in medium DSM65. Minimal media were prepared as following.  
P. aeruginosa was grown in AB minimal medium, B subtilis, B. megaterium, S. coelicolor 
and S. avermitilis in SMM minimal medium, E. coli in M9 minimal medium containing  
20 µM hemin for E. coli CSA. S. sp. A012304 was grown in seed medium for 4 days for 
genomic DNA extraction or in production medium for 5 days for alaremycin production. All 
strains were grown at 37°C and 200 rpm, except for the Streptomyces strains which were 
cultivated at 25°C and 150 rpm. M. barkeri was grown in low salt media under strictly 
anaerobic conditions for two to seven days at 37°C as described before (Karrasch et al., 
1989). Goethe, 1808  
All media were autoclaved for 20 min at 121°C. For solid media 1.5 % (w/v) agar-agar was 
added before sterilization. 
LB medium tryptone 1.0 % (w/v) 
 yeast extract 0.5 % (w/v) 
 NaCl 0.5 % (w/v) 
 in H2Odest; pH 7.0   
    
DSM425 medium oat meal 2.0 % (w/v) 
 in H2Odest; pH 7.2   
    
pIH12 pIH, with exchange of triplet TCT (nucleotides 1120-
1122) to GAT, protein carries Asp instead of Ser and 
exchange of triplet AAT (nucleotides 199-201) for 
CGT, protein carries Arg instead of Asn 
 
this work 
pIH13 pIH, with exchange of triplet TCT (nucleotides 1120-
1122) to GAT, protein carries Asp instead of Ser and 
exchange of triplet AAT (nucleotides 199-201) for 
TGG, protein carries Trp instead of Asn 
 
this work 
pIH46 pIH, with exchange of triplet AAT (nucleotides 199-
201) to CGT, protein carries Arg instead of Asn 
 
this work 
pIH47 pIH, with exchange of triplet AAT (nucleotides 199-
201) to TGG, protein carries Trp instead of Asn 
this work 
Materials and Methods
 
 
 
28
DSM65 medium glucose 0.4 % (w/v) 
 yeast extract 0.4 % (w/v) 
 malt extract 1.0 % (w/v) 
 in H2Odest; pH 7.2   
 
AB medium salt solution 1 10.0 % (v/v) 
 trace element solution 1 0.1 % (v/v) 
 MgCl2 x 6 H2O 0.02 % (w/v) 
 CaCl2 x 6 H2O 0.0015 % (w/v) 
 FeSO4 x 4 H2O 0.00056 % (w/v) 
 NaNO3 0.425 % (w/v) 
 glucose 0.36 % (w/v) 
 in H2Odest; pH 7.0   
    
salt solution 1 (NH4)2SO4 2 % (w/v) 
 Na2HPO4 4.8 % (w/v) 
 KH2PO4 3 % (w/v) 
 NaCl 2.9 % (w/v) 
 in H2Odest; pH 7.0   
    
trace element solution 1 CaSO4 x 2 H2O 0.02 % (w/v) 
 FeSO4 x 7 H2O 0.02 % (w/v) 
 MnSO4 x H2O 0.002 % (w/v) 
 CuSO4 x 5 H2O 0.002 % (w/v) 
 ZnSO4 x 7 H2O 0.002 % (w/v) 
 CoSO4 x 7 H2O 0.001 % (w/v) 
 Na2MoO4 x H2O 0.001 % (w/v) 
 H3BO4 0.0005 % (w/v) 
 in H2Odest; pH 7.0   
 
M9 medium salt solution 2 10.0 % (v/v) 
 glucose 0.02 % (w/v) 
 MgSO4 0.012 % (w/v) 
 thiamine hydrochloride 0.0005 % (w/v) 
 leucine hydrochloride 0.001 % (w/v) 
 in H2O; pH 7.0   
 
salt solution 2 Na2HPO4 6.0 % (v/v) 
 KH2PO4 3.0 % (w/v) 
 NH4Cl 1.0 % (w/v) 
 NaCl 0.5 % (w/v) 
 CaCl2 0.003 % (w/v) 
 in H2O; pH 7.0   
 
SMM medium (NH4)2SO4 0.2 % (w/v) 
 K2HPO4 1.4 % (w/v) 
 KH2PO4 0.6 % (w/v) 
 Na3 citrate x 2 H2O 0.1 % (w/v) 
 MgSO4 x 7 H2O 0.02 % (w/v) 
after autoclaving addition of: SMM mix 10.0 % (v/v) 
 trace element solution 2 1.0 % (v/v) 
 in H2Odest; pH 7.0   
    
SMM mix thiamine hydrochloride 0.001 % (w/v) 
 glucose monohydrate 10.0 % (w/v) 
 sodium pyruvate 5.5 % (w/v) 
 casamino acids 0.1 % (w/v) 
 in H2Odest; pH 7.0   
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trace element solution 2 CaCl2 x 2 H2O 0.08 % (w/v) 
 FeCl2 x 4 H2O 0.115 % (w/v) 
 MnCl2 x 4 H2O 0.01 % (w/v) 
 ZnCl2 0.017 % (w/v) 
 CuCl2 x 2 H2O 0.004 % (w/v) 
 CoCl2 x 6 H2O 0.006 % (w/v) 
 Na2MoO4 x 2 H2O 0.006 % (w/v) 
 in H2Odest; pH 7.0   
 
Seed medium glucose 4 % (w/v) 
 dry bouillon 1 % (w/v) 
 soy bean meal 0.3 % (w/v) 
 CaCO3 0.3 % (w/v) 
 in H2Odest; pH 7.0   
    
Production medium dextrin 6 % (w/v) 
 yeast extract 2 % (w/v) 
 NaCl 0.3 % (w/v) 
 CaCO3 0.3 % (w/v) 
 dry bouillon 0.1 % (w/v) 
 K2HPO4 0.1 % (w/v) 
 in H2Odest; pH 8.5   
 
Low salt medium salt solution 3 20 % (v/v) 
 trace element solution 3 1 % (v/v) 
 vitamin solution 1 % (v/v) 
 methanol 1 % (v/v) 
 resazurine solution 0.1 % (v/v) 
after anaerobization addition of: cysteine hydrochloride 0.07 % (w/v) 
 in H2Odest; pH 7   
after autoclaving addition of: sodium sulfide solution 0.002 % (v/v) 
    
salt solution 3 imidazole 1.35 % (w/v) 
 NaH2PO4 x H2O 0.0345 % (w/v) 
 Na2HPO4 x 2 H2O 0.044 % (w/v) 
 CaCl2 x 2 H2O 0.25 % (w/v) 
 MgCl2 x 6 H2O 0.4 % (w/v) 
 NH4Cl 0.25 % (w/v) 
 KCl 0.2 % (w/v) 
 NaCl 2 % (w/v) 
 in H2Odest; pH 6.4   
    
 
trace element solution 3 tritiplex 0.15 % (w/v) 
 pH 6.4 with KOH   
 MnSO4 0.05 % (w/v) 
 FeSO4 x 7 H2O 0.01 % (w/v) 
 CoCl2 x 6 H2O 0.01 % (w/v) 
 ZnSO4 x 5 H2O 0.001 % (w/v) 
 CuSO4 x 5 H20 0.001 % (w/v) 
 AlCl3 x 6 H2O 0.001 % (w/v) 
 H3BO3 0.001 % (w/v) 
 Na2MoO4 x 2 H2O 0.001 % (w/v) 
 NiCl2 x 6 H2O 0.003 % (w/v) 
 NaHSeO3 0.0015 % (w/v) 
 in H2Odest; pH 7   
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vitamin solution d-Biotin 0.0002 % (w/v) 
 folic acid 0.0002 % (w/v) 
 pyridoxin-hydrochloride 0.001 % (w/v) 
 thiamine-hydrochloride 0.0005 % (w/v) 
 riboflavin 0.0005 % (w/v) 
 nicotinic acid 0.0005 % (w/v) 
 D-L-Ca-pantothenate 0.0005 % (w/v) 
 vitamin B12 0.00001% (w/v) 
 p-aminobenzoic acid 0.0005 % (w/v) 
 D-L-α-liponate 0.0005 % (w/v) 
 in H2Odest   
    
resazurine solution resazurine 0.2 % (w/v) 
 in H2Odest   
    
sodium sulfide solution Na2S 2.8 % (w/v) 
 in H2Odest   
 
2.3.2 Media Additives 
Antibiotics and other additives were prepared as concentrated stock solutions, sterilized by 
filtration and added to the medium after autoclaving. Solutes and concentrations are 
summarized in Tab. 4. For the hemin stock solution, hemin was slowly diluted to 50 mL 
with H2O and a few drops of 5 M KOH were added to support solubilization. 
Tab. 4: Media additives 
 
 
2.4 Microbiological Techniques 
2.4.1 Sterilization 
All media were vapor sterilized at 121°C and 1 bar positive pressure for 20 min. Other 
substances and solutions were either vapor sterilized or, if temperature sensitive, sterilized 
by filtration (pore width 0.2 μm). 
2.4.2  Cultivation of Bacteria and Archaea 
Cells for recombinant protein production were grown under vigorous aeration. Pre-cultures 
(volume 100 mL) of E. coli BL21(DE3)RIL containing appropriate plasmids were grown 
overnight at 37°C and 200 rpm. 500 mL cultures were grown at 37°C until induction of 
Substance Solute  Concentration of stock 
solution 
Final concentration 
      
ampicillin H2O 100 mg/mL 100 µg/mL 
chloramphenicol ethanol (70 % (v/v)) 34 mg/mL 34 µg/mL 
hemin H2O; KOH 4 mg/mL 40 µg/mL 
isopropyl-1-thio-ß-D-
galactopyranoside (IPTG) 
H2O 1 M 100-250 µM 
kanamycin H2O 50 mg/mL 50 µg/mL 
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protein production with indicated amounts of IPTG. After induction cultures were incubated 
at 25°C overnight. For the generation of cell free extracts, strains P. aeruginosa, B. subtilis, 
B. megaterium, S. aureus, E. coli and E. coli CSA were grown at 37°C for 24 h at 200 rpm. 
S. avermitilis, S. coelicolor and S. sp. A012304 were grown at 25°C for 48 hours at  
150 rpm. Medium for M. barkeri was depleted of oxygen prior to inoculation with an 
actively growing M. barkeri culture in an anaerobic chamber. Cells were cultured under 
strictly anaerobic conditions for two to seven days at 37°C with repeated degassing. Flasks 
containing M. barkeri were submitted to a positive pressure of 0.2 bar to prevent intake of 
oxygen, since cells exposed to oxygen were hardly recovered for active growth. 
Agar plates were either utilized for plating 50 - 100 µL of a bacterial cell suspension with a 
Drigalski spatula, or for streaking cells with an inoculating loop with liquid culture or with a 
single colony. Plates were incubated aerobically at 37°C overnight, except for all 
Streptomyces strains which were incubated at 25°C for up to four days. 
2.4.3 Determination of Cell Density 
The cell density of liquid cultures was determined by measuring the optical density (OD) at 
a wavelength of 578 nm. For cell densities with an OD578 ≥ 0.6 dilutions were prepared 
before the measurement. An OD578 of 1 corresponds to approximately 1 x 109 E. coli 
cells/mL. In microtitre plates the optical density was determined at an OD600. 
2.4.4 Storage of Bacterial Strains 
Strains were kept on agar plates at 4°C for up to four weeks. For long-term storage glycerol 
stocks were prepared. For this purpose cultures were grown for 6 to 8 h, cooled on ice for  
30 min and 500 μL of the culture mixed with 500 μL of sterile glycerol (80 % (v/v)). Stocks 
were immediately frozen and kept at - 80°C. 
2.4.5 Determination of Minimal Inhibitory Constants 
MICs for alaremycin were determined in complex and defined media for B. subtilis,  
B. megaterium, P. aeruginosa, E. coli, S. coelicolor, S. avermitilis, S. sp. A012304,  
S. aureus and E. coli CSA, respectively, using a microdilution technique. An overnight 
culture was diluted in fresh media to achieve a cell density of an OD578 = 0.2. A volume of 
100 µL cell suspension was then added to 100 µL antibiotic serially diluted in the 
corresponding medium. For all strains at least four independent growth curves over a time 
period of 24 h with different alaremycin concentrations were recorded. The MIC was 
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considered to be the concentration at which the antibiotic prevented turbidity in the well for 
at least five hours at 37°C. 
 
2.5  Molecular Biology Techniques 
2.5.1 Preparation of DNA 
2.5.1.1 Preparation of Genomic DNA 
The respective strains were grown for an appropriate incubation time to yield 50 mL high 
density cell suspension and were harvested by centrifugation (5 min at 7,000 x g). Cell were 
washed once in TE buffer and suspended in 4 mL lysis buffer supplemented with  
0.2 mg/mL RNase A and 50 µg lysozyme. The samples were incubated at 37°C for 45 min. 
After addition of 500 µL N-laurosylsarcosinine (20 % (w/v)) and further incubation for  
5 min at 37°C the suspension was mixed with one volume of phenol and incubated under 
constant motion for 30 min at room temperature (RT). After subsequent centrifugation  
(20 min at 7,000 x g) the upper, aqueous phase was transferred into a fresh tube and 
submitted to 4 mL phenol/chloroform/isoamylalcohol (24:24:1). Following 15 min of 
incubation, samples were again centrifuged and the phenol-chloroform extraction was 
repeated. The upper, aqueous phase of this step was again transferred into a fresh tube and 
DNA precipitation initiated by addition of 10 mL pure ethanol and 500 µL of a 3 M sodium 
acetate solution (pH 4.8). The sample was centrifuged at 4°C for 30 min (7,000 x g and 4°C) 
and the DNA washed twice with 70 % (v/v) ethanol. After evaporation of residual ethanol, 
the DNA was solubilized in 200 μL TE buffer and stored at 4°C. 
Lysis buffer NaCl 0.6 % (w/v) 
 EDTA 7.3 % (w/v) 
 in H2Odest; pH 8.0   
TE buffer Tris-HCl 10.0 mM 
 EDTA 1.0 mM 
 in H2Odest; pH 8.0   
 
2.5.1.2 Preparation of Plasmid DNA (Mini Prep) 
4.5 mL of an overnight culture were harvested by centrifugation (5 min at 7,000 x g and 
4°C) and cells suspended in 300 μL of buffer P1. 300 μL of buffer P2 were added, the 
sample was carefully mixed by inverting the tube and incubated at RT for 5 min. Next,  
300 μL of buffer P3 were added, the sample was again carefully mixed and further 
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incubated in ice for 5 min. Following centrifugation (15 min at 15,000 x g and 4°C) 800 μL 
of the supernatant were added to 600 μL isopropanol in a fresh tube. Precipitation of 
plasmid DNA was allowed to proceed during a 10 min incubation step at 4°C, followed by a 
30 min centrifugation step at 4°C (15,000 x g). The DNA was washed twice with 70 % (v/v) 
ethanol. After all traces of ethanol had evaporated, the DNA was solubilized in  
50 - 100 μL H2Odest. 
Buffer P1 Tris-HCl 50.0 mM 
 ethylene diamine 
tetraacetic acid (EDTA) 
10.0 mM 
 RNaseA 200. µg/mL 
 in H2Odest; pH 8.0   
    
Buffer P2 NaOH 200.0 mM 
 sodium dodecyl sulfate 
(SDS) 
1.0 % (w/v) 
 in H2Odest; pH 8.0   
    
Buffer P3 potassium acetate 3.0 M 
 in H2Odest; pH 5.5   
 
2.5.2 Determination of DNA Concentration 
The concentration of a DNA solution was determined by measuring the absorbance at  
260 nm and additionally at 280 nm to account for protein impurities. For a pure DNA 
solution an OD260 of one corresponds to a dsDNA concentration of 50 μg/mL. The puritiy of 
the DNA solution can be deduced from the ratio of OD260 to OD280. With an OD260/OD280 
ratio of 1.8 – 2.0 the DNA was considered as pure. 
2.5.3 Transformation of Bacteria by the RbCl2 Method 
E. coli cells were grown aerobically in 500 mL vapor sterilized LB medium containing the 
required additives. When the culture reached an OD578 of 0.6 cells were harvested by 
centrifugation (10 min at 6,000 x g and 4°C), suspended in 200 mL TFB1 and incubated on 
ice for 5 min. After subsequent centrifugation (5 min at 3,000 x g and 4°C) cells were 
suspended in 2 volumes of TFB2 (referring to the volume of the cell sediment), incubated 
on ice for 30 min and divided into 40 μL aliquots. These were either immediately used for 
transformation or stored at – 80°C 
TFB1 potassium acetate 30 mM 
 CaCl2 10 mM 
 MnCl2 50 mM 
 RbCl2 100 mM 
 glycerol 15 % (v/v) 
 in H2Odest; pH 5.8   
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TFB2 MOPS 10 mM 
 CaCl2 75 mM 
 RbCl 10 mM 
 glycerol 15 % (v/v) 
 in H2Odest; pH 6.5   
 
Transformation of chemocompetent cells was applied as standard transformation method.  
40 μL of RbCl2-competent cells were combined with 1 - 2 μL DNA solution (50 µg/mL) 
and subjected to a heat shock for 45 s at 42°C. Immediately after the transformation cells 
were cooled on ice for 2 min. Afterwards 1 mL of preheated LB medium was added and 
cells were incubated at 37°C for 1 h. Depending on the expected colony density, different 
volumes were then streaked on agar plates containing the appropriate antibiotics and plates 
were incubated overnight at 37°C. 
2.5.4 Electrophoretic Separation of DNA 
For the analytical separation of DNA fragments, agarose gels consisting of 1 % (w/v) 
agarose in TAE buffer were prepared. For exceptionally small DNA fragments (below  
1000 bp) the agarose concentration was increased to 1.3 % (w/v). Depending on the size of 
the gel, a voltage of 80 - 100 V was applied. DNA fragments migrate towards the anode 
with a velocity that is proportional to the negative logarithm of their size. Prior to loading, 
DNA samples were mixed with loading dye to facilitate loading and to indicate the progress 
of the samples in the gel. GeneRuler™ DNA Ladder Mix or MassRuler™ DNA Ladder Mix 
were used as size standard according to the manufacturer’s instructions. After 
electrophoresis, gels were incubated in an ethidium bromide solution for 10 - 30 min, rinsed 
with H2O and the DNA was detected via its fluorescence under UV light (λ = 312 nm). In 
cases where DNA fragments were to be extracted from the gel, extraction was carried out 
using the QIAquick Gel Extraction Kit according to the manufacturer’s instructions. 
TAE buffer Tris-acetate 40.0 mM 
 EDTA 1.0 mM 
 in H2Odest; pH 8.0   
    
DNA loading dye bromphenol blue 0.35 mM 
 xylene cyanol FF 0.45 mM 
 orange G 0.25 mM 
 sucrose 115.0 mM 
 in H2Odest   
     
ethidium bromide solution ethidium bromide  0.1 % (v/v) 
 in H2Odest    
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2.5.5 Site-Directed Mutagenesis of DNA 
Single amino acids in a protein of interest can be exchanged by inserting site-specific 
mutations into the DNA sequence of the corresponding gene. The QuikChange Site-directed 
Mutagenesis Kit was employed in this work for mutational analysis of NtPPO2. The 
method, which is illustrated in Fig. 11, utilizes a dsDNA plasmid carrying the gene of 
interest and two synthetic oligonucleotide primers which contain the desired mutation (see 
Tab. 5) and are complementary to opposite strands of the vector. During polymerase chain 
reaction (PCR) with PfuTurbo DNA polymerase a mutated plasmid is generated. The PCR 
product is treated with DpnI, an endonuclease specifically digesting partially methylated 
DNA, here the parental template DNA. This allows isolation of the newly synthesized 
unmethylated DNA of the mutated plasmid, which is subsequently transformed into a 
suitable E. coli strain where DNA ligase closes the nicked DNA circles. 
 
 
 
Fig. 11: Outline of the QuikChange Procedure. 
 
Overview of the QuikChange Site-Directed Mutagenesis method (modified from Stratagene Instruction 
Manual, 1998). — parental DNA, — mutated DNA, X position of the desired mutation, Æ mutagenic primer,  
X introduced mutation. A detailed description is given in the text. 
 
PCR reactions with the QuikChange Site-Directed Mutagenesis Kit were carried out 
according to manufacturer’s instructions. Mutated plasmids were transformed into 
chemocompetent E. coli DH10b cells. Oligonucleotide primers listed in Tab. 5 and 
nucleotides exchanged in comparison to the wild type sequence are underlined. All mutated 
genes were subjected to DNA sequence determination. 
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Tab. 5: Oligonucleotide primers used for site-directed mutagenesis of tobacco protoporphyrinogen IX 
oxidase.  
 
 
Only oligonucleotide primers in forward orientation are listed. The second oligonucleotide (reverse) always 
corresponds to the reverse complementary sequence. 
 
2.5.6 Amplification of DNA Fragments by PCR 
2.5.6.1 Design and Synthesis of Oligonucleotide Primers 
Oligonucleotide primers for the amplification of the gene hemB from M. barkeri with the 
aim of subsequent cloning vector pET32a were designed. Recognition sequences for 
restriction endonucleases were inserted via these primers at both ends of the genes. 
Oligonucleotide primers are listed in Tab. 6. Recognition sequences of restriction 
endonucleases are underlined.  
 
Tab. 6: Oligonucleotide primers used for the amplification of DNA fragments.  
 
“Fwd” refers to forward primer and “rev” to reverse primer. 
 
Primer designation Sequence of oligonucleotide primer (5´Æ 3´) Additional information 
   
MbhemB-fwd CCGGAATTCCGGATGTTTCCAGATGTCAGGTTAAG EcoRI restriction site 
MbhemB-rev CCGCTCGAGCGGTTACTTCAACATGCGGGCAGC XhoI restriction site 
 
For subsequent cloning into the vector pET32a M. barkeri hemB (975 bp) was amplified 
using primers MbhemB-fwd and MbhemB-rev.  
 
Mutant designation Sequence of oligonucleotide primer (forward) (5´Æ 3´) 
  
R98A CCACTTTCACAAAACAAGGCCTACATTGCCAGAAATGG 
R98K CCACTTTCACAAAACAAGAAGTACATTGCCAGAAATGG 
R98E CCACTTTCACAAAACAAGGAGTACATTGCCAGAAATGG 
L356N GGGCTTTGGGGTTAATGTACCTTCCAAGGAGC 
L356V GGGCTTTGGGGTTGTTGTACCTTCCAAGGAGC 
L372N GACACTAGGCACCAACTTCTCTTCTATGATGTTTCC 
L372V GACACTAGGCACCGTCTTCTCTTCTATGATGTTTCC 
F392H CTCTATACTACTCATGTTGGTGGAAGCC 
F392E CTCTATACTACTGAGGTTGGTGGAAGCC 
N67R GGGATGAAGGGGCACGTACTATGACTG 
N67W GGGATGAAGGGGCATGGACTATGACTG 
S374D GACACTAGGCACCCTCTTCGATTCTATGATGTTTCC 
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2.5.6.2 PCR Conditions 
Taq DNA polymerase (Qiagen) was used for all reactions. After an initial DNA 
denaturation step, a cycle consisting of the three steps denaturation, primer annealing and 
primer elongation was completed 30 times and the reaction terminated by a final elongation 
step. The denaturation temperature of 95°C and the elongation temperature of 72°C 
remained unchanged. The annealing temperature depended on oligonucleotide length and 
G+C content and was furthermore influenced by the insertion of mismatches. The Tm was 
calculated as following: 
 
Tm [°C] = 69.3 + 0.41 (% G+C) - 650/n 
% G+C represented the G+C content of the primer in % and n represented the number of 
nucleotides. 
 
The duration of the elongation step was chosen according to the length of the DNA 
fragment to be amplified according to manufacturer’s instructions. 
Standard thermocycler program 95 ° C 5 min   
 95 ° C 1 min  
 50-60 ° C 30 s 30 x 
 71 ° C 1-4 min   
 71 ° C 5-10 min   
 4 ° C ∞    
     
2.5.6.3 Purification of PCR Products 
For quality controls of the amplified DNA, an aliquot of the reaction mixture was analyzed 
by agarose gel electrophoresis. By detection of one PCR product only, the entire sample was 
subjected to purification with the QIAquick PCR Purification Kit. If additional PCR 
products were detected, the entire reaction mixture was electrophoretically separated. The 
DNA fragment of interest was then excised from the gel and purified using the QIAquick 
Gel Extraction Kit. All kits were used according to the manufacturer’s instructions. 
 
2.5.7 Enzymatic Modification of DNA 
2.5.7.1 Restriction of DNA with Restriction Endonucleases 
Restriction of DNA (vectors and PCR products) was carried out using restriction 
endonucleases purchased from New England BioLabs. Reaction buffers, concentrations of 
enzymes and DNA as well as incubation temperatures were chosen according to the 
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manufacturer’s instructions. The digestion was allowed to proceed for 2 - 3 h and was, if 
possible, followed by heat inactivation of the restriction endonucleases (20 min at 65°C or 
80°C, depending on the enzyme). 
2.5.7.2 Ligation 
In order to avoid re-circularization of digested vector DNA, the 5’-phosphate groups of 
linearized vectors were removed prior to the ligation reaction. This was achieved by adding 
antarctic alkaline phosphatase (New England BioLabs) to the sample immediately after 
restriction (1 U /μg DNA) and incubation at 37°C for 30 min, followed by heat inactivation 
(15 min at 65°C). Ligation of DNA was carried out using T4 DNA ligase (MBI Fermentas) 
in a reaction buffer supplied by the manufacturer. An amount of  25 - 50 ng vector DNA 
was mixed with insert DNA in excess (insert to vector ratio with regard to molar 
concentrations ≈ 5:1). 1 - 2 U of T4 DNA ligase were added.  
2.5.7.3 DNA Sequencing 
DNA sequences were obtained with an Abi PrismTM 310 Genetic Analyzer in our 
laboratory. The required preparatory PCR with fluorescence-labeled ddNTPs and 
purification of the PCR product were carried out as described by the manufacturer. 
 
2.6 Protein Biochemical Methods 
2.6.1 Production and Purification of Pseudomonas aeruginosa 
Porphobilinogen Synthase 
2.6.1.1 Cell Growth for Protein Production 
10 x 500 mL vapor sterilized LB medium containing 100 µg/mL ampicillin and 34 µg/mL 
chloramphenicol in 1 L Erlenmeyer flasks were each inoculated with 5 mL of an overnight 
culture of E. coli BL21(DE3)RIL carrying  pGEXPahemB. Cultures were grown at 37°C 
and 200 rpm to an OD578 of 0.6 and expression of hemB was induced by addition of IPTG to 
a final concentration of 500 µM. Incubation was continued overnight at 25°C and 150 rpm. 
Cells were harvested by centrifugation for 15 min at 4,000 x g and 4°C. 
2.6.1.2 Cell Disruption 
The cell sediment was suspended in 10 mL PBS buffer containing 1 mM 
phenylmethanesulfonyl fluoride (PMSF). Cells were disrupted by a single passage through a 
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French Press at 1,500 p.s.i. Cell debris and insoluble protein fraction were removed by 
centrifugation for 45 min at 4°C and 25,000 x g. The resulting supernatant was loaded onto 
a glutathione sepharose column. All steps were performed at 4°C, protein solutions were 
stored on ice. 
2.6.1.3 First Affinity Chromatography Using Glutathione Sepharose 
The purification protocol for PaPBGS was established by Nicole Frankenberg in our 
laboratory (Frankenberg et al., 1999). A 12 mL glutathione sepharose column was 
equilibrated with 5 column volumes of PBS buffer containing 1 mM PMSF. After loading 
the supernatant, the column was washed with 10 column volumes of PBS containing 1 mM 
PMSF to remove unbound proteins (flow rate 1 mL/min). The PaPBGS-GST fusion protein 
was then eluted with elution buffer at a flow rate of 1 mL/min. The eluate was collected in  
1 mL fractions. Fractions containing PaPBGS-GST were identified by SDS polyacrylamide 
gel electrophoresis (SDS-PAGE), pooled and concentrated by ultrafiltration. Concentrated 
protein solutions were dialyzed overnight at 4°C against PreScission protease buffer. 
 
PBS buffer NaCl 140.0 mM 
 KCl 2.7 mM 
 Na2HPO4 10.0 mM 
 KH2PO4 1.8 mM 
 PMSF 1.0 mM 
 in H2Odest; pH 7.4   
 
Elution buffer Tris-HCl 50.0 mM 
 glutathione 10.0 mM 
 NaCl 150.0 mM 
 in H2Odest; pH 7.4   
    
PreScission protease buffer Tris-HCl 50.0 mM 
 NaCl 150.0 mM 
 EDTA 1.0 mM 
 dithiothreitol 1.0 mM 
 in H2Odest; pH 7.0   
 
2.6.1.4 PreScission™ Protease Cleavage and Second Affinity 
Chromatography 
PreScission™ Protease cleaves site-specifically at its recognition sequence between the 
GST domain and the target protein. 70 U of PreScissionTM Protease were added to the 
pooled and concentrated protein solution with the subsequent cleavage reaction proceeding 
in PreScissionTM protease buffer at 4°C overnight. A second affinity chromatography with 
glutathione sepharose was then performed to remove the separated GST-tag, uncleaved 
PaPBGS-GST fusion protein and the PreScissionTM protease, which is also a fusion with 
Materials and Methods
 
 
 
40
GST. The 12 mL glutathione sepharose column was again equilibrated with 5 column 
volumes of PBS buffer and the protein solution was loaded onto the column. The column 
was washed with PBS buffer and PaPBGS was collected with the flow through. In a final 
step the column was treated with elution buffer, thereby eluting the GST-tag, uncleaved 
fusion protein and PreScissionTM Protease. All steps were monitored by SDS-PAGE-
analysis. Fractions containing PaPBGS were again pooled and concentrated by 
ultrafiltration. 
 
2.6.2 Production and Purification of Methanosarcina barkeri 
Porphobilinogen Synthase 
2.6.2.1 Cell Growth for Protein Production 
Recombinant M. barkeri PBGS (MbPBGS) was produced using E. coli strain 
BL21(DE3)RIL. 10 x 500 mL vapor sterilized LB medium containing 100 µg/mL ampicillin 
and 34 µg/mL chloramphenicol in 1 L Erlenmeyer flasks were each inoculated with 5 mL of 
an overnight culture of E. coli BL21(DE3)RIL carrying pIH45. Cells were grown in LB 
medium at 37°C and 200 rpm until cultures reached an OD578 of 0.6. Gene expression was 
induced by the addition IPTG to a final concentration of 150 µM. Cells were further 
cultivated overnight at 17°C, 150 rpm and subsequently harvested. 
2.6.2.2 Cell Disruption 
The cell sediment obtained by centrifugation was washed with buffer B and suspended in a 
minimal volume of buffer B. Cells were disrupted by sonication (Bandelin HD 2070, 0.5 s 
sound, 0.5 s paused, MS73 tip, 70 % amplitude) and the cell debris was removed by 
centrifugation at 50,000 x g for 45 min. The resulting supernatant was loaded onto Ni-IDA 
chromatography. 
 
Buffer B Tris-HCl 50 mM 
 NaCl 300 mM 
 ZnCl2 10 µM 
 in H2Odest; pH 8.5   
 
2.6.2.3 Affinity Chromatography Using Ni-IDA Sepharose 
Recombinant MbPBGS was purified in a first step by Ni-IDA affinity chromatography 
using a 5 mL column equilibrated with 10 volumes of buffer B. All steps were carried out at 
RT, proteins were stored on ice. After loading the cell free extract at a flow rate of  
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500 µL/min, the column was washed with 10 volumes of buffer B to remove unbound 
proteins. Bound proteins including His-tagged MbPBGS were eluted using a linear gradient 
of 0 – 1 M imidazole in buffer B at a flow rate of 1 mL/min. Eluate fractions of 1 mL were 
collected, fractions containing recombinant MbPBGS were identified by SDS-PAGE, 
combined and concentrated by ultrafiltration.  
2.6.2.4 Ion Exchange Chromatography Using DEAE Sepharose 
Anion exchange chromatography using DEAE sepharose was performed at RT. Pooled 
fractions containing recombinant MbPBGS were applied at a flow rate of 1 mL/min to a  
3 mL DEAE Sepharose column equilibrated with buffer B. To remove unbound proteins the 
column was washed with 7 column volumes of buffer B. Bound proteins including 
recombinant MbPBGS were eluted with 300 mM NaCl in buffer B. Fractions containing 
recombinant MbPBGS were identified via SDS-PAGE-analysis, combined and concentrated 
by ultrafiltration. 
2.6.2.5 Gel Permeation Chromatography 
The last step of MbPBGS purification was performed by gel permeation chromatography at 
RT using a 30 mL Superdex 200 HR 10/30 equilibrated with buffer B. Combined fractions 
containing recombinant MbPBGS were chromatographed with a flow rate of 0.5 mL/min. 
Recombinant MbPBGS was identified by enzyme activity testing, SDS-PAGE analysis and 
Western Blotting. 
 
2.6.3 Production and Purification of Arabidopsis thaliana 
Uroporphyrinogen III Synthase 
2.6.3.1 Cell Growth for Protein Production 
Six times 500 mL of vapor sterilized LB media containing 100 µg/mL ampicillin and  
34 µg/mL chloramphenicol in 1 L Erlenmeyer flasks were each inoculated with an 
overnight culture of  E. coli BL21(DE3) RIL carrying either pUROSfull or pUROSmat. 
Cultures were grown at 37°C and 200 rpm to an OD578 of 0.7 and expression of hemD was 
induced by the addition of IPTG to a final concentration of 100 μM. Further incubation 
followed overnight at 25°C and 150 rpm. Cells were subsequently harvested by 
centrifugation (15 min at 4,000 x g and 4°C) 
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2.6.3.2 Cell Disruption 
Cells were washed with buffer D and suspended in a minimal volume of buffer D. Bacteria 
were disrupted via sonication (Bandelin HD 2070, 0.5 s sound, 0.5 s paused, MS73 tip,  
70 % amplitude) and the cell free extract cleared from insoluble protein and cell debris by 
centrifugation at 150,000 x g for 45 min. The resulting supernatant was loaded on to  
Ni-NTA chromatography.  
Buffer D Hepes 20.0 mM 
 MgCl2 5.0 mM 
 Triton X-100 0.01 % (v/v) 
 in H2Odest; pH 7.5    
 
2.6.3.3 First Affinity Chromatography Using Ni-NTA Sepharose 
Recombinant AtUROS was purified in a first step by Ni-chelating sepharose Fast Flow 
affinity chromatography using a 5 mL column equilibrated with 10 volumes of buffer D. 
After loading the supernatant at a flow rate of 0.7 mL/min, the column was washed with  
10 volumes of buffer D to remove unbound proteins. Bound proteins including His-tagged 
AtUROS were eluted using a linear gradient of 0 – 1 M imidazole in buffer D at a flow rate 
of 1 mL/min. Eluate fractions of 1 mL were collected, fractions containing recombinant 
AtUROS were identified by SDS-PAGE-analysis, combined and concentrated by 
ultrafiltration. 
2.6.3.4 Ion Exchange Chromatography Using DEAE Sepharose 
Anion exchange chromatography using DEAE sepharose was performed at RT. Pooled 
fractions containing recombinant AtUROS were applied at a flow rate of 1 mL/min to a  
3 mL DEAE Sepharose column equilibrated with buffer D. To remove unbound proteins the 
column was washed with 7 column volumes of buffer D. Bound proteins including 
recombinant AtUROS were eluted with 200 mM NaCl in buffer D. Fractions containing 
recombinant AtUROS were identified via SDS-PAGE-analysis, combined and concentrated 
by ultrafiltration. 
2.6.3.5 Gel permeation chromatography 
The last step of AtUROS purification was performed by gel permeation chromatography at 
RT using a 30 mL Superdex 200 HR 10/30 equilibrated with buffer D. The column was 
calibrated using bovine carbonic anhydrase (Mr = 29,000), bovine serum albumin  
(Mr = 66,000), yeast alcohol dehydrogenase (Mr = 150,000), and amylase (Mr = 200,000) as 
marker proteins. Combined fractions containing recombinant AtUROS were 
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chromatographed under identical conditions at a flow rate of 0.5 mL/min. Recombinant 
AtUROS was identified by enzyme activity testing, SDS-PAGE analysis and Western 
Blotting. 
 
2.6.4 Production and Purification Tobacco Protoporphyrinogen IX 
Oxidase 
2.6.4.1 Cell Growth for Protein Production 
Recombinant proteins were produced using E. coli BL21(DE3)RIL containing the plasmids 
encoding wildtype or mutant NtPPO2. For each variant five times 500 mL vapor sterilized 
LB medium containing 100 µg/mL ampicillin and 34 µg/mL chloramphenicol in 1 L 
Erlenmeyer flasks were each inoculated with 5 mL of an overnight culture. Cultures were 
grown at 37°C and 200 rpm to an OD578 of 0.7 and expression of hemY was induced by 
addition of IPTG to a final concentration of 250 µM. Incubation was continued overnight at 
25°C and 150 rpm. Cells were harvested by centrifugation for 15 min at 4,000 x g and 4°C.  
2.6.4.2 Cell Disruption 
The cell sediment obtained by centrifugation was washed with buffer Y and suspended in a 
minimal volume of buffer Y. Cells were broken by sonication (Bandelin HD 2070, 0.5 s 
sound, 0.5 s paused, MS73 tip, 70 % amplitude) and the cell free extract cleared by 
centrifugation at 75,000 x g for 45 min. The resulting supernatant was loaded on Ni-IDA 
chromatography. 
Buffer Y Tris-HCl 10.0 mM 
 NaCl 300.0 mM 
 MgCl2 10.0 mM 
 Triton X-100 0.01 % (w/v) 
 in H2Odest; pH 8.0    
 
2.6.4.3 Affinity Chromatography Using Ni-IDA Sepharose 
Recombinant wildtype and mutant NtPPO2 were purified by Ni-IDA affinity 
chromatography using a 5 mL column equilibrated with 10 volumes of buffer Y. After 
loading the supernatant at a flow rate of 0.5 mL/min, the column was washed with  
10 volumes of buffer Y to remove unbound proteins. Bound proteins including His-tagged 
wildtype or mutant NtPPO2 were eluted using a linear gradient of 0 – 1 M imidazole in 
buffer Y at a flow rate of 1 mL/min. Eluate fractions of 1 mL were collected, fractions 
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containing recombinant wildtype or mutant NtPPO2 were identified by SDS-PAGE-
analysis, combined and concentrated by ultrafiltration.  
2.6.5 Concentrating Protein Solutions 
Protein solutions were concentrated in a 50 mL or in a 10 mL stirred ultrafiltration cell with 
a YM30 membrane at 3 x 105 Pa until a protein concentrations of 2 - 20 mg/mL was 
reached. All recombinant concentrated proteins were stored at 4°C. 
2.6.6 Determination of Protein Concentration 
2.6.6.1 Bicinchoninic Acid Protein Assay 
Concentrations of protein solutions were determined using the Micro BCA Protein Assay 
Kit® according to manufacturer’s instructions. The Bicinchoninic Acid 8BCA9 Protein 
Assay combines the reduction of Cu2+ to Cu1+ by protein in an alkaline medium with the 
highly sensitive and selective colorimetric detection of the cuprous cation (Cu1+) by 
bicinchoninic acid. The intensity of the color produced is proportional to the number of 
peptide bonds participating in the reaction. Bovine serum albumin was used as a standard. 
2.6.6.2 Photometric Determination of Protein Concentration 
An optical density technique for measuring protein concentration was applied for highly 
purified recombinant proteins. The extinction coefficient indicates how much light a protein 
absorbs at a certain wavelength. From the OD280 of a homogeneous protein solution its 
concentration was calculated using the 280 nm extinction coefficient which is specific for a 
given amino acid sequence (Gill and von Hippel, 1989). 
2.6.6.3 Determination of Protein Concentrations via S•Tag Rapid Assay Kit 
Concentrations of proteins carrying a S•Tag were determined via S•Tag Rapid Assay Kit 
according to manufacturer’s instructions. 
2.6.7 Determination of FAD Content 
2.6.7.1 UV/VIS-Photometric Determination of the FAD Content 
To analyze the potential effects of the mutations on FAD binding by NtPPO2, UV/VIS 
spectra were recorded from 250 to 550 nm for both wild type and mutants under identical 
conditions in buffer Y (see page 43) at room temperature according to the method described 
by Maneli and coworkers (Maneli et al., 2003). The FAD content was then obtained by 
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measuring absorption at the maximum wavelength (450 nm). With an appropriate 
calibration curve with commercially obtained FAD the content was calculated and 
expressed as FAD/monomer. 
2.6.7.2 Fluorimetric Determination of the FAD Content 
As second method for the determination of the FAD content of wildtype and mutant 
NtPPO2 the fluorescence of FAD was determined as described by Ohno and coworkers 
(Ohno et al., 1986). Purified enzymes were immersed in boiling water for five minutes and 
cooled rapidly in melting ice water to extract non-covalently bound FAD. Denatured 
proteins were removed by centrifugation (10 min at 15,000 x g and 4°C). The fluorescence 
of the samples was measured with the excitation wavelength of 450 nm and the emission 
wavelength of 535 nm, using a Perkin-Elmer PA LS50B fluorescence spectrophotometer. 
Thereafter, the pH of the solutions was lowered to a value of 2.6 with 1 N HCI, and the 
fluorescence was determined again. Standard curves for commercially obtained FAD at pH 
8 and pH 2.6 were determined and the FAD content of the recombinant proteins calculated. 
The FAD content is expressed as FAD/monomer. 
2.6.8 Discontinuous SDS-PAGE 
Proteins were analyzed by SDS-PAGE as described by Laemmli (Laemmli, 1970) with 
modifications by Righetti (Righetti, 1990) for discontinuous SDS-PAGE. Protein samples 
were denatured by heating to 95°C for 10 min in SDS loading dye. Samples were loaded 
onto the gel which was run at 40 mA. During electrophoresis, proteins were first focused in 
the stacking gel and subsequently separated according to their relative molecular mass in the 
running gel. The size standard employed was Protein Molecular Weight Marker. Gels were 
stained with staining solution and destained with destaining solution until the protein bands 
were clearly visible. 
SDS gel   
   running gel [12 % (v/v)]          stacking gel [6 % (v/v)] 
acrylamide stock solution 2.0 mL 500.0 µL 
buffer for running gel 1.25 mL - 
buffer for stacking gel - 625.0 µL 
H2Odest 1.75 mL 1.375 mL 
APS solution 5.0 µL 3.0 µL 
tetramethylen diamine (TEMED) 50.0 µL 30.0 µL 
 
acrylamide stock solution Rotiphorese® Gel 30 (37.5:1) (Roth) 
  
APS solution Ammonium 
peroxodisulfate 
10.0 % (w/v) 
 in H2Odest   
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buffer for running gel Tris-HCl 1.5 M 
 SDS 0.4 % (w/v) 
 in H2Odest; pH 8.8   
    
buffer for stacking gel Tris-HCl 500.0 mM 
 SDS 0.4 % (w/v) 
 in H2Odest; pH 6.8   
    
Electrophoresis buffer Tris-HCl 14.5 mM 
 glycine 1.441% (w/v) 
 SDS 1.0 % (w/v) 
 in H2Odest; pH 8.4   
 
SDS loading dye Tris-HCl 100.0 mM 
 glycerol 40.0 % (v/v) 
 β-mercaptoethanol 10.0 % (v/v) 
 SDS 3.2 % (w/v) 
 bromphenol blue 0.2 % (w/v) 
 in H2Odest; pH 6.8   
    
Staining solution ethanol 30.0 % (v/v) 
 acetic acid 10.0 % (v/v) 
 Coomassie Brilliant 
Blue  G-250 
0.25 % (w/v) 
 in H2Odest   
    
Destaining solution ethanol 30.0 % (v/v) 
 acetic acid 10.0 % (v/v) 
 in H2Odest   
 
2.6.9 Western Blotting and Immunodetection of Immobilized Proteins 
For further analysis proteins separated during SDS-PAGE were transferred in a semi-dry 
process onto a polyvinylidenfluorid (PVDF)-membrane, which binds the proteins by polar 
interactions. PVDF-membranes were incubated in methanol for 10 min and similarly to the 
SDS-gel and blotting paper incubated in transfer-buffer and assembled in the following 
order on the blotting apparatus: Cathode, blotting paper, PVDF-membrane, SDS-gel, 
blotting paper, anode. A current of 0.8 mA/cm2 was applied for 30 min at 10 V. Non-
specific binding sites of the membrane were saturated overnight in blocking solution at 4°C 
and slight shaking. Proteins immobilized on a PVDF-membrane were specifically detected 
by antibodies. Primary antibodies were directed against GST or His-tag, secondary 
antibodies were directed against the primary antibody and were coupled to an alkaline 
Protein Molecular Weight Marker (MBI Fermentas)   
(indicated are approximate relative molecular weights)   
  
β-galacosidase, E. coli 116,000  
albumin, bovine 66,200  
albumin, egg 45,000  
lactate dehydrogenase, porcine muscle 35,000  
restriction endonuclease Bsp98I, E. coli 25,000  
β -lactoglobulin, bovine milk 18,400  
lysozyme, egg 14,400  
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phosphatase. Incubation with the primary antibody was carried out in blocking solution for 
1 h (RT) and slight shaking. Next, membranes were washed three times for 10 min with 
washing-buffer and incubated for 45 min with the secondary antibody. After four additional 
washing steps with PBS/Tween buffer for 10 min, membranes were incubated for 5 min in 
alkaline phosphatase buffer and exposed to staining solution until bands became visible. 
During exposure alkaline phosphatase, the enzyme bound to the antibody, catalyzes the 
reaction of 5-brom-4-chloro-3-indolylphosphate (BCIP) with nitroblue-tetrazolium (NBT).  
Transfer buffer Tris-HCl 25.0 mM 
 glycine 192.0 mM 
 methanol 20.0 % (v/v) 
 in H2Odest; pH 8.5   
    
Blocking solution  skim milk powder 5.0 % (w/v) 
 Tween 20 0.1 % (v/v) 
 PBS 10.0 % (v/v) 
 in H2Odest   
    
 
Washing solution skim milk powder 0.5 % (w/v) 
 Tween 20 0.1 % (v/v) 
 PBS 10.0 % (v/v) 
 in H2Odest;   
PBS/Tween-buffer  Tween 20 0.1 % (v/v) 
 PBS 10.0 % (v/v) 
 in H2Odest   
    
Alkaline phosphatase buffer Tris-HCl 100.0 mM 
 NaCl 100.0 mM 
 MgCl2 5.0 mM 
 in H2Odest; pH 9.5    
 
Staining solution NBT solution 0.33 % (v/v) 
 BCIP solution 0.33 % (v/v) 
 in alkaline phosphatase buffer  
NBT solution nitroblue-tetrazolium 10.0 % (w/v) 
 dimethylenformamide 
(DMF) 
70.0 % (v/v) 
 in H2Odest   
BCIP solution 5-brom-4-chloro- 
3-indolylphosphate 
5.0 % (w/v) 
 DMF  
   
2.7 Enzyme Activity Assays 
2.7.1 Determination of Porphobilinogen Synthase Activity 
2.7.1.1 Preparation of Bacterial Cell Free Extracts for Porphobilinogen 
Synthase Activity Testing 
Cell-free extracts of several bacterial strains, i.e. E. coli, E. coli CSA, B. subtilis,  
B. megaterium, S. aureus, P. aeruginosa, S. avermitilis, S. coelicolor and S. sp. A012304, 
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were required to investigate PBGS activity. To prepare the cell-free extracts, 1 L of the 
respective strain were grown for 24 h in complex medium at 37°C or for the Streptomyces 
strains at 25°C. Cells were harvested by centrifugation (15 min at 4,000 x g and 4°C) and 
washed with buffer C. Bacteria were disrupted via sonication (Bandelin HD 2070, 0.5 s 
sound, 0.5 s paused, MS73 tip, 70 % amplitude) and the cell free extracts cleared from 
insoluble protein and cell debris by centrifugation at 150,000 x g for 45 min at 4°C. The 
protein concentrations in cell free extracts were determined by BCA Protein Assay, adjusted 
to approximately 10 mg/mL and immediately used for the determination of PBGS activity. 
For background control, proteins from cell free extracts were heat inactivated for 10 minutes 
at 95°C. Furthermore, reactions without ALA-addition were determined to evaluate the 
contribution of cellular porphobilinogen.  
Buffer C Tris-HCl 50 mM 
 MgCl2 5 mM 
 ZnCl2 5 µM 
 in H2Odest; pH 7.0   
2.7.1.2 Porphobilinogen Synthase Activity Assay 
The activity of PBGS was determined using a modified Ehrlich’s test which is based on the 
reaction between the product porphobilinogen and 4-(dimethylamino)-benzaldehyde 
(DMBA). In the first reaction step between porphobilinogen and DMBA a pink reaction 
product with an absorbance maximum at 555 nm is formed, which reacts with a second 
porphobilinogen molecule to form colorless dipyrrolphenylmethane (see Fig. 12). Since the 
second reaction proceeds very slowly, porphobilinogen concentrations can be quantified via 
the Beer-Lambert law and the molar extinction coefficient of the colored intermediate of 
ε(complex) = 60,200 M-1cm-1.  
 
Fig. 12: Colorimetric detection of porphobilinogen.  
 
Porphobilinogen forms a coloured complex with DMBA which can be detected at OD555. This complex slowly 
reacts with a second porphobilinogen molecule to form colorless dipyrrolphenylmethane.  
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The Beer-Lambert law is as following: 
ε∗= d
Ac  
c = concentration of porphobilinogen [M] 
A = absorption 
d = cell diameter [cm] 
ε = molar extinction coefficient of the colored intermediate [M-1cm-1] 
2.7.1.3 Determination of Kinetic Parameters of Porphobilinogen Synthase 
A typical assay contained a final concentration of PaPBGS of 2 µg/mL, the concentrations 
of MbPBGS and HsPBGS were 25 µg/mL. The substrate ALA was dissolved to a 
concentration of 40 mM in kinetic buffer K1 with either 10 mM MgCl2 for PaPBGS or  
10 µM ZnCl2 for MbPBGS, respectively. For HsPBGS kinetic buffer K2 was applied. 
Kinetic buffers were chosen according to published data (Bhosale et al., 1995, Frankenberg 
et al., 1999, Jaffe et al., 2000). Stock solutions of protein, buffer and water were mixed and 
incubated at 37°C for 5 min. To start the reaction, substrate was added to a final 
concentration of 0 - 10 mM. The PBGS-catalyzed reaction was stopped at different time 
points (1 - 60 min) by adding equal amounts of ice cold stop reagent to the reaction mixture. 
Following centrifugation (3 min at 5,000 x g at RT), the supernatant was treated with an 
equal amount of Ehrlich reagent. After 15 min at RT, the amount of product was determined 
by measuring the OD555 and porphobilinogen formation was calculated using the Beer-
Lambert law as described above. The Michaelis Menten constant (KM), the maximal 
velocity vmax and the catalytic constant kcat were determined from substrate velocity plots by 
measuring the constant velocity formation of porphobilinogen over a substrate range from  
0 - 10 mM ALA. Values were determined by computerized Lineweaver Burke iterative 
curve fitting using SigmaPlot 8.0 Enzyme Kinetics v1.1. For the calculation of the catalytic 
efficiency kcat, the maximal velocity vmax was divided by the corresponding enzyme 
concentration.  
Buffer K1 bis-tris-propane 100 mM 
 in H2Odest; pH 8.5  
   
Buffer K2 KH2PO4 100 mM 
 β-mercaptoethanol 10 mM 
 ZnCl2 10 µM 
 in H2Odest; pH 7.0  
   
Stop reagent trichloroacetic acid 50 % (w/v) 
 HgCl2 100 mM 
 in H2Odest  
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Ehrlich reagent DMBA 2 % (w/v) 
 acetic acid 50 % (v/v) 
 perchloric acid 50 % (v/v) 
 
2.7.1.4 Determination of IC50 Values and Inhibition Constants for 
Porphobilinogen Synthase with Alaremycin 
To approximate the inhibitory potency of alaremycin, inhibitor concentrations reducing 
enzyme activity of PaPBGS, MbPBGS and HsPBGS to 50 % (IC50 values) were determined. 
For the determination of the IC50 for the human, M. barkeri and P. aeruginosa PBGS, 
enzyme velocity was evaluated at a single concentration of substrate with varying 
concentrations of the competitive inhibitor. For this purpose, alaremycin was dissolved to a 
concentration of 40 mM in the respective kinetic buffers. Reactions were carried out in the 
respective kinetic buffer with a final ALA concentration of 1 mM and alaremycin 
concentrations from 0 – 10 mM. PBGS and alaremycin were incubated at 37°C for 30 min 
prior to ALA addition. All further steps were carried out as described above. Results were 
plotted in a dose-response curve and IC50 values were deduced. Time dependency of 
inhibition was determined by pre-incubating the inhibitor with a fixed concentration of 
PBGS and ALA in kinetic buffer between 30 s and 30 min. The PBGS activity was 
determined as described above.  
2.7.2 Determination of Uroporphyrinogen III Activity via a Coupled 
Enzyme Activity Assay 
AtUROS activity was determined using a coupled enzyme activity assay as outlined in  
Fig. 13. Recombinant PaPBGS was purified as described before. Purified recombinant  
B. megaterium PBGD was kindly provided by Claudia Schulz from our laboratory.  
A standard assay mixture contained 25 μg of purified recombinant AtUROS, 0.2 mM ALA, 
10 μg PaPBGS and 10 μg PBGD in a total volume of 800 μL in buffer D. The reaction 
mixture was incubated for up to 120 min at 37°C in the dark. The reaction was stopped by 
addition of 300 μL KI/I2 solution and formed uroporphyrinogen III was oxidized to 
uroporphyrin III. Na2S2O5 solution was added to oxidize residual I2. Proteins were 
precipitated by the addition of 100 μL TCA solution and subsequent centrifugation (5 min at 
15,000 x g and 4°C).  
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Fig. 13: Coupled enzyme activity assay for uroporphyrinogen III synthase.  
 
UROS activity was monitored using a coupled enzyme activity assay with the photometric and fluorimetric 
detection of the oxidized reaction product uroporphyrin III. 
 
The amount of enzymatically formed uroporphyrinogen III was determined by fluorimetric 
detection of uroporphyrin III using a PE LS50B luminescence spectrometer with an 
excitation wavelength of 400 nm, an emission scan range of  
500 - 700 nm, a scan speed of 200 nm/min and a slit widths of 5 nm for emission and 
excitation. Furthermore, uroporphyrin III was detected by measuring the absorbance at  
408 nm. Chemical cyclization of pre-uroporphyrinogen to uroporphyrin I, which reveals 
similar spectroscopic and fluorimetric properties as uroporphyrin III, was ruled out by 
control experiments in an enzymatic test without AtUROS addition and in the presence of 
heat inactivated AtUROS.  
KI/I2 solution KI 0.5 % (w/v) 
 I2 1.0 % (w/v) 
 in H2Odest   
    
Na2S2O5 solution Na2S2O5 1.0 % (w/v) 
 in H2Odest   
    
TCA-solution trichloroacetic acid 50.0 % (w/v) 
 in H2Odest   
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2.7.3 Determination of Protoporphyrinogen IX Oxidase Activity 
2.7.3.1 Preparation of the Substrate Protoporphyrinogen IX 
The oxygen-dependent PPO activity assay was developed by Labbe and coworkers (Labbe 
et al., 1985). The substrate protoporphyrinogen IX is converted into protoporphyrin IX by 
PPO in the presence of molecular oxygen as electron acceptor. Excitation of the product at a 
wavelength of 409 nm results in an emission at 633 nm which was detected fluorimetrically 
and is therefore clearly distinguishable from the substrate as this reveals no fluorescence 
spectroscopic properties. The substrate protoporphyrinogen IX was obtained through the 
reduction of commercially obtained protoporphyrin IX according to modified instructions of 
Sano and Granick (Sano and Granick, 1961). For this purpose, 500 μmol protoporphyrin IX 
were dissolved in 3 mL buffer P under N2 exposure and reduced with 6 g of 3 % sodium-
amalgam. After 2 min incubation at 80°C the solution became colorless, indicating the 
reduction of protoporphyrin IX. Next, the solution was filtered through glass wool, 50 mM 
DTT was added and the pH was adjusted to 7-8 with 20 % (v/v) phosphoric acid. The 
protoporphyrinogen IX solution was aliquoted and stored anaerobically in the dark at - 20°C 
to avoid autooxidation of the substrate by oxygen or light. 
Buffer P KOH 10 mM 
 ethanol 20 % (v/v) 
 in H2Odest   
 
2.7.3.2 Determination of Kinetic Parameters of Tobacco 
Protoporphyrinogen IX by Fluorescence Stopped Flow Spectrometry 
NtPPO2 activity was monitored using a continuous assay via the detection of 
protoporphyrin IX fluorescence. Stopped-flow kinetic experiments were performed under 
aerobic conditions using a Jasco 810 stopped-flow spectrometer and obtained data were 
analyzed with Biokine Acquire Kinetics. Averages of three to five individual transients were 
analyzed. Protoporphyrinogen IX was dissolved in kinetic buffer P. Protoporphyrinogen IX 
solution and NtPPO2 preparations were mixed in a six to one ratio in a total volume of  
300 μL and fluorescence resulting from protoporphyrin IX formation was continuously 
recorded via an excitation at 409 nm and emission measurement above 450 nm. 
Approximately 8000 measurement points per assay were recorded. Protoporphyrin IX 
concentrations were calculated using an appropriate calibration curve. The Michaelis 
Menten constant (KM), the maximal velocity vmax and the catalytic constant kcat were 
determined from substrate velocity plots by measuring the constant velocity formation of 
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protoporphyrin IX from protoporphyrinogen IX over a substrate range from 1 - 25 μM and a 
time course of up to 2 hours at 20°C. The initial reaction rates were linear and values were 
determined by the computerized Lineweaver Burke iterative curve fitting using SigmaPlot 
8.0 Enzyme Kinetics v1.1. For the calculation of the catalytic efficiency kcat, the maximal 
velocity vmax was divided by the corresponding enzyme concentration. 
Kinetic buffer P MES 50 mM 
 Triton X-100 1 % (v/v) 
 in H2Odest; pH 6.0   
    
    
    
2.8 Crystallization of Pseudomonas aeruginosa Porphobilinogen 
Synthase 
2.8.1 Identification of Crystallization Conditions 
For the crystallization of purified PaPBGS the vapor diffusion method was applied, 
allowing a slow and controlled growth of protein crystals. Since it is difficult to predict 
conditions for nucleation and growth of well-ordered crystals, conditions were identified 
empirically using a variety of buffers, precipitants and salts. PaPBGS solutions containing 
alaremycin were generated by mixing aliquots of protein solution and alaremycin solution. 
Crystallization lead conditions were identified using Crystal Screen and Crystal Screen 2 in 
96-well sitting-drop CrystalClear strip racks with 100 µL of reservoir solution and drops of 
3 µL of reservoir and 3 µL of protein solution. Crystallization was attempted at 4°C and 
17°C, respectively.  Prior to X-ray data collection, crystals were washed in cryoprotective 
solution for 5 s and flash-frozen in liquid N2. 
Protein solution Tris-HCL 100 mM 
 MgCl2 10 mM 
 PaPBGS 20 mg/mL 
 in H2Odest; pH 7.5   
Alaremycin solution Tris-HCL 100 mM 
 MgCl2 10 mM 
 alaremycin 5 mM 
 in H2Odest; pH 7.5   
    
Cryoprotective solution PEG 400 20 % (v/v) 
 reservoir solution 80 % (v/v) 
 
2.8.1.1 Structure Determination 
Data collection was performed under cryogenic conditions using synchrotron radiation at 
beamLine BL1 (BESSYII, Berlin, Germany). Data analysis was kindly performed by  
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Wolf-Dieter Schubert from the group of Dirk Heinz, Helmholtz Centre for Infection 
Research, Braunschweig.  
2.8.1.2 Molecular Depictions  
Molecular depictions were prepared using PyMOL (Delano Scientific LLC, USA).  
 
2.9 Metabolite Extraction and Preparation 
2.9.1  Cofactor Extraction from Methanosarcina barkeri 
2.9.1.1 Heme Extraction 
Non-covalently bound heme was extracted from M. barkeri by a modification of a 
previously described method (Weinstein and Beale, 1983). An amount of 1 g of frozen cells 
were ground under liquid nitrogen, transferred to a test tube and suspended in 10 mL of 
icecold solution M. The mixture was allowed to stand 10 min on ice and 10 min at room 
temperature with occasional mixing followed by centrifugation in sealed steel beakers at 
10,000 x g for 30 min at 4°C. Four mL of peroxide-free diethyl ether were added to the 
supernatant. After mixing, 12.5 mL of cold H2Odest were added with further mixing. The 
heme-containing upper ether phase was transferred to a rotary evaporator flask and 
evaporated to dryness. For MALDI-TOF-MS analysis the dried fraction was suspended in 
100 µL solution T. 
 
Solution M acetone 90 % (v/v) 
 Hal 5 % (v/v) 
 in H2O   
    
Solution T acetonitrile 20 % (v/v) 
 trifluoric acid 1 % (v/v) 
 in H2O   
 
2.9.1.2 F430 and Vitamin B12 Extraction 
Coenzyme F430 is known to contain two methyl groups and vitamin B12 seven methyl groups 
all derived from S-adenosyl-L-methionine (Jaenchen et al., 1981, Warren et al., 2002). 
These cofactors were analyzed as controls as following. One mL of grown M. barkeri 
culture was centrifuged for 5 min and cells suspended in solution T. After sonication for  
3 min the extract was centrifuged (5 min at 15,000 x g and 4°C) and the resulting 
supernatant was analyzed by MALDI-TOF-MS. 
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2.9.1.3 Feeding on Radioactively Labeled Substrate 
The archaeon M. barkeri was cultivated anaerobically at 37°C with 250 mM methanol as 
sole carbon and energy source in low salt medium. For the quantification of the uptake of 
SAM and methionine by M. barkeri, 5 mL cell culture was fed on 0.1 µCi  
L-[methyl-14C]methionine or S-Adenosyl-L-[methyl-14C]methionine, respectively at 37°C 
for 48 hours. Cells were harvested and amounts of [14C]-SAM and [14C]-methionine in cell 
sediment and medium were determined using a Liquid Scintillation Analyzer. The 
scintillation cocktail employed was OptiPhase HiSafe 2. To determine the origin of the 
methyl groups of heme, M. barkeri was grown in 200 mL low salt medium supplemented 
with L-[methyl-D3]methionine (98 atom % D) added to the autoclaved medium to a final 
concentration of either 2 mM, 5 mM or 10 mM from a sterile stock solution. Growth was 
initiated with a 10 % inoculum (grown in absence of methionine) and followed 
photometrically at 578 nm. At the end of the exponential growth phase, cells were harvested 
anaerobically by centrifugation at 10,000 x g for 30 min at 4°C and stored under H2 
saturated atmosphere at - 20°C. Per 200 mL culture approximately 1 g cells (wet mass) were 
obtained. 
2.9.1.4 Identification of Cofactors via MALDI-TOF 
The mass spectra were kindly collected by Jörg Kahnt from the group of Rolf Thauer, Max-
Planck Institute for Terrestrial Microbiology, Marburg in the reflector positive ion mode. 
Samples were measured after an appropriate dilution of the sample with saturated α-cyano-
4-hydroxy cinnamic acid in solution F on a steel target. The spectra were determined with 
an Ultraflex from Bruker and commercially obtained hemin was used as standard. The 
natural isotopic distribution of protoheme, F430 and vitamin B12 were calculated aided by the 
isotope pattern calculator provided by the University of Sheffield at the ChemPuter site 
(http://winter.group.shef.ac.uk/chemputer/isotopes.html). The fraction of protoheme, F430 or 
vitamin B12 labeled with methyl-D3 was determined by solving the binomial equation 
(a+b)n for n = 2 (protoheme or F430) and n = 7 (B12) using the "Solver" facilities provided by 
Excel 97 as described by (Selmer et al., 2000). 
Solution F acetonitrile 70 % (v/v) 
 trifluoric acid 0.1 % (v/v) 
 in H2Odest   
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2.9.2 Preparation of Precorrin-2 
2.9.2.1 Combined Production of Porphobilinogen Synthase, 
Porphobilinogen Deaminase, Uroporphyrinogen III Synthase and 
Uroporphyrinogen III Methyltransferase 
Two times 500 mL vapor sterilized LB medium containing 100 µg/mL ampicillin and  
34 µg/mL chloramphenicol in 1 L Erlenmeyer flasks were each inoculated with 5 mL of an 
overnight culture of E. coli BL21(DE3)RIL carrying the pETcoco2 derivative vector pIH41 
encoding M. barkeri cobA, M. thermoautotrophicum hemB and B. megaterium hemC and 
hemD. Cultures were grown at 37°C and 200 rpm to an OD578 of 0.4 and the vector copy 
number was shifted from low copy to high copy state by addition of L-arabinose to a final 
concentration of 0.02 % (w/v). After 1 h incubation at 37°C and 200 rpm expression of the 
respective genes was induced by addition of IPTG to final concentration of 400 µM. 
Incubation was continued overnight at 25°C and 150 rpm. Cells were harvested by 
centrifugation for 15 min at 4,000 x g and 4°C.  
2.9.2.2 Cell Disruption 
The cell sediment obtained by centrifugation was washed with buffer R1 and suspended in a 
minimal volume of buffer R1. Cells were disrupted by sonication (Bandelin HD 2070,  
0.5 s sound, 0.5 s paused, MS73 tip, 70 % amplitude) and the cell debris was removed by 
centrifugation at 50,000 x g for 45 min. The resulting supernatant was loaded on Ni-IDA 
chromatography column. 
Buffer R1 Hepes 20 mM 
 NaCl 300 mM 
 MgCl2 5 mM 
 in H2Odest; pH 7.5   
 
2.9.2.3 Affinity Chromatography Using Ni-IDA Sepharose 
Recombinant proteins were purified by Ni-IDA affinity chromatography using a 3 mL 
gravity flow column equilibrated with 10 volumes of buffer R1. After loading the cell free 
extract, the column was washed with 10 volumes of buffer R1 to remove unbound proteins. 
Bound proteins were eluted with 1 M imidazole in buffer R1. Eluate fractions of 1 mL were 
collected and fractions containing recombinant proteins were identified by SDS-PAGE, 
combined and concentrated by ultrafiltration.  
All further steps were carried out under anaerobic conditions in an anaerobic chamber. For 
desalting, combined fractions containing recombinant proteins were applied to a PD-10 
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column equilibrated with buffer R2. Flowthrough was collected in 1 mL fractions and 
fractions containing recombinant proteins were identified by SDS PAGE and employed for 
precorrin-2 production. 
Buffer R2 Tris-HCl 50 mM 
 NaCl 100 mM 
 in H2Odest; pH 8.0   
 
2.9.2.4 Preparation of Precorrin-2 
For the production of precorrin-2, 200 µL protein solution (approx. 5 mg/mL) containing 
purified recombinant CobA, PBGS, PBGD and UROS, 1 mg ALA and 2 mg SAM were 
combined in a total volume of 1 mL buffer R2 under anaerobic conditions in the dark 
overnight. To separate recombinant proteins from synthesized precorrin-2, the solution was 
anaerobically applied to a 3 mL Ni-IDA gravity flow column equilibrated with 10 volumes 
of buffer R2 the and flowthrough containing precorrin-2 was collected.  
 
2.9.3 Preparation of Alaremycin from Culture Broth of Streptomyces sp. 
A012304 
2.9.3.1 Conditions for Alaremycin Production 
Alaremycin production was performed with a slight modification of the method described 
before (Awa et al., 2005). The major difference to the published method is the preparation 
of production medium. Dextrin was autoclaved separately and the pH of the medium was 
not adjusted to pH 7.0 but to pH 8.5. S. sp. A012304 was grown in 200 mL of seed medium 
inoculated with a single colony for four days at 25°C and 250 rpm. Once the growing seed 
culture altered the color of the medium to dark brown, indicating secondary metabolite 
expression (Matseliukh, 2006), production of the antibiotic was initiated by inoculation of 
400 mL production medium with 20 mL of seed culture and cells were allowed to grow for 
5 days at 25°C and 250 rpm. Cultures were subjected to centrifugation for 45 min, 4,000 x g 
at 4°C and culture supernatant was used for alaremycin preparation.   
2.9.3.2 Alaremycin Preparation 
Alaremycin was extracted from the culture broth by a slight modification of the method 
described by Awa and coworkers (Awa et al., 2005). Culture supernatant was sterile 
filtrated to remove residual cells and applied to Diaion HP-20 hydrophobic interaction 
chromatography. The flowthrough was adjusted to pH 2.0 with 1 N HCl and extracted with 
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freshly purchased ethyl acetate. The organic layer was further extracted with water pH 9.0 
and applied to a cation exchange column using a gravity flow column with fibrious cation 
exchange resign (Whatman). The flowthrough was carefully adjusted to pH 2 with 1 N HCl 
and extracted with ethyl acetate. The organic layer was evaporated to dryness and 
alaremycin was stored at - 20°C. 
 
2.10 Comparative Genome Analysis 
Comparative genome analysis was employed for the identification of open reading frames 
(ORF) potentially involved in archaeal heme biosynthesis. This computational approach is 
based on the assumption that a second ancient heme biosynthesis pathway with conserved 
proteins solely exists in a certain group of organisms. If so, these proteins should be found 
exclusively in these organisms but not in those which synthesize heme via the common 
pathway or in such that do not produce heme at all. This potential feature was evaluated 
using a specific BLAST analysis. The BLAST analyses were performed using NCBI 
BLAST version 2.2.14-x64 (Altschul et al., 1997). In order to evaluate and control the 
BLAST analyses a Java (version 1.5) based software running on a 64 bit dual processor 
computer was implemented. All analyzed amino acid sequences were downloaded from the 
Integr8 database release 44 (Kersey et al., 2005). Two proteins were assigned as homolog 
once the e-value of the BLAST hit was less than 10-10. The corresponding bioinformatic tool 
was developed by Karsten Hiller from our institute.  
Several organisms of which the complete genome sequence has been determined were 
examined for their ability to synthesize heme by intensive literature research. If so, the 
deduced proteomes were screened for the occurrence of common heme biosynthesis protein 
homologs and organized into three groups. The first group consisted of organisms which 
synthesize heme via the ancient pathway, i.e. they are capable of synthesizing heme but do 
not possess the proteins operating in the common pathway. Therefore, the proteomes of  
M. barkeri, M. acetivorans, M. mazei, Archaeoglobus fulgidus, Sulfolobus solfataricus, 
Sulfolobus tokodaii, Halobacterium salinarium, Pyrobaculum aerophilum and Aeropyrum 
pernix were included in this group. The second group comprised organisms that are not 
capable of synthesizing heme: Caenorhabditis elegans, Lactococcus lactis,  
M. thermoautotrophicum, Mycoplasma genitalium, Mycoplasma pneumoniae, Mycoplasma 
pulmonis, Pyrococcus abyssi, Pyrococcus horikoshii, Thermotoga maritima, Treponema 
pallidum, Streptococcus pneumoniae, Streptococcus pyogenes, Borellia burgdorferi and 
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Ureaplasma urealyticum. Finally, the third group consisted of organisms that synthesize 
heme via the common pathway, i.e. they possess the corresponding proteins: Drosophila 
melanogaster, Homo sapiens sapiens, Saccharomyces cerevisiae, Plasmodium falciparum, 
B. subtilis, Schizosaccharomyces pombe, E. coli and P. aeruginosa. 
The comparative genome analysis was performed in three steps, which are visualized in Fig. 
34: Firstly, the set of all proteins that are common for all organisms belonging to group one 
was determined. Therefore, each protein of the first group was blasted against the proteomes 
of all organisms of this group and collected only those proteins that yielded in significant 
BLAST hits in all organisms of this group. Secondly, all proteins from this “intersection” 
that feature homologs in any of the organisms of group two were removed. Finally, all 
sequences that have homologs in group three were removed from the set of collected 
proteins.  
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3 RESULTS AND DISCUSSION 
This thesis investigated several different steps of heme biosynthesis in archaea, bacteria and 
plants.  
3.1 The Molecular Function of Alaremycin 
The function of a newly discovered antibiotic, named alaremycin due to its structural 
similarity to ALA, was investigated at the cellular, enzymatic and finally at the atomic level. 
The novel antibiotic was purified, tested on various bacteria, on purified PBGS from 
different sources and was finally co-crystallized with one of the target enzymes.  
3.1.1 Purification of Alaremycin Produced by Streptomyces sp. A012304 
The original purification scheme was provided by Masaaki Wachi and coworkers from the 
Tokyo Institute of Technology, Japan (Awa et al., 2005). M. Wachi kindly provided us with 
the corresponding Streptomyces strain and we tried to reproduce the published purification 
procedure which employs several steps of organic and inorganic extraction. Alaremycin is 
negatively charged at pH 9 due to the abstraction of a proton from its carboxyl group at a 
basic pH. In contrast, at a pH 2, the antibiotic is uncharged and thus soluble in organic 
solvents. This chemical feature was employed for the extraction of alaremycin from the 
culture broth. The extraction procedure was carried out as described under MATERIALS 
AND METHODS. 
We realized that also the pH value of the producing culture was crucial for alaremycin 
biosynthesis and excretion. In the published protocol the pH of the production medium had 
been adjusted to pH 7. However, no alaremycin was recovered from the culture broth at this 
condition. Finally, adjustment of the production medium to a pH of 8.5 yielded amounts of 
alaremycin between 5 mg/L and 50 mg/L. Interestingly, the producer strain S. sp. A012304 
possesses at least three different phenotypes in liquid and on solid LB media (see Fig. 14). 
The “white” and “yellow” phenotypes shared the same coccoid multicellular organization, 
whereas in “brown” colonies the cells were aligned in chains (see Fig. 14 C and D). It was 
referred to as the “brown” phenotype due to the secretion of a brownish substance into the 
medium after an incubation exceeding four days, which is most likely a secondary 
metabolite (Matseliukh, 2006). The “brown” phenotype produced white spores (see  
Fig. 14 B), whereas the yellow and white phenotype did not show spore formation. In 
production medium, S. sp. A012304 possesses a phenotype similar to the described 
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“yellow” one. In order to find the most efficient alaremycin producer, cells from the various 
phenotypes were tested as source for liquid preliminary cultures. Highest alaremycin yields 
were obtained with “yellow” S. sp. A012304 (50 mg/L compared to 5 mg/L for the “white” 
and 10 mg/L for the “brown” phenotype, respectively). 
 
Fig. 14: Different phenotypes of Streptomyces sp. A012304 on LB media.  
 
(A+B) LB Agar Plates. S. sp. A012304 cells were grown at 30°C for 3 days. Scale bar = 2 cm. (A) Left the 
“yellow” and right handed the “white” phenotype are shown. (B) The “brown” phenotype with white spores is 
visible. (C+D) Confocal micrographs of fixed cells, stained with SYBR Green II. Scale bar = 5 µm. (C) The 
“yellow” phenotype formed coccoid packs of 4 and multiples of 4 cells. (D) The “brown” phenotype formed 
cell chains and unordered clusters. Confocal micrographs were kindly made by Sebastian Hannemann from the 
group of Oliver Fackler, Hygiene Institute University Hospital Heidelberg. 
 
3.1.2 Antimicrobial Activity of Alaremycin on Various Organisms 
One interesting feature of many antibiotics is their capability to affect the growth of a broad 
range of different bacteria. However, the antimicrobial capacity of the lately discovered 
antibiotic alaremycin was solely investigated on E. coli. Consequently, MICs for several 
Gram positive and Gram negative bacterial species including the pathogens P. aeruginosa 
and S. aureus were determined. Alaremycin exhibited minimal inhibitory concentrations 
values of 4 mM to 18 mM, detailed values are given in Tab. 7. Antibiotic activity was lower 
in defined media compared to complex media, i.e. for example 4 mM and 10 mM for  
E. coli, respectively. This feature is probably due to the differences in growth rates between 
the two tested conditions. In complex medium bacteria usually develop a significantly faster 
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growth compared to minimal media. Therefore, in complex medium growth inhibitory 
effects are more profound and require lower amounts of antibiotics. Since S. aureus did not 
reveal growth with any of the used minimal media, no inhibition parameters for this 
condition could be deduced. Even though all tested bacterial strains showed inhibition of 
growth by the antibiotic at varying concentrations, the producer strains S. sp. A012304 was 
not affected by alaremycin concentrations up to 20 mM. In contrast, the two Streptomyces 
species, i.e. S. coelicolor and S. avermitilis showed growth inhibition in complex and 
minimal media at 8 mM and 14 mM, respectively, indicating that Streptomyces strains are 
not tolerant to alaremycin per se. Thus, S. sp. A012304 must have developed a resistance 
against its own antibiotic which is effective at even high concentrations.  
 
Tab. 7: Minimal inhibitory concentrations of alaremycin for various Gram negative and positive 
bacteria.  
 
 
MICs were determined as described in MATERIALS AND METHODS. The standard deviation of the shown 
results was between 10 and 15 %. The MIC for S. aureus on minimal media could not be determined since  
S. aureus failed to grow on any of the employed media. 
   Complex media   Minimal media 
E. coli 4 mM 10 mM 
P. aeruginosa 12 mM 18 mM 
B. subtilis 14 mM 18 mM 
B. megaterium 4 mM 10 mM 
S. coelicolor 8 mM 14 mM 
S. avermitilis 8 mM 14 mM 
S. aureus 14 mM / 
S. sp. A012304 > 20 mM > 20 mM 
 
The evaluated MICs revealed that alaremycin is a broad range antibiotic which exhibits 
antimicrobial activity against several Gram positive and Gram negative bacterial species, 
including human pathogens such as S. aureus and P. aeruginosa.  
3.1.3 Bacterial Heme Biosynthesis is the Target of Alaremycin Activity 
The overall structure of alaremycin is similar to ALA. Consequently, we tested its activity 
on heme biosynthesis of E. coli. For this purpose the heme auxotrophic and heme permeable 
E. coli strain E. coli CSA (hemA-, env) was used. The usually employed E. coli laboratory 
strains have lost their capability to transport heme through the outer membrane. However, 
the generation of a strain permeable to heme through chemical mutagenesis has been 
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described before (McConville and Charles, 1979). For the generation of such an E. coli 
strain, the hemA deficient E. coli EV61 was employed. This strain lacks active glutamyl-
tRNA reductase and cannot synthesize heme de novo. It thus grows as very small dwarf 
colonies on LB media after two days. Due to chemical mutagenesis of E. coli EV61 a strain 
was recovered that is capable to utilize external heme sources and forms normal sized 
colonies if grown on heme containing LB media. This strain was designated E. coli CSA 
and was kindly provided by Claudia Schulz from our laboratory.  
Since heme was fed to this strain, its growth was independent of intrinsic heme 
biosynthesis. Consequently, if alaremycin is inhibiting heme biosynthesis, this E. coli strain 
should show normal growth in the presence of heme and alaremycin. However, E. coli CSA 
showed inhibition of growth at alaremycin concentrations of 10 mM and 18 mM for 
complex and minimal media with heme, respectively. Clearly, the cells showed significantly 
reduced growth inhibition compared to common E. coli strains, which were inhibited at  
4 mM and 10 mM for complex and minimal media, respectively. This indicates that heme 
biosynthesis was indeed the target of alaremycin. For the residual inhibition of E. coli CSA 
growth due to alaremycin treatment, it has to be taken into account that E. coli is not solely 
heme dependent but also requires other tetrapyrroles such as siroheme (Zeghouf et al., 
2000). The inhibition of the biosynthesis of these compounds by alaremycin as well may 
account for the observed growth defect at high alaremycin concentrations. However, we 
cannot exclude that alaremycin has additional toxic side effects and antibacterial activity of 
alaremycin may not be restricted to heme biosynthesis alone. Nevertheless, one may surely 
conclude that heme biosynthesis is the main target of alaremycin antibacterial activity. 
3.1.4 Alaremycin Inhibits Various Porphobilinogen Synthases 
As outlined before, alaremycin carries typical features of ALA. Since ALA is the substrate 
for PBGS, this enzyme is the obvious target for alaremycin. Therefore, we tested the impact 
of alaremycin on PBGS activity in cell free extracts of various bacteria. PBGS activities of 
S. coelicolor, S. avermitilis, S. sp. A012304, E. coli, B. megaterium, B. subtilis,  
P. aeruginosa, E. coli and E. coli CSA were determined with a standard activity test with 
the addition of none, 5 mM and 10 mM alaremycin. In all cell free extracts comparable 
PBGS activity was detected and set to 100 % for the respective strain. Completely different 
responses of the various tested bacterial PBGS towards alaremycin treatment were observed 
and are presented in Tab. 8. E. coli and E. coli CSA cell free extract PBGS activities were 
similar and disappeared after addition of 10 mM alaremycin, whereas P. aeruginosa (25 %) 
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and B. subtilis (30 %) cell free extracts showed residual PBGS activity at this concentration. 
At 5 mM, all Streptomyces cell free extracts revealed 68 - 90 % residual activity, whereas at 
10 mM alaremycin S. coelicolor PBGS activity was abolished. In contrast, S. sp. A012304 
revealed 78 % residual activity at 10 mM alaremycin.  
 
Tab. 8: Inhibition of porphobilinogen synthase activity in cell free extracts from various Gram negative 
and positive bacteria by the addition of alaremycin.  
 
PBGS activity was measured as described under MATERIALS AND METHODS. Activity in cell free extracts 
without alaremycin addition was referred to as 100 % for the corresponding strain. Alaremycin was added to 
final concentrations of 5 mM and 10 mM. PBGS synthase activity in cell free extracts is given in % PBGS 
activity. The standard deviation of the shown results was between 10 and 15 %.  
 
     5 mM alaremycin  10 mM alaremycin 
E. coli 30 % < 1 % 
P. aeruginosa 92 % 25 % 
B. subtilis 61 % 30 % 
B. megaterium 3 % < 1 % 
S. coelicolor 77 % 22 % 
S. avermitilis 68 % < 1 % 
E. coli CSA 36 % < 1 % 
S. sp. A012304 90 %  79 % 
 
The obtained results are in line with the assumption that alaremycin exhibits its mode of 
action via inhibition of PBGS. All tested cell free extracts responded to alaremycin addition 
and showed reduction in PBGS activity. Most interestingly, PBGS activity of the producer 
strain S. sp. A012304 seemed to possess a certain immunity against the alaremycin 
antibiotic action. With more than three quarters of residual activity at a concentration of  
10 mM inhibitor in cell free extracts, it seemed improbable that this feature is solely 
explained by differences in PBGS concentrations between the various assayed extracts. It 
implies a modified PBGS active site, which may have evolved in parallel to the capability of 
alaremycin production. In summary, one may conclude that the target of alaremycin is 
indeed PBGS. 
3.1.5 Cloning, Purification and Characterization of Recombinant 
Porphobilinogen Synthases 
The obtained results for PBGS activity in cell free extracts indicated that alaremycin 
exhibits its mode of action via the inhibition of PBGS activity. To further investigate this 
feature, magnesium dependent PBGS from P. aeruginosa was recombinantly produced, 
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purified and tested for its response to alaremycin. In order to determine if alaremycin mode 
of action is restricted to bacterial PBGS, an archaeal, zinc-dependent enzyme from  
M. barkeri and the human zinc-dependent protein were employed for activity and inhibition 
testing as well. 
3.1.5.1 Recombinant Porphobilinogen Synthase from Pseudomonas 
aeruginosa 
The production and purification of recombinant P. aeruginosa PBGS (PaPBGS) has been 
established by Nicole Frankenberg in our laboratory. PaPBGS was produced in E. coli 
BL21(DE3)RIL and purified to apparent homogeneity using glutathione-S-sepharose. In a 
first chromatographic step, the fusion protein consisting of PaPBGS and the N-terminal 
GST-tag was isolated. After PreScissionTM Protease cleavage of the GST-PBGS fusion 
protein, recombinant PaPBGS was separated from the released GST-tag and the GST-
tagged protease by a second affinity chromatography. Fig. 15 provides documentation of the 
purification procedure.  
Fig. 15: Production, purification and 
processing of recombinant P. aeruginosa 
porphobilinogen synthase produced in E. coli.  
 
Proteins were separated by 12 % SDS-PAGE and 
visualized by staining with Coomassie Brilliant 
Blue. Lane 1: molecular weight marker; lane 2: 
total cellular extract after overnight induction of 
gene expression with 250 μM IPTG; lane 4: eluate 
from the glutathione sepharose column; lane 5: 
protein solution after digestion with prescission 
protease lane 6: purified MbPBGS after removal 
of the GST-tag with a second glutathione 
sepharose column.  
 
SDS PAGE analysis of the purified protein (lane 8 in Fig. 15) revealed a single band 
corresponding to a protein with a relative molecular mass of about 38,000, which is in good 
agreement with the calculated molecular mass of 36,831 Da. About 5 mg of purified 
recombinant PaPBGS were obtained per liter cell culture. 
Kinetic parameters for PaPBGS were evaluated in a standard activity test with a final 
concentration of 2 µg/mL recombinant PaPBGS. Different substrate concentrations were 
employed in the activity test, i.e. 0 mM, 0.1 mM, 0.2 mM, 0.5 mM, 1 mM, 2 mM, 5 mM 
and 10 mM ALA, respectively. As displayed in Fig. 16, product formation was increased 
over time in a substrate concentration dependent manner. In order to determine kinetic 
parameters of PaPBGS time dependent porphobilinogen formation was recorded and kinetic 
parameters computed using Sigma Plot 8.0 Enzyme Kinetics module v1.1. For PaPBGS the 
Results and Discussion
 
 
 
66
KM was 0.32 mM, the kcat 16.1 s-1 and kcat/KM 50.3 mM-1s-1, respectively. All kinetic 
parameters are listed in Tab. 9. These kinetic properties of PaPBGS resembled previously 
described results for the same enzyme (Frankenberg et al., 1999). 
 
Fig. 16: Outline of porphobilinogen synthase activity assay in 
microtitre plates.  
 
Using a modified Ehrlich´s test, porphobilinogen formation was 
evident from the resulting color formation which is recorded at 
A550 nm. From left to right substrate concentrations were raised. 
Time was increased from bottom to top. Product formation is 
dependent on substrate concentration and time. 
 
 
 
 
 
 
 
 
3.1.5.2 Recombinant Porphobilinogen Synthase from Methanosarcina 
barkeri 
The cloning of M. barkeri hemB was accomplished by PCR using primers based upon the 
sequence of Maeder and coworkers. (Maeder et al., 2006) (Genbank accession CP000099.1; 
locus tag Mbar_A1463) and genomic M. barkeri DNA as template. The obtained sequence 
for the cloned hemB gene was similar to the published one. Recombinant M. barkeri PBGS 
(MbPBGS) was produced in E. coli BL21(DE3)RIL and the resulting His-fusion protein 
was purified via Ni-NTA affinity chromatography. Recombinant MbPBGS eluted with  
500 mM imidazole (Fig. 17, lane 4). Fractions containing MbPBGS were combined and 
applied to a DEAE Sepharose column at a concentration of 0.7 mg/mL column volume. 
Recombinant protein was eluted with 300 mM NaCl. Fractions containing MbPBGS were 
combined (Fig. 17, lane 5), concentrated and purified via gel permeation chromatography to 
apparent homogeneity. SDS-PAGE analysis of the purified protein (Fig. 17, lane 6) revealed 
a predominant protein band corresponding to a protein with a relative molecular mass of 
about 62,000. This is in good agreement with the calculated molecular mass of the fusion 
protein of 63,444 Da. An amount of 9 mg recombinant MbPBGS per liter cell culture were 
yielded. Purified MbPBGS did not show any detectable degradation at 4°C for more than 
two months.  
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Fig. 17: Production and purification of 
recombinant M. barkeri porphobilinogen 
synthase produced in E. coli.  
 
Proteins were separated by 12 % SDS-PAGE 
and visualized by staining with Coomassie 
Brilliant Blue. Lane 1: molecular weight 
marker; lane 2: total cellular extract without 
induction of gene expression; lane 3: total 
cellular extract after overnight induction of 
gene expression with 250 μM IPTG; lane 4: 
eluate from the Ni-NTA column with  
500 mM imidazole; lane 5: eluate from DEAE 
sepharose column; lane 6: purified MbPBGS 
after gel filtration.  
 
Purified recombinant MbPBGS was tested for activity under standard assay conditions with 
25 µg/mL MbPBGS referred to the native enzyme without fused tags. For MbPBGS the KM 
was 0.07 mM, the kcat 0.012 s-1 and kcat/KM 0.17 mM-1s-1, respectively. All kinetic 
parameters are listed in Tab. 9. Features of MbPBGS have previously been described for the 
native purified enzyme, which possesses a specific activity of 0.39 µmol min-1mg-1 (Bhosale 
et al., 1995). The recombinant enzyme thus revealed a high substrate affinity and showed, 
compared to the native protein a comparable specific activity of 0.61 µmol min-1mg-1.  
3.1.5.3 Recombinant Human Porphobilinogen Synthase 
Recombinant purified human PBGS variant N59/C162A (HsPBGS) was kindly provided by 
Eileen Jaffe, Fox Chase Cancer Center, Philadelphia, USA. The enzyme was stable at  
-80°C for at least two month. For determination of kinetic parameters the protein 
concentration was adjusted to a final concentration of 25 µg/mL with substrate 
concentrations as described above. For HsPBGS at pH 7.0 the KM was 1.0 mM, the  
kcat = 0.049 s-1 and kcat/KM = 0.049 mM-1s-1, respectively. Formerly obtained results from 
Tang and coworkers showed a KM of 0.25 mM and a vmax of 55 µmol h-1 mg-1 (Tang et al., 
2005). In this study a vmax of 8.8 µmol h-1mg-1 was obtained. Obviously, substrate affinity 
and turnover were reduced. Since the purified enzyme was shipped, these slight differences 
might be due to loss of activity during transportation.  
3.1.6 Single Enzyme Inhibition Studies with Recombinant Porpho-
bilinogen Synthase 
The so far obtained results for the mode of action of alaremycin indicated that the antibiotic 
activity is exhibited by inhibition of PBGS and thus via blocking of the biosynthesis of 
essential tetrapyrroles. However, this has not been directly experimentally proven by testing 
of purified PBGS enzymes so far. Now, PBGS from three sources, bacterial, archaeal and 
Results and Discussion
 
 
 
68
eukaryotic, were purified and showed catalytic activity. To evaluate the inhibitory potency 
of alaremycin on recombinant PBGS, activity tests were performed in the presence and 
absence of the antibiotic in various concentrations. Inhibitor concentrations reducing 
enzyme activity by 50 % (IC50) were determined using various protein concentrations as 
described above and ALA concentrations of 1 mM. Different amounts from 1 – 10 mM of 
alaremycin were added to the activity tests. Dose response curves were obtained for all three 
recombinant proteins and IC50 values were deduced (Tab. 9).  
 
Tab. 9: Kinetic parameters and IC50 values for alaremycin for P. aeruginosa, M. barkeri and human 
porphobilinogen synthase.  
 
 
The Michaelis Menten constant KM, the kcat and the kcat/KM values for the various PBGS were determined from 
substrate velocity plots by measuring the constant velocity formation of porphobilinogen from ALA over a 
substrate range from 1 - 10 mM. Values were determined by the computerized Lineveaver Burk iterative curve 
fitting (SigmaPlot 8.0 Enzyme Kinetics v1.1). For inhibition studies 0 - 10 mM alaremycin was added to the 
enzyme activity test at an ALA concentration of 1 mM. 
            PaPBGS                  MbPBGS            HsPBGS 
    
KM   0.32 ±0.04 mM 0.07 ±0.012 mM 1.009 ±0.11  mM 
kcat  16.11 ±1.25 s-1 0.012 ±0.001 s-1 0.049 ±0.002 s-1 
kcat/KM  50.3 ±0.15 mM-1s-1 0.17 ±0.032 mM-1s-1 0.049 ±0.0057 mM-1s-1
      
IC50    2.1 ±0.4 mM 2.2 ±0.5 mM 4.1 ±0.9 mM 
 
All three recombinant enzymes showed inhibition by alaremycin at concentrations from  
2 - 4 mM, with the human enzyme showing a slightly higher tolerance compared to the 
archaeal and bacterial PBGS. When measuring the IC50 values, time-dependence of 
inhibition was detected. The obtained IC50 values are within the range of earlier tested 
inhibitors for PaPBGS (Frere et al., 2006, Gacond et al., 2007). The inhibitory effect of 
alaremycin is slightly more effective than for levulinic acid at an IC50 = 10 mM (Frere et al., 
2002). Possibly, the inhibitory effect of alaremycin is only on an average level compared to 
formerly tested inhibitors due to its bulky nature, since large PBGS inhibitors have been 
shown to reveal reduced inhibition capacities compared to smaller ones (Gacond et al., 
2007). Nevertheless, alaremycin may serve as a lead structure for chemically engineering of 
more effective derivatives. Furthermore, the inhibition capacity of alaremycin on enzymes is 
not restricted to the bacterial variants. The archaeal PBGS from M. barkeri revealed similar 
inhibition behavior as the P. aeruginosa enzyme. The human enzyme was inhibited by 
alaremycin in slightly higher concentrations. In summary, the obtained results revealed that 
PBGS is indeed the molecular target of alaremycin. The antibiotic reduced PBGS activity 
and thus disturbed tetrapyrrole biosynthesis, which consequently lead to significantly 
reduced bacterial growth. 
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3.1.7 Co-Crystallization of Pseudomonas aeruginosa Porphobilinogen 
Synthase with Alaremycin 
Since alaremycin selectively inhibits PBGS activity, it was of high interest to determine the 
exact molecular mode of alaremycin inhibition at the atomic level. Knowledge of the 
alaremycin coordination chemistry is one basis for further rational drug design. In previous 
co-crystallographic studies it has been shown that chemically synthesized inhibitors of 
PBGS are usually located in the active site of the enzyme and interact with one or both 
catalytic lysines. Consequently, the crystallization of PaPBGS in complex with the natural 
antibiotic alaremycin was attempted.  
The crystal structure of wildtype PaPBGS has been previously solved by Nicole 
Frankenberg in our laboratory in cooperation with the group of Dirk Heinz at the Helmholtz 
Centre for Infection Research, Braunschweig (Frankenberg et al., 1999). To obtain protein 
crystals in the presence of alaremycin similar conditions were employed using Crystal 
Screen I and II with a protein concentration of 10 mg/mL and alaremycin concentrations 
from 1 - 5 mM. Finally, crystallization was achieved by the sitting drop vapor diffusion 
method and crystals grew within two to three days. Most homogeneous crystals (see  
Fig. 18 A) were obtained with 10 mg/mL PaPBGS and 5 mM alaremycin in 100 mM Hepes 
pH 7.5, 200 mM MgCl2 and 30 % PEG400 at 17°C. Data collection was performed under 
cryogenic conditions using synchrotron radiation at beamline BL1 (BESSYII, Berlin, 
Germany) yielding a data set with diffraction up to 1.75 Å (Fig. 18 B + C). The following 
data analysis and manipulations were performed by Wolf-Dieter Schubert from the group of 
Dirk Heinz, Helmholtz Centre for Infection Research, Braunschweig. Data were indexed, 
integrated and scaled using HKL2000 (Otwinowski and Minor, 1997). All further 
manipulations were performed using the CCP4 suite of programs (Collaborative 
Computational Project Number 4, 1994). Data statistics are listed in Tab. 10. The structure 
of PaPBGS in complex with alaremycin was determined by molecular replacement using 
Phaser (McCoy et al., 2005) and the A-chain of a previous crystal structure of the same 
protein (PDB code 1B4K, Frankenberg et al., 1999) as a structural search model. The 
structure was refined using simulated annealing techniques (Brunger et al., 1998), followed 
by restrained refinement with TLS-protocols (Murshudov et al., 1997). For manual 
adjustments and quality control the graphics program Coot was used (Emsley and Cowtan, 
2004).  
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Fig. 18: Crystallization of P. aeruginosa porphobilinogen synthase and data collection. 
 
(A) Crystals obtained with 20 mg/mL PaPBGS and 5 mM Alaremycin in 100 mM Hepes pH 7.5, 200 mM 
MgCl2 and 30 % PEG400 at 17°C. (B) Diffraction pattern of PaPBGS in complex with alaremycin. Crystals 
diffracted up to 1.75 Å (C) Magnification of the diffraction pattern reveals ordered scattering. 
 
 
 
Tab. 10: Data collection and refinement statistics for the P. aeruginosa porphobilinogen synthase - 
alaremycin co-crystals 
 
 
a >1σ; b value for shell of highest resolution in parentheses; c ( )∑∑ ÷−= ihihih hihmerge IIIR ,,, ,100  
where summation is over all observations Ih,i contributing to the reflection intensities Ih.; e 5 % of data were 
omitted from refinement. f determined using Coot; g Calculated using Refmac. 
 
Crystallographic data  
Space group I422 
Cell dimensions: a;b;c (Å) 84.4; 84.4; 158.5 
Total reflections (>1σ) 401 885 
Unique reflections 29 316 
Resolution range (Å)b 28–1.75 (1.78-1.75) 
Completeness (%)b 100 (99.9) 
Redundancyb 13.7 (8.6) 
Rmergec 6.9 (50.4) 
I/σIb 46.0 (5.3) 
Temperature factor (Å2) 18.7 
 
Refinement  
Resolution range (Å) 27.9–1.75 
Reflectionsa 27 8236 
Non-H protein atoms/monomer 2 646 
Solvent molecules/monomer 195 
Ions/monomer: Na+; Mg2+ 2; 1 
Average B-factor (Å2) 16.2 
R-factor (%); Rfree (%)e 14.2; 18.2 
R.m.s. deviation from idealist: bond lengths (Å); bond angles (deg.)g 0.018; 1.54 
Estimate overall coordinate error, based on maximum likelihood (Å) 0.11 
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3.1.8 Co-Crystal Structure of Porphobilinogen Synthase with Alaremycin 
The high-resolution structure of PaPBGS at 1.75 Å in complex with a single alaremycin 
gives an ambiguous picture of the inhibitor’s binding. PaPBGS is a homooctameric protein 
composed of four dimers arranged around a central four-fold axis (Frankenberg et al., 1999, 
Frere et al., 2002). The extended N-terminal arm of each monomer closely wraps around its 
dimeric partner. The PaPBGS monomer is a classic TIM-barrel (see Fig. 19). The PBGS 
monomer is a single domain protein showing (βα)8-barrel-fold where eight parallel  
β-strands form a circular and closed β-barrel that is surrounded by α-helices linking 
neighboring β-strands. In the crystal, however, there is no ordered electron density for the 
nine amino acid residues attached to the N-terminus derived from the site-specific cleavage 
of the GST-tag and the first five native amino acids. This is in agreement with earlier 
findings (Frankenberg et al., 1999). As in all known (βα)8-barrel-containing enzymes, the 
active site of PBGS is located at the C-terminal side of the β-barrel, where extended loops 
and additional secondary structure elements restrict the opening. The entrance to the active 
site in PaPBGS is shielded from the surrounding solvent by a “lid” constituted by two short 
α-helices. The opening of the active site has previously been shown to possess two different 
conformations, an “open” and a “closed” form. However, in contrast to the previously 
described crystal structures from PaPBGS in complex with various inhibitors (Frankenberg 
et al., 1999, Frere et al., 2006), the dimer in the obtained structure is not asymmetric (see 
below). A single alaremycin is located in the active site (Fig. 19). 
 
Fig. 19: Stereo ribbon diagram showing the fold of P. aeruginosa porphobilinogen synthase monomer A 
in complex with alaremycin.  
 
The N-terminus is labeled. β-strands are shown in yellow, α-helices in red and loops in green. The unordered 
lid covering the active site is colored in grey. The side chains of the two active site lysines Lys260 and Lys205 
are also shown in light blue. Alaremycin (orange) is covalently attached to Lys260 via a Schiff base.  
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The overall structure was unaffected by inhibitor binding which is in agreement with earlier 
studies (Frere et al., 2006). In summary, the crystal structure is very similar to the ones 
previously obtained in our laboratory and co-crystallization of alaremycin in complex with 
PaPBGS was successful. 
3.1.8.1 A Monovalent Cation in the Active Site 
The crystal structure of PaPBGS in complex with alaremycin showed a monovalent cation 
in the active site which has been observed previously (Frere et al., 2002). As depicted in 
Fig. 20, the monovalent sodium ion was located in the active site in a position where in a 
single case a divalent magnesium ion has been described (Frere et al., 2006). Sodium is 
coordinated by three aspartates, Asp131, Asp139 and Asp176. Asp131 and Asp139 have 
been postulated to participate in the coordination of Mg2+ in the active site of Mg2+ 
dependent PBGS (Frankenberg et al., 1999). Additionally, Asp139 has previously been 
shown to play an important role in the formation of a “closed” lid conformation shielding 
the active site from the surrounding medium (Frankenberg et al., 1999, Frere et al., 2002). 
The lid which covers the active site had, as mentioned previously, two different 
conformations in former studies: An ordered “closed” form including two α-helices in 
monomer A as well as a more unordered “open” form in monomer B. The importance of the 
lid region for the enzyme's catalytic function is reflected by the high degree of amino acid 
conservation for this part of the region in all known PBGSs (Frankenberg et al., 1999). 
Surprisingly, this structure of PaPBGS in complex with alaremycin revealed an intermediate 
conformation for both monomers with a partly unordered lid in the region Ser220 – Asn227 
resembling the situation in monomer B. The conformation of Asp139 pointing towards the 
active site resembles the one usually found in monomer A with the ordered lid (see Fig. 20). 
The adjacent loop regions (residues 134-149) are as well alike to monomer A.  
The obtained results indicate that alaremycin binding to both monomers of the dimer fixes 
them in an intermediate state and prevents the formation for a completely closed 
conformation, however letting Asn139 already adopt a closed monomer conformation. 
Consequently, part of the lid which prevents solvent exposure during catalysis, remains in a 
partly unordered position, not fully developing the short α-helical structure typical for the 
ordered closed lid conformation (α-helix 8).  
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Fig. 20: Sodium binding site in the active 
centre of P. aeruginosa porphobilinogen 
synthase in complex with alaremycin.  
 
Sodium (dark blue) is coordinated by three 
aspartates, Asp131, Asp139 and Asp176, 
depicted in blue. Alaremycin is depicted in 
orange, active site lysines in cyan. Waters are 
colored in grey. Ionic interactions of Na+ are 
indicated in yellow, all other ionic 
interactions are shown in grey. 
 
 
 
 
 
 
3.1.8.2 Binding of Alaremycin 
In the obtained crystal structure, a single alaremycin was found to be located within the 
active site. This is in line with earlier findings for PBGS inhibitors co-crystallized in the 
active site cavity of PaPBGS (Frere et al., 2006, Frere et al., 2002). In these studies 
synthetic inhibitors were designed to investigate the enzymatic mechanism converting the 
two ALA substrates to porphobilinogen. Most of these inhibitors were found to bind to the 
active lysines via Schiff base formation.  
Alaremycin is as well coordinated by the two active lysines (Lys205 and Lys260) in the 
active site, which usually coordinate the two ALA via Schiff base formation. Similarly, a 
Schiff base is formed between the amino group of the P-site lysine (Lys260) and C4 of 
alaremycin. This coordination resembles the binding of the substrate ALA and is 
comparable to the conformation of the inhibitors levulinic acid and 5-fluorolevulinic acid in 
the active site cavity (Frankenberg et al., 1999, Frere et al., 2002). Due to a double bond 
within the inhibitor molecule, its conformation is rigid and stable in the active site (Fig. 21). 
Furthermore, this conformation is stabilized by two hydrogen bonds of the carboxyl-group 
of the antibiotic with Ser286. The same has previously been reported for a  
5-hydroxylevulinic acid (5-OH-LA) molecule, a substrate analog, in the P-site of PaPBGS 
(Frere et al., 2006). This indicates that alaremycin imitates the substrate ALA in the P-site 
rather than the product porphobilinogen. The second Schiff-base of the inhibitor with 
Lys205 in the A-site is not present. Instead a hydrogen-bridge is formed between the amino 
group of A-site lysine (Lys205) and the keto group of C7 of alaremycin. This conformation 
is stabilized by hydrophilic interactions of the inhibitor with water molecules which in turn 
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interact with polar amino acids and the sodium ion, respectively. The part of the antibiotic 
which blocks the A-site of the active site reveals a similar conformation as previously 
observed for inhibitors mimicking the intermediate of the condensation reaction (Frere et 
al., 2006).  
Due to the crystal structure of PaPBGS in complex with alaremycin it is unambiguous that 
PaPBGS is indeed the molecular target of the antibiotic. The active site is efficiently 
blocked by an inhibitor in a rigid and stable conformation. Alaremycin displays the first 
natural antibiotic to be crystallized within the active site cavity of PBGS.  
Fig. 21: The active site of  
P. aeruginosa porphobilinogen 
synthase in complex with 
alaremycin.  
 
Labels are according to PaPBGS 
numbering. Lys205 and Lys260 
are colored in cyan, alaremycin is 
colored in orange. Water 
molecules are depicted in grey. 
Surrounding residues are colored 
in red. Alaremycin is bound to 
Lys205 (A-site) and Lys260 via a 
hydrogen bond and a Schiff base, 
respectively. Ionic interactions are 
marked as grey dots. 
 
 
3.1.9 Alaremycin Induces “Small Colony Variants” of Staphylococcus 
aureus 
S. aureus strains deficient in heme biosynthesis have been isolated from persistent infections 
in humans. They revealed a significantly higher tolerance towards antibiotics and a reduced 
growth phenotype. So called “small colony variants” (SCV) lack a functional PBGS due to a 
mutation in the hemB gene or its promoter (von Eiff et al., 2006). S. aureus strains with a 
genomic knockout of hemB have been chosen as model organism for genomic and 
proteomic investigations of SCV. 
If alaremycin inhibits PBGS from S. aureus as seen for PBGS in cell free extracts, the 
induction of a SCV has to be expected. Therefore, investigations of growth phenotypes of  
S. aureus on solid media were carried out at 0 mM, 5 mM and at 10 mM alaremycin on  
LB-Agar media. S. aureus formed dwarf colonies (see Fig. 22) with 5 mM alaremycin and 
showed no growth at 10 mM alaremycin on solid media. The obtained results imply that 
alaremycin gives rise to an inducible S. aureus SCV phenotype. This observation may be 
suitable for a wide range of applications in S. aureus infection research. Currently, research 
is done with an irrevocable genomic hemB knockout. Nevertheless, further studies of 
Results and Discussion
 
 
 
75
alaremycin antimicrobial activity, employing different S. aureus strains including the 
mentioned S. aureus hemB- strain and clinical isolates will give further insight into this 
feature. 
 
Fig. 22: S. aureus phenotypes with and without alaremycin treatment.  
 
S. aureus was grown on solid LB-Agar for 20 h at 37°C and subjected to no (A+C) or 5 mM (B+D) 
alaremycin. At 5 mM of the antibiotic, the cells grew as dwarf colonies indistinguishable to the S. aureus SCV. 
(A+B) Scale bar = 1 cm; (C+D) Scale bar = 1 mm. 
3.1.10 Conclusions from the Investigation of the Molecular Target of 
Alaremycin 
It was shown in the framework of this thesis, that alaremycin, produced by S. sp. A012304, 
is a potent, broad spectrum antibiotic which exhibits its function via selective PBGS 
inactivation. The antibiotic was an inhibitor of recombinant purified PBGS from the 
bacterium P. aeruginosa, the archaeon M. barkeri and in higher concentrations also of the 
human enzyme.  
Since the human enzyme also responded to alaremycin, it is most likely that alaremycin will 
not serve as a therapeutically relevant antibiotic. Furthermore, first experiments revealed 
cytotoxic effects on human cells at the alaremycin concentrations employed in this study 
(Masaaki Wachi, personal communication). Nevertheless, there are further possible 
applications for this natural inhibitor of heme biosynthesis. Even though alaremycin 
concentrations needed to be in a molar ratio, it may serve as a potent lead structure for the 
development of novel antibiotics targeted on heme biosynthesis. Furthermore, there is the 
perspective to identify a resistant PBGS from the producer strain S. sp. A012304. Since the 
M. barkeri enzyme was also inhibited, alaremycin may serve as a selective agent applicable 
in archaeal genetic systems. Today, there are only a few antibiotics available which are 
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appropriate as a selection marker in archaea. Another interesting feature of this antibiotic 
was the creation of inducible S. aureus SCV, which may lead to further applications in 
infection biology research. Until now, S. aureus strains carrying a permanent genomic 
knockout of hemB serve as model organism to mimic the highly infective SCV. An 
inducible SCV model may simplify research since it prevents problems associated with the 
slow growth of S. aureus SCV at early stages of an experiment. 
 
3.2 Plant Uroporphyrinogen III Synthase 
Enzymes of the tetrapyrrole biosynthesis pathways have been intensively studied over the 
past decades. Yet, the identity of the plant enzyme catalyzing the conversion of pre-
uroporphyrinogen to uroporphyrinogen III has not been established via simple database 
miming. Therefore, the laboratory of Alison Smith, Cambridge, UK sought to identify the 
gene encoding A. thaliana UROS (AtUROS) via an approach using functional 
complementation of a corresponding yeast mutant (S150-2B::ΔHEM4) (Tan et al., 
unpublished data). They identified an ORF encoding 321 amino acids which was 
furthermore able to complement an E. coli hemD mutant defective in UROS. The amino 
acid sequence of the ORF was used to query all GenBank, EMBL, DDBJ and PDB 
sequences in the databases with BLAST (Altschul et al., 1997) on the NCBI server. This did 
not identify UROS genes described from other organisms. Comparison of the sequence of 
AtUROS with that of the human enzyme revealed conservation of the seven invariant 
residues identified for UROS, including three shown to be important for enzyme activity. 
Furthermore, a structure-based homology search of the protein data base with AtUROS 
identified the human crystal structure.  
An N-terminal extension of about 81 residues was identified as a chloroplast targeting 
sequence with the precursor protein of Mr = 34,000 being targeted to the chloroplasts and 
processed to the mature size of 30,000 in vivo. For a final identification, it was essential to 
determine the enzymatic function for the recombinant protein. Therefore, the AtUROS was 
recombinantly produced, purified and tested for activity.  
3.2.1 Purification of Putative Arabidopsis thaliana Uroporphyrinogen III 
Synthase 
In the laboratory of Alison Smith genes for two protein variants of AtUROS have been 
constructed. Full length AtUROS was encoded by pUROSfull and the mature form lacking 
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the 81 amino acid signal peptide was encoded by pUROSmat, respectively. Recombinant full 
length and mature UROS were produced in E. coli BL21(DE3)RIL carrying the respective 
plasmids. The recombinant production of full length protein resulted in solely insoluble 
protein. Therefore, the truncated version was chosen for further studies. Recombinant 
putative mature A. thaliana UROS was produced in E. coli BL21(DE3)RIL and the resulting 
fusion protein was purified via Ni-NTA affinity chromatography. Recombinant protein 
eluted with 300 mM imidazole (Fig. 23, lane 4) and fractions containing recombinant 
AtUROS were combined and applied to a DEAE sepharose column at a concentration of  
0.5 mg per mL column volume.  
Fig. 23: Production and purification of 
recombinant A. thaliana uroporphyrinogen 
III synthase.  
 
Proteins were separated by 12 % SDS -PAGE 
and visualized by staining with Coomassie 
Brilliant Blue. Lane 1: molecular weight marker; 
lane 2: total cellular extract without induction; 
lane 3: total cellular extract after overnight 
induction of gene expression with 100 μM 
IPTG; lane 4: eluate from the Ni-NTA column 
with imidazole; lane 5: eluate from DEAE 
sepharose column; lane 6: purified AtUROS 
after gel filtration.  
 
 
Recombinant AtUROS was eluted with 200 mM NaCl and fractions were combined (Fig. 
23, lane 5), concentrated and purified by gel permeation chromatography to apparent 
homogeneity. SDS-PAGE analysis of the purified protein (Fig. 23, lane 6) revealed a 
predominant protein band which corresponded to a protein with a relative molecular mass of 
about 30,000. Approximately one mg recombinant AtUROS per liter cell culture was 
obtained. 
3.2.2 Determination of Arabidopsis thaliana Uroporphyrinogen III 
Synthase Activity 
To determine enzymatic activity of AtUROS in vitro, a coupled enzyme activity test had to 
be established. The linear pre-uroporphyrinogen substrate of UROS is highly instable and 
spontaneously cyclizes to uroporphyrinogen I. Therefore, it is not commercially available. 
Consequently, pre-uroporphyrinogen was formed enzymatically from ALA using purified 
recombinant PaPBGS and B. megaterium PBGD. PaPBGS was purified as described before, 
purified B. megaterium PBGD was kindly provided by Claudia Schulz from our laboratory. 
Purified recombinant putative AtUROS was tested for UROS activity under assay 
conditions described in MATERIALS AND METHODS, using two different systems for 
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the detection of uroporphyrinogen III formation. Recombinant AtUROS was able to convert 
pre-uroporphyrinogen into uroporphyrinogen III as demonstrated by both fluorimetric and 
spectroscopic detection of the oxidized product uroporphyrin III in a coupled enzyme assay. 
Due to enzymatic conversion of ALA to uroporphyrinogen III, the absorbance at 408 nm for 
the oxidized reaction product uroporphyrin III increased over time (5 to 120 minutes) from 
0.03 to 0.87. Furthermore, the amount of enzymatically formed uroporphyrinogen III was 
determined via fluorimetric detection of uroporphyrin III with fluorescence maxima at  
600 nm and 620 nm (Fig. 24 A). Both applied methods revealed that the ORF identified by 
the laboratory of Alison Smith indeed encoded active A. thaliana UROS.  
 
Fig. 24: Uroporphyrinogen III synthase activity assay for the recombinant purified A. thaliana enzyme.  
 
Assays were carried out as described in MATERIALS AND METHODS. The enzymatic activity of 
recombinant AtUROS was measured in a coupled enzyme activity assay with PBGS and PBGD, thus the 
conversion of ALA to uroporphyrinogen III. The amount of enzymatically formed uroporphyrinogen III was 
determined via fluorimetric detection of its oxidized form uroporphyrin III which has fluorescence maxima at 
600 nm and 620 nm. Presented are the emission spectra from 540 to 700 nm with an excitation wavelength of 
400 nm. (A) A standard enzyme activity assay was used, the reaction was carried out for 5 (—), 30 (—),  
60 (—), 90 (—) and 120 (—) minutes at 37°C. Uroporphyrin III formation was increased over time.  
(B) A spectrum of commercially available uroporphyrin III (—) is depicted. A standard assay without (—) or 
with heat inactivated AtUROS (—) revealed no detectable uroporphyrin III formation.  
 
Since all previously studied UROS were sensitive to heat denaturation, enzyme activity was 
evaluated after 2 minutes incubation at 60°C as described for the E. coli enzyme (Alwan et 
al., 1989). The in this way treated purified recombinant enzyme revealed no residual 
activity as shown in Fig. 24 B. Heat-instability is also known from UROS human 
erythrocytes (Tsai et al., 1987) which possesses almost identical properties. At room 
temperature AtUROS lost approximately 30 % of its activity over two hours, but was 
relatively stable at 4°C (60 - 80 % residual activity over night). Nevertheless, this feature in 
combination with the instability of the substrate pre-uroporphyrinogen and the resulting 
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necessity to employ a coupled enzyme activity assay complicated the determination of 
reliable kinetic parameters.  
3.2.3 Subunit Structure of Arabidopsis thaliana Uroporphyrinogen III 
Synthase 
During the purification of AtUROS, the last step involved gel filtration chromatography. By 
reference to the elution of molecular mass standards, the AtUROS was estimated to have a 
relative molecular mass of 62,000 ± 5,000, compared to the predicted mass of 29,994 Da for 
the monomeric protein with an N-terminal His6-tag. All other analyzed UROSs from 
spinach, rat liver, Euglena gracilis, human erythrocytes and E. coli were found to be 
monomers (Shoolingin-Jordan, 1995). It is unlikely that the plant enzyme should behave 
differently. Rather, the unusual asymmetric shape of the protein, as seen in the crystal 
structure of the human enzyme (Mathews et al., 2001), may well interfere with the gel 
filtration process. 
3.2.4 Conclusions from Investigations of Arabidopsis thaliana 
Uroporphyrinogen III Synthase 
Most of the genes encoding tetrapyrrole biosynthetic enzymes can be easily identified 
through amino acid sequence similarity searches using a known homolog. Many of the 
ubiquitous enzymes of heme synthesis have been identified this way (Hansson et al., 1991). 
However, contrary to almost all the other enzymes of the pathway, UROS has very little 
sequence conservation between unrelated organisms. The complexity of the reaction 
performed by the UROS is not reflected in the primary structure of the enzyme. It is 
possible that the enzymatic conformation of UROS may require the conservation of only a 
few residues, while the rest are under little or no selection pressure, leading to the primary 
sequence divergence of homologs found in different organisms. Hence, for this unique 
enzyme, a conserved tertiary structure may play a more important role for its catalytic 
properties.  
With the obtained results it was now possible to confirm the identity of A. thaliana UROS 
which led to identification of further putative plant UROS encoding ORFs from rice, wheat 
and the green algae Ostreococcus lucimarinus and Ostreococcus tauri via BLAST 
searching. These proteins were all very similar to one another (about 50 % identity) 
suggesting that they have diverged from the UROSs found in other kingdoms early on in 
evolution. The plant enzymes shared 26 % identity with that from cyanobacteria. In 
summary, with the obtained results it was possible to clearly identify the first gene encoding 
Results and Discussion
 
 
 
80
a plant UROS, which is the first step towards a closer biochemical and structural 
investigation. 
 
 
3.3 Investigation of the Substrate Binding Site of Tobacco 
Protoporphyrinogen IX Oxidase 
The penultimate step of heme biosynthesis is the conversion of protoporphyrinogen IX to 
protoporphyrin IX. This six electron oxidation is catalyzed by PPO which in eukaryotes is a 
flavin-containing, oxygen-dependent protein. A mutation in the corresponding gene in 
humans may result in defective PPO, which leads to a disease commonly known as 
variegate porphyria (VP). Manifestations of VP may include cutaneous photosensitivity and 
systemic symptoms arising from neurologic dysfunction. In contrast, the inhibition of PPO 
is deliberately induced in plant treatment by substrate analogs such as diphenylether 
herbicides.  
The crystal structure of tobacco enzyme was solved in 2004 by Koch and coworkers (Koch 
et al., 2004) and represented the first structural information available for proto-
porphyrinogen IX oxidases. This raised the possibility to determine the structural basis for 
substrate binding, herbicidal mode of action and the human disease VP. The NtPPO2 
structure in complex with the inhibitor 4-bromo-3-(50-carboxy-40-chloro-20-fluoro-
phenyl)-1-methyl-5-trifluoro-methyl-pyrazol revealed that its active site is located between 
the FAD- and the substrate-binding domain. The inhibitor represents ring A and B of the 
tetrapyrrole substrate. In Fig. 25 the modeling of the substrate protoporphyrinogen IX into 
the active site is depicted. Modeling was kindly performed by Michael Koch, Laboratoire de 
Biologie et de Génomique Structurales, Cedex, France. The substrate-binding site beneath 
the FAD is a flat cavity that is formed by a number of aromatic and aliphatic amino acids as 
well as by Asn67 and Arg98 (Koch et al., 2004). Based on a model that was calculated from 
the solved crystal structure of NtPPO2, it was deduced in silico that amino acid residues 
Arg98, Leu356, Leu372 and Phe392 play a central role in substrate coordination.  
 
 
Results and Discussion
 
 
 
81
 
Fig. 25: Modeling of the substrate protoporphyrinogen IX into the binding pocket of tobacco 
mitochondrial protoporphyrinogen IX oxidase.  
 
(A) The inhibitor (green) is shown surrounded by its molecular surface (green) in the active site of NtPPO2 
(surface of NtPPO2 depicted in orange). (B) The position of the substrate protoporphyrinogen IX (grey) shown 
inside its molecular surface (blue) is illustrated in its good fitting into the active site cavity of NtPPO2 
(orange). (C) The active site residues and the FAD of NtPPO2 are depicted around the bound inhibitor (green) 
and the modeled substrate, protoporphyrinogen IX (grey) in the shape of the substrate surface (blue). 
 
In animal PPOs including human PPO, the conserved Arg59 plays an important catalytic 
role. In 94 % of the cases in South Africa, the human disease VP is caused by a single 
mutation of Arg59 to tryptophan. In the structure of NtPPO2, Ser374 that is conserved 
between various plant species is in a position opposite to Asn67. The corresponding residue 
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in animal PPOs is the conserved Asp349 that is likely to form a salt bridge with Arg59. The 
disruption of this salt bridge may play a central role in the human disease. Nevertheless, 
none of these assumptions deduced from the crystal structure have been proven 
experimentally so far. To further investigate these features of NtPPO2, the enzyme and 
respective mutants were recombinantly produced, purified and kinetically characterized. 
3.3.1 Purification and Biochemical Characterization of Tobacco 
Protoporphyrinogen IX Oxidase 
Recombinant NtPPO2 was produced using E. coli strain BL21(DE3)RIL as outlined in 
MATERIALS AND METHODS. The resulting fusion protein was purified via affinity 
chromatography on a Ni-IDA resin. Recombinant NtPPO2 eluted with 500 mM imidazole 
(Fig. 26, lane 4). SDS-PAGE analysis of the purified protein revealed a predominant protein 
band which corresponded to a protein with a relative molecular mass of about 68,000, which 
is in good agreement with the calculated molecular mass of the fusion protein of 70,670 Da. 
Only about 0.5 mg recombinant NtPPO2 per liter cell culture were obtained. Most of the 
recombinant protein was found insoluble. 
The PPO activity assay was carried out under standard conditions via detection of the 
fluorescence of the reaction product protoporphyrin IX. The enzymatic reaction was, as 
expected, oxygen-dependent. 
 
Fig. 26: Recombinant production and affinity 
chromatography purification of N. tabacum 
protoporphyrinogen IX oxidase.  
 
Proteins were separated by 12 % SDS-PAGE as 
described in MATERIALS AND METHODS and 
visualized by staining with Coomassie Brilliant Blue. 
Lane 1: molecular weight marker; lane 2: total cell 
extract made from culture without induction of gene 
expression; lane 3: total cell extract after overnight 
induction of gene expression with 250 μM IPTG; lane 
4: eluate from the Ni-IDA resin with 500 mM 
imidazole. 
 
Under anaerobic conditions no noteworthy amount of protoporphyrin IX was formed (data 
not shown). The Michaelis Menten constant (KM), the maximal velocity vmax and the 
catalytic constant kcat were determined from substrate velocity plots by measuring the 
constant velocity formation of protoporphyrin IX from protoporphyrinogen IX over a 
substrate range from 1 - 25 µM and a time course of up to 2 hours at 20°C. Values were 
determined by the computerized Lineveaver Burk iterative curve fitting (SigmaPlot 8.0, 
Enzyme Kinetics modulev1.1). The FAD content of wildtype and mutant NtPPO2 were 
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determined spectroscopically. The apparent KM value of purified wildtype NtPPO2 protein 
for its substrate was 1.17 μM with a kcat value of 6.0 s-1. The determined kinetic parameters 
were within the range of values measured for PPOs from other organisms, e.g. KM = 1.0 μM, 
kcat = 0.0031 s-1 for B. subtilis (Corrigall et al., 1998), KM = 0.1 μM for S. cerevisiae 
(Camadro et al., 1994), KM = 2.8 μM for A. aeolicus, (Wang et al., 2001) and KM = 0.85 μM 
and for H. sapiens either a kcat = 0.175 s-1 (Dailey and Dailey, 1996) or a kcat = 5.95 s-1 
(Maneli et al., 2003), respectively. The FAD content of wildtype NtPPO2 was measured as 
described in MATERIALS AND METHODS and was 0.63 moles FAD/subunit NtPPO2. 
The incomplete saturation of NtPPO2 with FAD was in agreement with earlier findings of 
Dailey and coworkers who determined 0.4 - 0.5 FAD/subunit in M. xanthus (Dailey and 
Dailey, 1996). 
3.3.2 Functional Investigation of the Substrate Binding Site of 
Protoporphyrinogen IX Oxidase 
The crystal structure of NtPPO2 revealed a close insight into the three-dimensional structure 
of the enzyme. The substrate protoporphyrinogen IX was modeled into the active site and is 
outlined in Fig. 27. Residues Arg98, Phe392, Leu372 and Leu356 coordinate the inhibitor  
4-bromo-3-(50-carboxy-40-chloro-20-fluoro-phenyl)-1-methyl-5-trifluoromethyl-pyrazol, 
which was co-crystallized within the active site of NtPPO2. These four amino acid residues 
were found highly conserved throughout the PPO family of proteins. Ring A is coordinated 
via aromatic stacking with Phe392 (Fig. 27) (Koch et al., 2004). 
 
 
Fig 27: Active site of tobacco PPO2 with the modeled substrate protoporphyrinogen IX.  
 
Depicted are the investigated amino acid residues Arg98, Leu356, Leu372 and Phe392. Phe392 is shown to 
coordinate ring A of the protoporphyrinogen IX. Leu356 and Leu372 stack protoporphyrinogen IX ring B 
from the “back” and the “front”, Arg98 is supposed to coordinate the propionate carboxylate group of the 
protoporphyrinogen IX ring C, respectively (Heinemann et al., 2007). 
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The side chains of Leu356 and Leu372 interact hydrophobically with ring B. The side chain 
of residue Arg98 forms a salt bridge to the propionate carboxyl group of ring C, which 
additionally might be stabilized by flipping and subsequent stacking of the conserved 
residue Phe392. The dome conformation of the substrate is probably stabilized by the 
carbonyl oxygen of the highly conserved Gly175.  
3.3.2.1 Mutagenesis of the Amino Acid Residues Arg98, Leu356, Leu372 and 
Phe392 
According to the crystal structure of NtPPO2 and the deduced model for substrate binding, 
the highly conserved residues Arg98, Leu356, Leu372 and Phe392 are suspected to be 
involved in substrate coordination. In order to evaluate their chemical contribution to 
substrate binding and catalysis, a strategy of introducing conservative and non-conservative 
amino acid exchanges for these residues was applied and single amino acid exchanges were 
conducted. Phe392 is involved in the coordination of substrate ring A and was replaced by 
histidine and glutamate, respectively. Residues Leu356 and Leu372, which coordinate 
substrate ring B via hydrophobic interactions, were replaced by valine and asparagine, 
respectively. Residue Arg98 forms a salt bridge to the propionate carboxyl group of ring C 
and was replaced by alanine, lysine and glutamate, respectively. The mutated enzyme 
variants were produced in E. coli BL21(DE3)RIL and purified to apparent homogeneity 
under conditions identical to those established for the wild type enzyme. All mutant proteins 
were analyzed for their FAD content and their overall PPO activity.  
3.3.2.2 Catalytic Activity and FAD Content of Active Site Mutants from 
Tobacco Protoporphyrinogen IX Oxidase  
For all recombinant mutant proteins kinetic parameters and the FAD content were 
determined as described for the wildtype enzyme and are listed in Tab. 11.  
Ring A. The crystal structure and the respective modeling revealed that ring A of the 
substrate is kept in position by aromatic stacking with residue Phe392, which stabilizes the 
electron transfer over the ring during the reaction. An amino acid exchange to Glu392 in the 
variant F392E was tolerated within the active site cavity and resulted in inferior binding of 
the substrate protoporphyrinogen IX (KM = 11.2 μM). However, once the substrate was 
bound, its conversion was catalyzed sufficiently (kcat = 11 s-1). 
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Tab. 11: Kinetic parameters of wildtype tobacco protoporphyrinogen IX Oxidase and corresponding 
active site mutants.  
 
The Michaelis Menten constant KM, the kcat and the kcat/KM values for wildtype and mutant NtPPO2 were 
determined from substrate velocity plots by measuring the constant velocity formation of protoporphyrin IX 
from protoporphyrinogen IX over a substrate range from 1-25 µM. The FAD content was calculated using 
commercially obtained FAD. The standard deviation of the shown results was between 5 and 10 %. 
 
Protein variant   KM 
[µM] 
kcat  
[s-1]  
kcat/KM 
 [µM-1s-1] 
  FAD content  
  [mol/subunit] 
Wildtype    1.17     6 5.1 0.63  
     
Substrate binding ring A     
F392H n.d. n.d. n.d. 0.58  
F392E    11.2   11 1.0 0.60  
      
Substrate binding ring B     
L356N    11   38 3.4 0.55  
L356V     7.3 300 41.1 0.62  
L372N   16.4     7 0.4 0.60  
L372V 103 597 5.8 0.53  
      
Substrate binding ring C     
R98K     2.6   37 14.4 0.50  
R98E   12.5   34 2.7 0.51  
R98A     8.3 365 44 0.57  
n.d. not detectable 
 
The tetrapyrrole ring is made positive by the hydride abstraction at the N5 atom of FAD. 
Thus the negative charge of the introduced glutamate might stabilize the ring and catalysis 
may proceed equally fast. In this case only the stabilization of the substrate by aromaticity is 
lowered and as a result its binding is weaker. Additionally, the NtPPO2 variant F392H was 
found to be virtually inactive. Determination of reliable kinetic parameters was not possible. 
Histidine at a pH below its pK at 6.1 is positively charged. Here at pH 6.0, this held true for 
most histidine molecules of NtPPO2. The positive charge of the histidine ring at this 
position lead to repulsion and obstructed substrate binding, consequently reaction kinetics 
collapsed. Detailed kinetic parameters of the mutant proteins are listed in Tab. 11.  
Ring B. In the model for substrate binding deduced from the NtPPO2-inhibitor crystal 
structure, ring B of protoporphyrinogen IX is sandwiched between the conserved residues 
Leu356 and Leu372. Both amino acid residues were exchanged to either valine or 
asparagine, respectively. In both cases the conservative amino acid exchange to valine 
enhanced catalysis up to 100-fold (kcat = 300 s-1 and kcat = 597 s-1, respectively). However, 
by exchange of the amino acid Leu372 to valine, binding of the substrate 
protoporphyrinogen IX was reduced 100-fold (KM = 103 μM). In contrast, the NtPPO2 
variants L356N and L372N showed a slightly inferior binding capacity, only,  compared to 
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the wildtype and revealed comparable catalytic activities (see Tab. 11). Valine possesses 
comparable hydrophobic features to leucine. However, the carbon backbone of the side 
chain is shorter than that of leucine. Probably the appropriate location of the hydrophobic 
residue in relation to the coordinated substrate ring is essential, explaining the increasing  
KM values of L356V and especially L372V. Once the substrate was bound, catalysis was 
found enhanced for both mutants. Most likely the smaller side chain of valine better 
accommodated the necessary complex arrangement of the substrate during catalysis. On the 
other hand, asparagine obviously provided the necessary side-chain length and chemical 
character to supplement for leucine in both positions.  
Ring C. The next investigated amino acid residue potentially involved in substrate binding 
was Arg98. It was deduced from the NtPPO2 crystal structure that Arg98 provides the 
counter charge for the carboxylate group of the inhibitor which most likely mimics the 
propionate group of ring C of protoporphyrinogen IX. The NtPPO2 variants R98K, R98E 
and R98A were chosen to evaluate the contribution of this positively charged amino acid. 
While the conservative exchange R98K improved enzyme activity (kcat = 37 s-1), the non-
conservative exchange R98E resulted in inferior substrate binding (KM = 12.5 μM). Thus, 
the introduced negative charge could prohibit the ionic interaction necessary for the 
stabilization of ring C. In agreement with this assumption, the replacement of Arg98 with 
the non polar amino acid alanine resulted in an enzyme variant (R98A) with an eight-fold 
increased KM value. Interestingly, all three variants in position 98 showed an increased  
kcat value, especially variant R98A (kcat = 309 s-1), indicating improved turnover in the 
absence of ionic interactions between enzyme and substrate. Nevertheless, the overall 
response of NtPPO2 towards the introduced amino acid exchanges in position 98 was nicely 
reflected by the kcat and KM values.  
The FAD content of all mutant enzymes was quite similar and thus the introduced amino 
acid exchanges do not seem to have an impact on FAD binding.  
3.3.2.3 Conclusions from the Active Site Mutagenesis Studies 
The obtained results for mutants of amino acids residues from NtPPO2 located close to the 
modeled substrate strongly implied that the well conserved amino acid residues Arg98, 
Phe392, Leu356 and Leu372 were indeed functionally involved in substrate coordination 
within the active site. Most likely all four rings of the protoporphyrinogen IX substrate of 
NtPPO2 were coordinated during substrate binding by NtPPO2. Ring A was stacked by 
Phe392, ring B was sandwiched in between Leu356 and Leu372 and the propionate 
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carboxylate of ring C was bound to Arg98. Moreover, ring D might have been stacked 
against the A ring of the isoalloxazine moiety of the FAD. Most of the generated NtPPO2 
variants were characterized by an increase in KM and kcat values. Nevertheless, it was 
surprising to find that some amino acid exchanges even enhanced catalysis, even though 
most mutations resulted in a decrease of substrate affinity. Furthermore, a misplaced 
substrate did not have a prominent effect on FAD binding, since the FAD content was rather 
unaffected. One may conclude that NtPPO2 was optimized during evolution rather towards 
a stringent substrate recognition and discrimination than towards catalytic turnover.  
3.3.3 Investigation of Amino Acid Residues Involved in Variegate 
Porphyria  
The dominantly inherited genetic disorder VP in humans results from impaired PPO activity 
as a consequence of an amino acid residue exchange. In more than 94 % of the VP cases in 
South Africa, Arg59 is mutated to tryptophan (Meissner et al., 1996). The corresponding 
residue to human Arg59 in the NtPPO2 is Asn67. It is positioned on a long loop between a 
β-strand and an α-helix between the FAD binding and substrate-binding sites (Fig. 28). The 
residue is conserved in all known mitochondrial and plastidic plant PPO amino acid 
sequences. However, in the NtPPO2 crystal structure Ser374 is the residue opposite to 
Asn67. The corresponding residue in human PPO is Asp349 conserved in all known animal 
PPOs as well. Asp349 is likely to form a salt bridge with Arg59, which would sterically fit 
in this area of the protein (Koch et al., 2004). 
 
Fig. 28: Residues involved in human variegate porphyria assigned to tobacco protoporphyrinogen IX 
oxidase.  
 
In the human enzyme a mutation of Arg59 to tryptophan is the main cause for VP. The corresponding amino 
acid residue in the tobacco enzyme is Asn67, which forms a salt bridge to Ser374. Depicted amino acid 
residues Asn67 and Ser374 are located in close proximity to the modeled substrate protoporphyrinogen IX 
(Heinemann et al., 2007).  
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3.3.3.1 Mutagenesis of the Residues Asn67 and Ser374 
Since the corresponding residue to Arg59 in the human enzyme is Asn67 in the tobacco 
enzyme, the protein was first mutated to resemble the human variant and further adapted to 
the disease causing situation. Furthermore, the tobacco enzyme was adapted towards its 
human counterpart by the introduction of a salt bridge to Ser374. The mutant enzymes were 
produced in E. coli BL21(DE3)RIL and purified to apparent homogeneity under conditions 
identical to those established for the wildtype enzyme (see MATERIALS AND 
METHODS).  
3.3.3.2 Catalytic Activity and FAD Content of Variegate Porphyria Mutants 
from Tobacco Protoporphyrinogen IX Oxidase  
All mutant proteins were analyzed for their FAD content and their overall PPO activity. 
Obtained results are listed in Tab. 12. In order to mimic the human enzymes situation on the 
basis of the related NtPPO2 crystal structure, Asn67 was mutated to arginine. The obtained 
mutant N67R was found to be reasonably active. Even though the mutation resulted in 
inferior substrate binding, the catalytic efficiency was acceptable (see Tab. 12 for detailed 
kinetic parameters). This observation was in agreement with the findings of Maneli and 
coworkers (Maneli et al., 2003) who underlined the importance of a hydrophilic, favorably 
positively charged amino acid at position Arg59 in the human enzyme. Replacing Asn67 by 
tryptophan abolished enzyme activity. The bulky nature of an aromatic tryptophan in 
position Asn67 resulted in impaired enzyme activity. Thus, the enzymatic defect responsible 
for most VP cases in humans can be transferred onto NtPPO2 and the spatial structure of 
NtPPO2 can be used as a model for human PPO.  
In order to further adapt NtPPO2 towards the human counterpart, Ser374 was mutated to 
aspartate. The S374D single mutant showed reduced substrate binding capacity with a 
significantly increased kcat value (kcat = 208 s-1). Subsequently, Asn67 of protein variant 
S374D was mutated to arginine to reconstruct the assumed salt bridge Asp374/Arg67 in the 
human enzyme for our tobacco VP model. The resulting N67R/S374D double mutant 
showed an almost wildtype level KM value (KM =1.4 µM). Thus, this NtPPO2 variant had 
almost wildtype like substrate recognition and even improved catalytic properties  
(kcat = 111 s-1) caused by a reconstruction of the salt bridge in the tobacco enzyme. These 
results argue for the existence of a salt bridge linking Arg59 and Asp349 in the human 
enzyme as well. 
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Tab. 12: Kinetic parameters and FAD content of tobacco protoporphyrinogen IX oxidase mutant 
enzymes reflecting the variegate porphyria genotype.  
 
 
The Michaelis Menten constant KM, the kcat and the kcat/KM values for wildtype and mutant NtPPO2 were 
determined from substrate velocity plots by measuring the constant velocity formation of protoporphyrin IX 
from protoporphyrinogen IX over a substrate range from 1 - 25 µM. Values were determined by the 
computerized Lineveaver Burk iterative curve fitting (SigmaPlot 8.0 Enzyme Kinetics module v1.1). The FAD 
content of wildtype and mutant NtPPO2 was determined spectroscopically. The FAD content was calculated 
using commercially obtained FAD. The standard deviation of the shown results was between 5 and 10 %. 
 
Protein variant KM            
[µM] 
kcat  
[s-1]  
kcat/KM     
 [µM-1s-1]  
FAD content  
[mol/subunit] 
Wildtype 1.17 6 5.1 0.63 
   
S374D 10.9 208 18.5 0.55 
N67R 97.0 97 1.0 0.61 
N67W n.d. n.d. n. d. 0.48 
     
N67R/S374D   
(“human PPO“) 1.4 111 79.4 0.65 
N67W/S374D  
(“human VP“) 21.0 12 0.57 0.38 
n.d. not detectable 
The double mutation N67W/S374D, mimicking VP in the human enzyme significantly 
reduced enzyme activity. The KM value was 20-fold increased while the kcat/KM value 
decreased 10-fold. Obviously, the also reduced FAD content of 0.38 moles FAD/subunit for 
NtPPO2 variant N67W/S473D, representing approximately 60 % of the wildtype enzyme 
content, did not account for the observed decrease in enzyme activity. Similar observations 
were made for the human R59W mutant enzyme before (Maneli et al., 2003). In contrast to 
most other generated mutant enzymes this NtPPO2 variant showed an increased KM with a 
parallel decreased kcat compared to the double mutant N67R/S374D. Both amino acids 
neighboring Asp349 (Ser374 in NtPPO2) in the human enzyme have previously been 
characterized. A mutation of tryptophan in position 348 of the human enzyme to cysteine 
resulted in a wildtype-like KM value and a tenfold reduced kcat (Maneli et al., 2003). A 
mutation of Ser350 to proline in the human enzyme abolished enzyme activity (Roberts et 
al., 1998). These observations underscore that the structural integrity of this region is 
important for enzyme activity.  
3.3.3.3 Conclusions from Mutagenesis Studies of Amino Acid Residues 
Involved in Variegate Porphyria  
The results showed that the enzymatic defect responsible for causing VP in humans can be 
mimicked with the NtPPO2 model. Therefore, NtPPO2 represents a useful model system for 
the understanding of the structure-function relationship underlying detrimental human 
enzyme defects. 
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3.4 Investigation of a Proposed Alternate Heme Biosynthesis 
Pathway in Methanosarcina barkeri 
In the majority of prokaryotes not all genes required for heme biosynthesis have been 
identified. A database search performed in 2002 considered all 69 prokaryotes of which the 
entire genome had been sequenced at that date (Panek and O'Brian, 2002). This approach 
revealed that in about two-thirds of the genomes one or several genes of the heme 
biosynthetic pathway were missing. In the genomes of several heme synthesizing archaea 
only the genes required for uroporphyrinogen III formation were detected. This raises the 
possibility of an alternative pathway for the remaining steps. It has been shown earlier that 
D. vulgaris utilizes a pathway for heme biosynthesis which differs from the well 
investigated one (Ishida et al., 1998). In D. vulgaris the pathway for heme biosynthesis 
branches from the common pathway after uroporphyrinogen III formation, which is 
converted into precorrin-2 via two methylation reactions utilizing SAM. Next, precorrin-2 is 
converted to 12,18-(didecarboxy)-precorrin-2 which is afterwards deacylated to 
coproporphyrinogen III. At this point the alternate route for D. vulgaris was proposed to 
reenter the common pathway. However, this last step is improbable to occur in archaea 
since the genes for the enzymes necessary for the reactions from coproporphyrinogen III to 
heme have not been found in the respective genomes. A possible alternate route would be 
the oxidation of coproporphyrinogen III to coproporphyrin III which is than decarboxylated 
to protoporphyrin IX. Iron chelation may either be the last step in this pathway or may occur 
at an earlier time point.  
Since the late heme biosynthesis genes are missing in the genomes of M. barkeri, 
Methanosarcina acetivorans (Galagan et al., 2002) and Methanosarcina mazei 
(Deppenmeier et al., 2002), we chose M. barkeri for further studies. M. barkeri is a strictly 
anaerobic methanogenic archaeon that is able to grow on H2 and CO2, acetate, methylamines 
or methanol as sole carbon and energy sources. It is a member of the order 
Methanosarcinales, which are all known to contain cytochromes b and c and other proteins 
with protoheme derived prosthetic groups (Kamlage and Blaut, 1992, Kuhn and Gottschalk, 
1983). The organism also contains the nickel tetrapyrrole coenzyme F430 (Diekert et al., 
1981) and the cobalt tetrapyrrole hydroxybenzimidazolyl cobamide, which is a vitamin B12 
homolog (Thauer and Sauer, 1999). These tetrapyrroles are involved in different steps of 
methanogenesis and thus absolutely essential for the organism. M. barkeri in low salt media 
grows in clusters of 8-32 cells (see Fig. 29). If the above outlined pathway applies to 
archaea, protoheme should similarly be synthesized from precorrin-2 in the heme forming 
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methanogenic archaeon M. barkeri and should involve the SAM-dependent methylation of 
uroporphyrinogen III. In the common pathway no such methylation step occurs. 
 
Fig. 29: Phenotype of M. barkeri in low salt media.  
 
Cells were grown in low salt media under strictly anaerobic 
conditions at 37°C for 3 days. Scale bar = 5 µm. Micrographs 
of fixed cells stained with SYBR Green II were kindly taken by 
Sebastian Hannemann from the group of Oliver Fackler, 
Hygiene Institute, University Hospital, Heidelberg.  
 
 
 
 
Two different approaches were used in order to identify the possible alternative heme 
biosynthetic pathway. The in vivo approach included the incorporation of labeled precursors 
such as SAM to follow the possible methylation steps during heme biosynthesis. 
Furthermore an in silico approach was employed using comparative genomics to identify 
enzymes potentially involved in alternative heme biosynthesis.   
3.4.1 First Steps Towards an Alternative Pathway  
A first step in the investigation of the unknown pathway in M. barkeri was to determine the 
fate of uroporphyrinogen III. In vivo integration of methyl groups from SAM in 
uroporphyrinogen III with the formation of precorrin-2 and its subsequent conversion into 
heme was probed. The use of [14C] labeled and deuterated transferable methyl groups 
should allow for mass spectrometry identification of SAM-derived methyl groups in heme. 
Isolated heme carrying [14C] labeled or deuterated methyl groups should be identified by the 
mass increase compared to regular heme. 
First experiments revealed that M. barkeri was not able to take up radioactively labeled 
[14C]-SAM from the media in sufficient amounts. Cells were grown in the presence of  
0.1 µCi [14C]-SAM per mL cell culture for 2 - 72 hours, harvested and washed twice with 
media. The 14C-content of the cells was measured with a scintillation counter as described 
under MATERIALS AND METHODS. Less than 0.5 % of the added radioactivity was 
recovered from the cells. In contrast, [14C]-methionine uptake was rather efficient, as up to 
17.5 % of the deployed 14C was found within the cells after 72 hours at the end of the 
exponential growth phase. Therefore, the methanogenic archaeon was grown on methanol in 
the absence and presence of L-[methyl-D3]methionine, which is better applicable for 
MALDI-TOF determination due to its additional mass when incorporated into heme. 
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Methionine is a precursor of SAM, an incorporation of methyl-groups derived from SAM 
into protoheme should consequently result in the introduction of labeled methyl-groups. At 
the end of the exponential growth phase, cells were harvested and non-covalently bound 
protoheme was extracted from M. barkeri as described in MATERIALS AND METHODS. 
Coenzyme F430 is known to contain two methyl groups (Jaenchen et al., 1981) and vitamin 
B12 seven methyl groups, all derived from S-adenosyl-L-methionine (Warren et al., 2002). 
These cofactors were analyzed as controls. The mass spectra were collected by Jörg Kahnt 
and Bärbel Buchenau from the laboratory of Rolf Thauer, Max-Planck-Institute for 
Terrestrial Microbiology, Marburg. Mass spectra of commercially obtained protoheme, of 
heme extracted from unlabeled cells and of heme extracted from cells grown in the presence 
of 2 mM, 5 mM and 10 mM labeled L-[methyl-D3]methionine, respectively, are shown in 
Fig. 30. 
 
Fig. 30: MALDI-TOF mass spectra of heme extracted from  
M. barkeri. 
 
(A) protoheme, (B) heme extracted from M. barkeri cells grown in the 
absence of L-[methyl-D3]methionine and (C) heme extracted from  
M. barkeri cells grown in the presence of 2 mM, (D) 5 mM and  
(E) 10 mM L-[methyl-D3]methionine. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The mass spectra of commercially obtained protoheme (Fig. 30 A) and of heme extracted 
from the unlabeled cells (Fig. 30 B) were found to be almost identical. The highest peak 
representing a mass of 616 Da corresponds to the mass of protoheme composed of only 12C, 
14N and 56Fe. The other peaks with masses of 614, 615, 617, 618, 619 and 620 Da reflect the 
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natural abundance of 13C (1.1 %), 15N (0.37 %) and 54Fe (5.82 %), 56Fe (91.72 %),  
57Fe (2.1 %) and 58Fe (0.3 %), respectively, in this molecule. The relative peak heights 
agreed well with those calculated for this isotope composition. The mass spectroscopic 
analysis thus yielded reliable results. 
In Fig. 30 C the mass spectrum of heme extracted from M. barkeri cells grown in the 
presence of 2 mM L-[methyl-D3]methionine is shown. The spectrum revealed the presence 
of 37 % unlabeled protoheme (616 Da), 44 % protoheme with a mass of 619 Da and 19 % 
with a mass of 622 Da. This observation is consistent with one and two methyl groups, of 
protoheme being derived from the methyl group of methionine. When the L-[methyl-
D3]methionine concentration in the growth medium was 5 mM the percentage of protoheme 
with a mass of 622 Da (two methyl groups from methionine) was 33 %. The corresponding 
percentage of 10 mM was 56 % (Fig. 30 D, E). A similar methionine concentration 
dependency has been reported for coenzyme F430 labeling in Methanothermobacter 
marburgensis (Jaenchen et al., 1981, Selmer et al., 2000). 
As an internal control, the incorporation of the methyl group of L-[methyl-D3]methionine 
into F430 and B12 was determined via mass spectrometry in the same experiment. F430 
contains two methyl groups and vitamin B12 seven methyl groups derived from methionine 
via SAM. Labeling efficiency followed the same concentration dependence as found for 
protoheme (Fig. 31). This clearly indicates that the mass increase of 6 Da observed in the 
case of protoheme is due to the incorporation of two intact methyl groups derived from  
L-[methyl-D3]methionine during protoheme biosynthesis in M. barkeri. 
 
Fig. 31: Incorporation of methyl groups in 
cofactors of M. barkeri.  
 
Methyl group of methionine incorporated into 
heme (○), F430 (U) and B12 () after growth of  
M. barkeri in the presence of L-[methyl-
D3]methionine at different concentrations. The 
labeling efficiency represents the methyl-D3-
labeled fraction of the total methyl content of 
the sample. 
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3.4.2 The Participation of Precorrin-2 in the Alternative Heme 
Biosynthesis Pathway 
3.4.2.1 Preparation of Precorrin-2 
The recombinant production of proteins required to form precorrin-2 from ALA was 
achieved by coexpression of all the corresponding genes hemB, hemC, hemD and cobA from 
various organisms. The resulting His-tagged fusion proteins were applied to Ni-IDA affinity 
chromatography, eluted with 1 M imidazole (Fig. 32 A, lane 4) and desalted via a gel 
filtration PD-10 column. Recombinant proteins were employed for precorrin-2 production 
under anaerobic conditions as described under MATERIALS AND METHODS. Precorrin-2 
production was successful with commercially obtained ALA, clearly visible from the lime 
green color (see Fig. 32 B). However, the production of radioactively labeled precorrin-2 
with [14C]-ALA as initial substrate in parallel was unsuccessful (Fig. 32 C). [14C]-ALA is 
shipped in 1 N HCl. Nevertheless appropriate adjustments of the pH to 8.0 and addition of 
equal amounts of non-labeled ALA did not improve the formation of precorrin-2. 
 
Fig. 32: Preparation of precorrin-2. 
 
(A) Combined production and purification of recombinant M. barkeri CobA, M. thermoautotrophicum PBGS, 
B. megaterium PBGS and UROS. Proteins were separated by 12 % SDS-PAGE as described in MATERIALS 
AND METHODS and visualized by staining with Coomassie Brilliant Blue. Lane 1: molecular weight marker; 
lane 2: total cellular extract without induction; lane 3: total cellular extract after overnight induction of gene 
expression with 400 μM IPTG; lane 4: Ni-NTA column elution with imidazole. (B) Preparation of precorrin-2 
with commercially obtained ALA as substrate. Precorrin-2 formation is detected by the lime-green color of 
precorrin-2. (C) Employment of [14C]-ALA did not lead to precorrin-2 formation.   
 
Approximately 100 µg unlabeled precorrin-2 in 100 µL were added to 200 µL crude cell 
extract or cell free extract under strictly anaerobic conditions. Precorrin-2 turn over was 
monitored by measuring the absorbance at 500 nm. Unfortunately, no turn over from 
unlabeled precorrin-2 in either M. barkeri crude cell extract or M. barkeri cell free extracts 
was observed. Presumably, cellular enzyme concentrations were too low to be tested in cell 
free extract as observed for other organisms. Moreover, yet unknown cofactors, co-
substrates or metals may be necessary to retrieve precorrin-2 turnover. 
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3.4.3 Implications from Genomic Arrangements in Methanosarcina barkeri  
The data shown above make it very likely that the first step of the alternative heme 
biosynthetic pathway in M. barkeri after uroporphyrinogen III formation is the 
incorporation of the two methyl groups yielding precorrin-2. In all sequenced 
Methanosarcina strains (i.e. M. barkeri, M. acetivorans and M. mazei) and  
M. thermoautotrophicum a gene encoding an uroporphyrinogen III methyltransferase 
(CobA) is located in an operon structure with UROS (see Fig. 33). The M. barkeri CobA 
protein was employed for precorrin-2 production as shown above and will most probably 
fulfill the same function in vivo. This genomic arrangement further underscores the 
probability of the methylation step occurring as part of the archaeal heme biosynthesis 
pathway.  
 
 
Fig. 33: Operon structures around the cobA gene in several archaea retrieved from BRENDA 
(Schomburg et al., 2004).  
 
In several archaea uroporphyrinogen III methyltransferase (CobA-like protein) is located in an operon 
structure with the anterior protein of the heme biosynthesis pathway, UROS. In Halobacterium sp. NRC-1 a 
large operon has been postulated which includes PBGS and proteins with unknown function. Open reading 
frames with unassigned function are depicted in light grey, whereas open reading frames with assigned 
function are depicted in dark grey with numbering as following. (1, 2, 3) ribonuclease Z; (4) GSAM;  
(5) phosphoribosyl- amino- imidazole- succino- carboxamide synthase: (6) glutamine- fructose- 6 -phosphate 
transaminase.  
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3.4.4 Identification of Enzymes Involved in the Alternate Heme 
Biosynthesis Pathway In Silico 
In order to identify candidate proteins possibly participating in the ancient heme 
biosynthesis pathway, the approach of comparative genome analysis was chosen. Several 
organisms were chosen and grouped according to their capability to synthesize heme. 
The intersection of group one contains proteins which are common to all organisms 
possessing heme but not the proteins necessary for its synthesis. The intersection of group 
two contains proteins common to organisms which do not synthesize heme. The intersection 
of group three consists of proteins in common to organism capable of heme biosynthesis in 
the well investigated pathway. A scheme of this analysis is depicted in Fig. 34. 
1 2
3
1b
1a
 
Fig. 34: Comparative genome analysis.  
 
(1) Intersection: Proteins with homologs in organisms synthesizing heme via the ancient pathway: M. barkeri, 
M. acetivorans, M. mazei, A. fulgidus, S. solfataricus, S. tokodaii, H. salinarium, P. aerophilum and A. pernix 
K1. (1a) Proteins present in heme-synthesizing archaea but absent in organisms which do not produce heme. 
(1b) Proteins present in heme-synthesizing archaea but absent in organisms which produce heme via the 
common pathway or not at all. (2) Proteomes of organisms which do not synthesize heme: C. elegans,  
L. lactis, M. thermoautotrophicum, M. genitalium, M. pneumoniae, M. pulmonis, P. abyssi, P. horikoshii,  
T. maritima, T. pallidum, S. pneumoniae, S. pyogenes, B. burgdorferi and U. urealyticum. (3) Proteomes of 
organisms synthesizing heme via the common pathway: D. melanogaster, H. sapiens, S. cerevisiae,  
P. falciparum, B. subtilis, S. pombe, E. coli and P. aeruginosa. 
 
To evaluate whether the chosen method was suitable, the comparative genome analysis was 
applied in order to find proteins operative in the common heme biosynthesis pathway. 
Therefore, an intersection of proteins from group two was calculated and proteins which 
gave significant hits in proteomes of groups one or three were removed. Only proteins 
which are not operative in organisms either synthesizing heme in the ancient pathway or not 
synthesizing heme at all should appear as a final result. The computational analysis of 
genomes of organisms containing or not containing the genes necessary for common heme 
biosynthesis was performed as described under MATERIALS AND METHODS. 
Surprisingly, only proteins fulfilling solely one function remained, i.e. UROD, a protein 
functional in the common pathway of heme biosynthesis. All heme biosynthesis proteins 
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except CPO and PPO were found in the intersection, which is reasonable since E. coli lacks 
a HemY (Panek and O'Brian, 2002), B. subtilis a HemF (Hippler et al., 1997) and all 
eukaryotes a HemN homolog. Due to their function in F430 biosynthesis and probably as 
well in the ancient heme biosynthesis pathway PBGS, PBGD, and UROS were removed 
because they gave significant hits in group one or three. FC was withdrawn because  
S. pneumoniae possesses a FC homolog. Therefore, the finding of only UROD was 
congruent with our expectations.   
After the method was shown to be suitable, it was applied to determine potential proteins 
functional in the ancient heme biosynthesis pathway. The intersection of group one consists 
of 4129 proteins performing about 400 different functions. After the removal of proteins 
that feature homologs in group two, 541 proteins fulfilling about 100 different functions 
remained. One third of these proteins function in genetic information processing, whereas 
another third represents hypothetical proteins. Once having removed all proteins that feature 
homologs in group three, the final set consisted of ten proteins (see Tab. 13). Since most 
heme containing archaea synthesize protoheme using the alternate pathway via precorrin-2, 
they should have proteins for this pathway in common and thus be present in all proteomes 
of organisms listed in the first group. These proteins should not be found in the proteomes 
of organisms listed in the second or third group. The ten retrieved proteins were classified in 
four functional groups. The M. barkeri homologs are depicted in Tab. 13. A further analysis 
of these ORFs revealed that three of the four groups are unique to archaea. The only 
exception is the hypothetical protein Q46CH6 where homologs in many taxonomic groups 
were identified. These encode for proteins operational in heme d1 biosynthesis, i.e. NirH. 
The protein Q46E11, assigned to be a putative heat shock protein has homologs in 
crenarchaeota and euryarchaeota but as well in three bacterial proteomes, i.e. Pelodictyon, 
Thermoanaerobacter and Psychromonas. The remaining proteins are Q46GA9, a probable 
SSU ribosomal protein and Q46C74, a probable DNA primase small subunit. Unfortunately, 
none of these proteins seems to be a suitable candidate for the ancient pathway of heme 
biosynthesis. It may be the case that either one of the organisms from group one does not 
posses this pathway or employs non-homolog proteins or that there is more than one 
alternative to the common heme biosynthesis pathway.  
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Tab. 13: Results of a comparative genomics analysis.  
 
Functional 
group 
BLAST result 
(Swissprot ID) assigned function organism 
M. barkeri homolog 
(Swissprot ID) 
     
Q8PXG4 Putative heat shock protein M. mazei 
Q9HSS6 Putative heat shock protein H. halobium 
Q8PXG3 Putative heat shock protein M. frisia 
1 
Q8THE4 Hypothetical protein M. acetivorans 
Q46E11 
     
Q975Y5 Hypothetical protein S. tokadai 2 
Q9YBV2 Hypothetical protein A. pernix 
Q46CH6 
Q8PV36 SSU ribosomal protein S14P M. mazei 3 
Q8TRT3 Ribosomal protein S14P M. acetivorans 
Q46GA9 
   
Q9YEZ8 
Probable DNA primase small 
subunit A. pernix 
4 
Q97Z83 
Probable DNA primase small 
subunit S. solfataricus 
Q46C74 
 
3.4.5 Conclusions from the Investigation of Heme Biosynthesis in 
Methanosarcina barkeri 
The obtained results identified the existence of an alternative pathway for heme biosynthesis 
in M. barkeri which has previously exclusively been described for the sulfate-reducing  
δ-proteobacterium D. vulgaris. Tetrapyrrole biosynthesis in M. barkeri proceeded via the 
incorporation of two methyl groups from S-adenosyl-L-methionine into protoheme. 
Nevertheless, the nature of the of intermediates and enzymes involved in the proceeding 
steps remained a mystery.  
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4 SUMMARY 
This thesis approached four open questions regarding the pathway for the biosynthesis of 
heme and involved enzymes in bacteria, archaea and plants.  
 
1. The novel antibiotic alaremycin was shown to inhibit porphobilinogen synthase from 
various bacterial, archaeal and eukaryotic sources. A co-crystal structure of 
alaremycin with Pseudomonas aeruginosa porphobilinogen synthase was obtained. 
Thus, the molecular basis of alaremycin function was solved at the atomic level. 
 
2. Bioinformatic approaches failed to detect the uroporphyrinogen III synthase gene in 
plants. Our cooperation partner Alison Smith at Cambridge University, UK, had 
genetically isolated a potential open reading frame from Arabidopsis thaliana. In 
this thesis the corresponding protein was recombinantly produced and 
uroporphyrinogen III synthase activity was demonstrated, providing final proof for 
the identity of the gene.     
 
3. The recently solved crystal structure of tobacco protoporphyrinogen IX oxidase was 
used as basis for the functional definition of the corresponding substrate binding site. 
Furthermore, the structural constellation causing the human disease variegate 
porphyria was functionally explored. For this purpose 14 enzyme variants were 
generated, produced, purified and tested for their kinetics and FAD contents. A 
detailed picture of the various chemical reactions occurring during substrate-enzyme 
interactions was obtained. The chemical basis for the enzymatic defect responsible 
for variegate porphyria was elucidated. 
 
4. An alternative pathway for the biosynthesis of hemes in archaea was discovered and 
initially characterized. It was shown that in the archaeon Methanosarcina barkeri 
heme is synthesized via precorrin-2. Therefore, the last four to five steps of archaeal 
heme biosynthesis are completely different to their bacterial and eukaryotic 
counterparts.  
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5 OUTLOOK 
Interaction between Porphobilinogen synthase and alaremycin 
As outlined above, the results of this work provided insight into the molecular target of 
alaremycin. The following questions have to be addressed in future experiments.  
 
1) Evaluation of the resistance of the porphobilinogen synthase from the producer 
strain Streptomyces sp. A012304 towards alaremycin. 
2) Investigation of the effect of alaremycin on Staphylococcus aureus hemB− strains. 
3) Determination of the suitability of alaremycin for the generation of inducible  
S. aureus small colony variants. 
 
Plant uroporphyrinogen III synthase 
In this study it was possible to confirm the identity of Arabidopsis thaliana 
uroporphyrinogen III synthase. The recombinant protein showed the corresponding enzyme 
activity. This was the first step towards a characterization of plant uroporphyrinogen III 
synthase. Further studies have to be carried out to determine its features more closely. 
 
1) Determination of kinetic parameters and pH dependence. 
2) Investigations on the oligomeric state of the native protein. 
3) Crystallization of plant uroporphyrinogen III synthase. 
 
Alternative heme biosynthesis 
In this study evidence for an alternative pathway for heme biosynthesis was obtained. The 
first step deviating from the common pathway is the methylation of uroporphyrinogen III 
via S-adenosyl-L-methionine to form precorrin-2. Nevertheless, it is necessary to perform 
further investigations to identify intermediates and enzymes participating in the ancient 
pathway. 
 
1) Genomic knockout of M. barkeri uroporphyrinogen III methyltransferase to clarify 
its participation in the ancient heme biosynthetic pathway. 
2) Identification of possible intermediates via further labeling experiments. 
3) In vitro protein purification attempts to isolate involved enzymes.  
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